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ABSTRACT 
Evidence is accumulating that polymorphisms in plmdr 1 and plcrt are involved in 
resistance to the quinoline based blood schizontocides and possibly artemisinin 
derivatives; and mutations in the cytochrome b gene (cytb) are strongly associated with 
resistance to atovaquone. With this in mind, we studied sensitivity, drug interactions and 
uptake in a range of Plasmodium lalciparum lines, including pfmdr 1 transfectants, plcrt 
mutated lines 106/1 and K76I, and an atovaquone-resistant isolate (NGATVOl) with a 
unique point mutation (tyr268asn). 
In vitro susceptibility studies and genetic characterisation supported the role of plmdr 1 
and plert polymorphisms in the sensitivity of parasite lines to a range of structurally 
diverse antimalarials. Mutations in plcrt conferred chloroquine resistance modulated by 
changes in plmdr 1, while the wild-type genes were associated with reduced sensitivity to 
mefloquine, halofantrine, lumefantrine and dihydroartemisinin. 
Drug interaction studies in vitro using a modified isobologram method showed that 
dihydroartemisinin in combination with chloroquine, amodiaquine or the new 
bisquinoline piperaquine was antagonistic in all parasite lines examined. The response 
was synergistic when the drug was combined with mefloquine, halofantrine or 
lumefantrine against chloroquine-sensitive (wild-type plmdrl and plcrt), but additive 
against chloroquine-resistant parasite lines. However, in the 7G8-m<fIP10 transfectant 
(wild-type plmdrl and mutated plert), synergy was shown between each of these three 
drugs and dihydroartemisinin. These results suggest that the interaction profile of 
dihydroartemisinin with arylaminoa1cohols depends on mutations in plmdrl in the 
presence of other chloroquine resistance mutations. In the D 1 0_mdr7G8 transfectant, the 
introduction of the mutated plmdr 1 converted the synergy between lumefantrine and 
dihydroartemisinin or artemether to addition; supporting the idea that interactions 
between artemisinin-derivatives and lumefantrine are dependent on mutations within 
pfmdr 1 alone. An exception was seen when dihydroartemisinin was combined with 
arylaminoa1cohol quinine. It showed a strain-specific effect not related to resistance 
polymorphisms, although a similar change to synergy in the 7G8-md~10 transfectant as 
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for the other arylaminoalcohols was seen. A verapamil-reversible change in the quinine 
and dihydroartemisinin interaction from additive to synergistic was also noted with the 
introduction of a mutated PfCRT codon 76 in K76I. An antagonistic effect of 
dihydroartemisinin with pyrimethamine, was observed in all pyrimethamine-sensitive 
parasites, but the effect was additive in pyrimethamine-resistant parasites. In contrast to 
the quinolines, this was not associated with inhibition of eH]-dihydroartemisinin uptake. 
The interaction between atovaquone and proguanil was strongly synergistic in 
atovaquone-sensitive lines Kl and T996 and moderately synergistic in the atovaquone-
resistant NGATVOI isolate. While the interaction between atovaquone and 
dihydroartemisinin was additive in the NGATVOI isolate, the interaction was 
antagonistic in the atovaquone-sensitive strains tested. 
Mutations in plmdr 1 and plert had no effect on uptake of eH]-dihydroartemisinin, 
although eH]-chloroquine accumulation was strongly affected by these polymorphisms. 
Uptake studies in combination with other antimalarials indicated that some of the 
quinoline-related drugs and arternisinin-derivatives competed with the uptake of the two 
radiolabelled drugs. 
This work highlights the important role of drug resistance polymorphisms in sensitivity, 
interaction and uptake of structurally diverse antimalarials. The unusual pattern of 
antagonism between dihydroartemisinin and pyrimethamine seen in vitro is supported by 
observations in vivo with artemisinin in rodent parasites. These and other differing 
interactions between dihydroartemisinin and antimalarials could have particularly 
important implications for the design of drug combinations in the future. 
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ABBREVIATIONS 
APAD 3-acetyl pyrimidine NAD 
AO acridine orange 
AQ amodiaquine 
ATM artemether 
ATV atovaquone 
avo average 
bp base-pairs 
CM complete RPMI culture medium 
conc. concentration of drug 
cpm counts per minute 
CQ chloroquine 
CQR chloroquine-resistant 
CQS chloroquine-sensitive 
CYTb cytochrome b protein (encoded by cytb gene) 
dHzO distilled water (ddHzO: autoclaved distilled water) 
DHA dihydroartemisinin 
DHFR dihydrofolate reductase (encoded by dhfr gene) 
DHPS dihydropteroate synthetase (encoded by dhps gene) 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dpm disintegrations per minute 
dNTP deoxyribonuc1eoside tri-phosphate 
EIPA 5-(N-ethyl-N-isopropyl)amiloride 
FIC fractional inhibitory concentration 
FPIX ferriprotoporphyrin IX or haemin (FeIlI)§ 
g relative centrifugal force 
haem (Fell) ferroprotoporphyrin IX (haem)§ 
HAL halofantrine 
§ In order to avoid confusion, haem containing the reduced ferrous iron (ferroprotoporphyrin IX - Fell) 
will be designated haem (Fell) while haem containing ferric iron (haemin, ferriprotoporphyrin IX - FellI) 
will be designated FPIX. In cases where the oxidation state is not clear, the term haem will be used. 
Hb haemoglobin 
ICso drug concentration required to inhibit parasite growth by 50% 
1M incomplete RPMI culture medium 
kb kilobase-pairs 
LDH lactate dehydrogenase 
MDR multidrug resistant 
mm minute(s) 
mRNA messenger RNA 
MNNG N-methyl-N-nitro-nitrosoguanidine 
MQ mefloquine 
MSP mefloquine/pyrimethamine/sulfadoxine combination (Fansime~) 
mtDNA mitochondrial DNA 
nld not determined 
NAD nicotinamide-adenine dinucleotide (oxidised form) 
NADH nicotinamide-adenine dinucleotide (reduced form) 
NADP nicotinamide-adenine dinucleotide phosphate (oxidised form) 
NADPH nicotinamide-adenine dinucleotide phosphate (reduced form) 
NHE Na+lH+ exchanger 
nM nanomolar (1 x 10-9 moles per litre) 
nm nanometre (1 x 10-9 metres) 
NPP new permeability pathways 
PABA p-aminobenzoic acid 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEN penfluridol 
pfert P.falciparum chloroquine resistance transporter gene (codes PfCRT) 
pfmdr 1 P. falciparum multi drug resistant gene-l (codes for Pgh-l) 
PG proguanil 
Pgh-l P-glycoprotein homologue-l (encoded by pfmdr 1) 
PPM parasite plasma membrane 
PPQ piperaquine 
PVM parasitophorous vacuole membrane 
pRBC parasitised red blood cell (infected RBC) 
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PYR pyrimethamine 
QHS artemisinin 
QN qumme 
RBC red blood cell (erythrocyte) 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
ROS reactive oxygen species 
rpm revolutions per minute 
SD standard deviation 
SDX sulfadoxine 
SEM standard error of the mean 
SP sulfadoxine/pyrimethamine combination (Fansidar®) 
TCTP translation-controlled tumour protein 
TVM tubovesicular-membrane network 
U unit 
(v/v) volume by volume 
% viability percentage viability of parasite growth 
VP verapamil 
WM wash medium (CM without serum) 
WHO World Health Organisation 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 The Malaria Parasite 
18 
Over 40% of the world's population - more than 2100 million people in a 
hundred different countries - are at risk of malaria annually. There are an estimated 300-
500 million cases and up to 2.7 million deaths from the disease each year (Gardner et al., 
2002). Approximately 90% of these deaths occur in African children (Barradell and 
Fitton, 1995). 
Through repeated infection, people living in malaria endemic areas usually 
acquire some degree of immunity. Many of these people show few or no symptoms, and 
could serve as transmission reservoirs of the malaria parasites. Clinical symptoms 
include intermittent fever preceded by slight hypothermia with shivering, followed by a 
sweating stage. Other common symptoms include headaches, jaundice, vomiting and 
diarrhoea. Anaemia can occur due to the destruction of erythrocytes by the parasite and 
by the host response. Hypoglycaemia, renal failure, and tissue congestion leading to 
hypoxia, often contribute to malarial death (Oaks et al., 1991; Bustos et al., 1994; 
Barradell and Fitton, 1995). The WHO regards vaccination as the best route to 
eradication. Various vaccine prototypes have been developed over the years, but have 
had little success (Richie and Saul, 2002). 
Assessing the burden of malaria accurately is difficult as most of the malaria-
related deaths occur at home and often the clinical symptoms are similar to those of other 
infectious diseases. Factors such as drug and insecticide resistance, war, 
environmentaVclimatic changes, and migration of people between malaria-endemic and 
malaria-free regions contribute to the increasing burden of malaria. Deaths from severe 
malaria-related anaemia are increasing due to concerns over the therapeutic use of blood 
transfusions in communities which have a high infection prevalence of the human 
immunodeficiency virus (HIV). Due to the large popUlation at risk from malaria in 
Africa, the cost of a basic control programme that will cover the whole population has 
been estimated to be as much as US$2 billion each year for an indefinite period 
(Greenwood and Mutabingwa, 2002). 
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Figure 1.1: Life cycle of Plasmodium fa/ciparum. Picture from http://whyfiles.org. 
in mosquito gul 
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1.1.1 Life cycle of the malaria parasite 
19 
In humans, malaria can be caused by 4 species of parasitic protozoa of the genus 
Plasmodium: P. ovale, P. vivax, P. malariae and the most virulent, P. jalciparum. 
Parasites are transmitted by the bite of an infected female Anopheles mosquito, or by 
inoculation with infected blood. The life cycle of the P. jalciparum parasite has many 
stages involving sexual and asexual stages (sporogony) in the mosquito, and asexual 
(pre-erythrocytic/erythrocytic) stages which differentiate to dormant presexual forms in 
human blood (Figure 1.1). Sporozoites are injected into the human bloodstream from the 
salivary gland of infected mosquitoes. The sporozoites find their way to the liver - via 
the blood stream - where they penetrate hepatocytes and multiply asexually, 
transforming into large tissue schizonts that contain many merozoites (pre-erythrocytic 
schizogony). Tissue schizonts rupture after 5.5 to 7 days and release the merozoites into 
the blood stream where they infect erythrocytes. This begins the second asexual stage 
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that causes the disease malaria (erythrocytic cycle). The merozoite undergoes 
development through ring to trophozoites and schizont which after maturation then 
divides up to 32 merozoites. The merozoites initiate another wave of erythrocyte 
invasion and the cyclic event continues. 
However, some merozoites develop into male or female gametocytes that are 
taken up by a feeding Anopheles mosquito. Once inside the mosquito gut, male and 
female gametes develop which fuse to form a zygote, which invades the gut wall to form 
an oocyst. This oocyst matures and asexual multiplication occurs to form sporozoites. 
The oocyst bursts to liberate sporozoites that invade the mosquito salivary glands, and 
begin the life cycle again (Oaks et a/., 1991). 
P. vivax and P. ovale infect only immature erythrocytes. P. malariae infects 
mature cells, while P. Jalciparum infects erythrocytes of all ages. High levels of 
parasitaemia can occur in individuals with P. falciparum infections - due to 
sequestration and spleen avoidance - resulting in severe haemolysis, which along with 
sequestration and organ damage can be fatal if left untreated, particularly in non-immune 
individuals. A variable proportion of injected sporozoites of P. vivax and P. ovale form 
dormant tissue forms (hypnozoites), which can persist for long periods in the liver before 
releasing invasive merozoites (Oaks et al., 1991; Price et al., 1996). 
1.1.2 Nutrient pathways of the parasite 
1.1.2.1 Haemoglobin degradation 
The invasion of the host RBC by the parasite poses significant challenges with 
regard to obtaining nutrients from the plasma. The rapid propagation of the parasite 
produces nutritional demands which are partially met by the digestion of the host 
haemoglobin (Hb) in lysosomes. Hb is the single major protein used by the maturing 
parasite to provide amino acids for protein synthesis (Goldberg et al., 1990) and may be 
used for energy metabolism (Sherman, 1977). The malaria parasite does have a limited 
capacity for de novo amino acid synthesis and can take up amino acids from plasma 
(Sherman, 1977) as Hb is a poor source of certain amino acids and contains no isoleucine 
(Francis et al., 1997). Hb proteolysis releases toxic free haem or ferriprotoporphyrin IX 
(FPIX) which is neither metabolised nor recycled, but stored as an inert, insoluble 
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complex of dimers fonning chains linked by hydrogen bonds known as haemozoin or 
malaria pigment (Pagola et al., 2000). If the free FPIX within the digestive vacuole was 
not dimerised and allowed to accumulate, vacuolar concentrations could reach around 
400 11M (Francis et aI. , 1997). P. Jalciparum lacks the enzyme haem oxygenase, used by 
mammalian cells during the breakdown of Hb, and thus could not breakdown FPIX into 
non-toxic bile pigments (Eckman et aI., 1977). 
Figure 1.2: Proposed pathway of haemoglobin degradation in the malaria parasite. 
Adapted from Francis et a/. (1997). 
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It was originally estimated that 60% to 80% of Hb in an infected erythrocyte is 
degraded (Ball et al., 1948; Morrison and Jeskey, 1948; Orjih and Fitch, 1993). A 
number of lower estimates have also been reported, but these assessments are thought to 
be from less mature parasites still in the process of Hb consumption (Francis et aI., 
1997). Using chemical analysis, Egan et al. (2002) recently reported that the trophozoite 
(within a parasitised erythrocyte) contains about 61 % of the iron content, of which about 
92% is located within the digestive vacuole; and of this, about 88% is in the fonn of 
haemozoin. In P. Jalciparum, Hb is taken up from the RBC cytoplasm by 
Chapter I: General Introduction 22 
micropinocytosis (Rudzinska et a!., 1965; Slomianny et al., 1983; Slomianny, 1990). It is 
thought that the small cell mouths or cytostomes pinch off a small part of the RBC 
cytosol, becoming acid vesicles and initiate Hb degradation (Figure 1.2). As the 
digestion proceeds, the outer membranes of the double-membrane vesicles fuse, forming 
single membrane-enclosed digestive or food vacuoles which contain haemozoin crystals 
(Slomianny, 1990). Once this digestive vacuole is formed, it appears to be the main site 
of Hb degradation (Goldberg et al., 1990). In P. berghei, vesicles containing a tiny 
haemozoin crystal can sometimes be seen as evidence of Hb digestion (Francis et al., 
1997) 
1.1.2.2 Nutrient acquisition 
Compounds moving from the external medium or serum to the interior of the 
parasite have to cross three membranes - the host cell membrane, the parasitophorous 
vacuole membrane (PVM) and the parasite plasma membrane (PPM; Desai et a!., 2000). 
Within 48 hours of RBC invasion the parasite has grown to many times its own size and 
then divides to produce many new parasites. To fuel this rapid growth the parasite needs 
nutrients from outside the host cell. However, the RBC is unable to take up some of the 
nutrients the parasite desperately needs for growth and multiplication (Kirk, 2000). The 
mature RBC membrane has many membrane transport systems. In some cases these 
serve unknown purposes in the RBC. They are thought to be remnants of systems which 
were needed in the developmental stages of the RBC (Kirk, 2001). The membrane of the 
infected RBC undergoes a dramatic increase in its permeability to a variety of both 
charged and uncharged solutes (Ginsburg et al., 1983; Ginsburg et al., 1985; Kirk, 2000). 
This induction of a broad specificity pathway in the RBC membrane is known as the new 
permeability pathway (NPP; Ginsburg et al., 1983; Huber et al., 2002).Various channels 
have been reported to be present within the RBC membrane once the cell is infected 
(Desai et al., 2000). The question arises of whether increased solute transport is due to a 
change in the activity of endogenous systems or to the induction of new pathways due to 
Plasmodium-encoded xenoproteins accumulating in the RBC membrane (Kirk, 2001; 
Huber et al., 2002). There have been a number of studies showing enhanced transport in 
malaria-infected RBC via pathways showing characteristics very similar to those 
endogenous systems in the normal host cell membrane (Kirk, 2001). A recent study by 
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Huber et al. (2002), using patch-clamp techniques, demonstrated that the parasite could 
activate an endogenous chloride channel within the RBC membrane by applying 
oxidative stress to the host membrane. However, the mechanisms underlying the 
increased rate of transport of substrates via pathways having the characteristics of 
endogenous RBC transporters is yet to be clarified; and some reports of host cell NPP's 
have shown properties quite different from those of the endogenous transporters (Kirk, 
2001). 
The PVM is formed when the merozoite invades the RBC and is necessary for 
intracellular proliferation (Haldar et al .• 2001). The parasite remains enclosed within the 
PVM, which increases in size as it matures. At the same time, a variety of tubular and 
vesicular membrane structures form in the RBC cytosol. This tubovesicular-membrane 
network (TVM) is thought to extend outside from the PVM with functional connections 
with the modified host cell membrane (Haldar et al .• 2001; Kirk, 2001). There has been 
increased discussion of the role of the TVM and whether the parasite may have access to 
the external medium other than via transport across the host erythrocyte membrane into 
the RBC cytoplasm (Kirk, 2001). There are a several indications of how the parasite may 
acquire nutrients. Pouvelle et al. (1991) suggested that the parasite has direct access to 
the extracellular solution via a parasitophorous duct - a tubular membranous structure 
that extends between the PVM and the RBC membrane. Lauer et al. (1997) disagree with 
the parasitophorous duct hypothesis and suggest that the parasite has access to the 
extracellular solution via an extension of the TVM to the RBC membrane. Desai and 
Rosenberg (1997) also disagree with the parasitophorous duct hypothesis and suggest 
that the parasite has access to large soluble macromolecules in the RBC cytosol via a 
channel or a molecular sieve which can pass macromolecules of up to 1400 kDa. 
There is no substantial literature on the accumulation of antimalarials by transport 
pathways from the serum to the parasite cytosol and whether any antimalarials target 
these pathways. However, several recent studies have highlighted the potential of 
transport pathways in the malaria-infected erythrocyte as potential drug targets (Kirk, 
2001). 
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1.2 Common Antimalarial Drugs 
The major drugs used for the control of P. falciparum include: the 4-
aminoquinolines (chloroquine, amodiaquine); the arylaminoalcohols (quinine, 
me flo quine, halofantrine, lumefantrine); the 8-aminoquinolines (primaquine); the 
bisquinolines (piperaquine); the antifolates (pyrimethamine, proguanil, sulfadoxine); the 
artemisinin-derivatives (artesunate, artemether); antimitochondrials (tetracycline and its 
derivatives, clindamycin, atovaquone); and the antiapicoplast drugs (also include 
clindamycin, tetracycline). See Figures 1.3, 1.4 and 1.5. 
1.2.1 Chloroquine: accumulation and mode of action 
The first treatment for malaria to reach the Western world came from the bark of 
the cinchona tree which is indigenous to certain parts of South America. In 1820, the 
powder prepared from the bark of the tree was discovered to contain alkaloids quinine 
(QN) and cinchonidine, and the use of quinine as an antimalarial agent began (Raynes, 
1999). The development of the synthetic quinoline-based antimalarials began with the 
discovery of the antimalarial properties of methylene blue, and further research on the 
heterocyclic ring systems and side chains led to the development of the 4-
aminoquinolines including chloroquine (CQ). This and related drugs are thought to act 
by interacting with the digestion and detoxification of Hb and its degradation products in 
the asexual erythrocytic stages of the malaria life cycle. 
Clinical investigations into the antimalarial activity of CQ reported that the drug 
action was limited to those stages of the parasite life cycle which were actively degrading 
Hb (Slater, 1993). Langreth et al. (1978) noted that mature non-feeding schizonts and 
merozoites were unaffected by CQ concentrations which caused cell damage and death 
in both rings and trophozoites. Similar observations with gametocytes were made by 
Sinden (1982) whereby the CQ sensitivity of an immature gametocyte degrading Hb is 
lost once the parasite has matured into a late-stage gametocyte. 
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Figure 1.3: Structures of the quinoline-based and related antimalarial drugs. 
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1.2.1.1 Accumulation and localisation of chloroquine in the parasite 
Since the introduction of CQ worldwide, efforts towards the understanding of the 
drug action has, to date, produced three theories explaining the mode of uptake and 
action of the drug: I} CQ binding to FPIX driving its accumulation; 2} proton-trapping of 
CQ within the digestive vacuole; 3} and the role of a permease in transporting the drug 
into the parasite digestive vacuole. 
1.2.1.1.1 Chloroquine targets the parasite digestive vacuole 
Evidence of CQ exerting its effects in the vacuole has been observed using 
ultrastructural studies of malaria parasites in the presence of CQ. Damage to the 
lysosomal system is the first morphological change detected after exposure to CQ. Both 
Warhurst and Hockley (1967a; 1967b), and Macomber and Sprinz (1967) saw clumping 
of digestive vesicles in P. berghei of rodents; and later Yayon and Ginsburg (1983) 
observed that in P. Jalciparum during CQ exposure, the endocytosis of RBC cytoplasm 
and its trafficking to the large digestive vacuole continues normally, but the lysosome 
vesicles - containing undigested RBC cytosol - accumulate within the vacuole without 
any further digestion, suggesting an inhibitory function of the drug upon Hb degradation. 
Under a light microscope, after exposure to CQ or AQ, it appears that the haemozoin 
pigment within the vacuole was shown to become granular, and eventually clump during 
a process called CQ-induced pigment clumping - although it is the vesicles which clump 
and not the pigment grains themselves (Warhurst, 1984). Other changes to the digestive 
vacuole, including swelling, have been observed in both P. Jalciparum trophozoites 
(Langreth et al., 1978) and immature gametocytes (Sinden, 1982). 
The exact mechanism for the accumulation of CQ into the malarial parasite is not 
completely understood. There have been many conflicting theories and mechanisms 
describing CQ accumulation and its mode of action in P. Jalciparum (Raynes et al., 
1999). These include a saturable intracellular receptor or drug binding site (Fitch, 1970; 
Bray et al., 1999a), active drug uptake by a saturable permease or drug transporter 
(Warhurst, 1986; Sanchez et al., 1997), or a proton-trapping process driven by 
accumulation of acid within the vacuole by a proton pump (Homewood et al., 1972; 
Ginsburg and Stein, 1991). 
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1.2.1.1.2 Formation of the chloroquine-ferriprotoporphyrin IX complex 
Earlier work shows that more CQ accumulates inside an infected RBC as 
opposed to an uninfected RBC (Yayon et a/., 1984; Diribe and Warhurst, 1985; Geary et 
a/., 1986b). The activity of CQ depends on a high level accumulation within the parasite 
and CQ resistance is characterised by reduced intracellular concentration of the drug (see 
Section 1.3.1.1; Bray et al., 1999a). Fitch (1969; 1970) initially recorded a several 
hundred-fold concentration of CQ into infected P. Jalciparum parasites from the medium 
compared to a ten-fold concentration into uninfected cells. Fitch's group then proposed 
that the binding of CQ to a specific receptor was driving the selective concentration of 
the drug; that this receptor was FPIX - the degradation product of Hb; and that it was 
only present in infected RBC. Along with earlier work Chou et al. (1980) highlighted 
that the interaction of CQ with FPIX had high affinity in chloroquine-sensitive (CQS) P. 
berghei and proposed that FPIX within the digestive vacuole was the receptor. It was 
thought that formation of the toxic CQ-FPIX complex, along with the intracellular free 
FPIX, could lead to parasite lysis and ultimately cell death (Chou and Fitch, 1980; Orjih 
et al., 1981; Fitch et al., 1982). The hypothesis suggested that CQ acts by binding to 
FPIX preventing detoxification of FPIX into haemozoin within the parasite digestive 
vacuole (see Section 1.1.2.1). 
However, in the reviews by Yayon (1985), Ginsburg and Geary (1987) and 
Schlesinger et al. (1988) the authors argued that the binding of CQ to FPIX cannot fully 
explain the uptake of the drug as there is a lack of detection of significant quantities of 
FPIX to act as a receptor for all the CQ accumulated. There are also problems with 
comparing known times for CQ uptake events: accumulation of CQ into the pRBC 
(within minutes); lysis by CQ-FPIX (seconds); inhibition ofCQS parasites at therapeutic 
CQ levels (about 2 hours) and retention of CQ (several hours). Additionally, the weak 
base ammonium chloride can displace all the CQ from an infected RBC but it has no 
effect on the amount of CQ-FPIX formed. Another explanation for selective CQ 
accumulation is therefore required. 
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1.2.1.1.3 Proton-trapping or non-ionic diffusion mechanism 
Homewood et al. (1972) suggested that the antimalarial effect of CQ was due to 
its weak base properties which allowed it to accumulate to high levels in the acid 
digestive vacuole or lysosome. The 4-aminoquinoline weak bases have amine functional 
group(s) with pKa values in the physiological range, such that at low pH the molecule is 
protonated; while at neutral or alkaline pH it is either in a neutral or protonated state. 
Neutral-weak bases also have lipophilic properties and show reduced membrane 
permeability when positively charged (Slater, 1993). A membrane permeable weak base 
could therefore sequentially enter a cell, and then pass into an acidic compartment such 
as the digestive vacuole where the molecule becomes protonated (positively charged) 
and membrane impermeable. Continuous secretion of protons into the vacuole by the 
proton pump could drive the selective concentration of CQ (PKa\ = 8.1 for quinoline ring 
nitrogen, pKa2 = 10.1 for side chain terminal nitrogen). The smaller the pH gradient 
between the vacuole and the extracellular environment, the smaller the expected CQ 
accumulation (Geary et al., 1986b). The acidic pH of the vacuole is maintained by a 
dynamic equilibrium between an inward vacuolar membrane-based ATP-dependent 
proton pump and an outward proton leakage (Krogstad et al., 1985). This proton pump 
has been proposed to be similar to that of mammalian lysosomes as both types are 
specifically inhibited by the fungal antibiotic, bafilomycin Al - which also leads to a 
reduction in CQ accumulation (Bray et al., 1992b). Once in the vacuole, the drug base 
becomes protonated (doubly, positively charged) and becomes trapped within the 
vacuole as it cannot permeate the membrane. This might alter the vacuolar pH but this is 
easily accommodated by the vacuole buffering capacity. It is postulated that in 
mammalian cells, further influx of charged drug eventually exceeds the proton pump 
capacity of the vacuole, and disrupts the vacuole buffering capacity leading to a rise in 
vacuole pH. In malaria parasites, the increased pH could result in inhibition of parasite 
proteases, halting Hb digestion and ultimately terminating the parasite nutrient supply 
(de Duve et al., 1974). 
This selective accumulation of weak bases was confirmed in P. falciparum using 
pH sensitive fluorescent probes attached to large molecules such as dextran by Yayon et 
al. (1984) and Krogstad et al. (1985). In both cases the probes were located in the 
vacuole via endocytosis and the pH of the vacuole was confirmed to be about 5.2. Yayon 
et al. (1984) concluded that drug accumulation in malaria-infected erythrocytes can be 
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fully accounted for by steady-state proton gradients across the barriers delineating 
various cellular compartments and acidotropic properties of the drug. 
1.2.1.1.4 The permease or membrane transporter theory 
Early CQ uptake studies by Fitch (1970) and co-workers (Fitch et al., 1974a), 
followed by more recent investigations by Sanchez et al. (1997), demonstrated that CQ 
accumulation was saturable, energy-dependent and could be competitive for some 
compounds including other 4-aminoquinolines. The CQ uptake consisted of both 
saturable and non-saturable components. The initial, saturable phase of drug uptake is 
characterised by high-affinity, low-capacity uptake which is saturated at an external CQ 
concentration of 100 nM (Hawley et al., 1996). This finding suggests that a mechanism 
other than passive diffusion and proton-trapping is responsible for CQ uptake and 
accumulation in P. Jalciparum. The second non-saturable phase is distinguished by a 
low-affinity, high-capacity component. 
The massive influx of CQ into the parasite digestive vacuole is expected to 
overcome the vacuolar proton pump and raise the pH (Homewood et al., 1972). Early 
attempts to measure pH in P. Jalciparum acid vesicles (Krogstad et al., 1985) gave values 
very similar to that of lysosomes in mammalian cells (MacIntyre and Cutler, 1993). 
Studies with mammalian cells have found that an external CQ concentration of 100 JlM 
increases the pH from approximately 5.0 to 6.0 (Ohkuma and Poole, 1978), compared to 
CQS parasites which are killed at 10 - 30 nM in vitro. This suggests that malaria 
trophozoites must be in the order of 104 times more sensitive than mammalian cells to 
CQ-induced increases in vacuolar pH (Slater, 1993). Krogstad et al. (1992) have 
subsequently estimated that the malaria vacuole accumulates CQ about 600-fold more 
than mammalian cells, which is more than can be accounted for by its weak base 
properties alone. These results could point to an active drug transporter or some other 
concentrating mechanism. 
As an addition to the proton-trapping theory proposed by Homewood et al. 
(1972), Warhurst (1986) suggested the presence of a CQ importer pump or permease on 
the plasma or digestive vacuole membrane. This permease would be influenced by an 
ATP-dependent proton gradient similar to those found in bacterial transport systems. The 
hypothesis requires that the cytoplasm of the RBC should be maintained at a pH below 
Chapter 1: General Introduction 30 
that of the parasite cytoplasm. Studies of the cytoplasmic pH of infected RBC have 
reported values of 6.8 in P. Jalciparum (Friedman et al., 1979) and pH values as low as 
6.6 in P. chabaudi (Mikkelsen et al., 1982) - far lower than the pH of 7.2 in uninfected 
RBC (Warhurst, 1986). These values correlate well with the pH of 6.9 in an infected 
RBC reported earlier by Yayon et al. (1984). It is unlikely that the passage of CQ from 
the extracellular medium (PH 7.4), through the acidic RBC compartment (PH 6.6), 
followed by the alkaline parasite cytosol (PH 7.6), and ultimately to the acidic vacuole 
(pH 5.0) would be possible. The protonated drug would have to diffuse from an area of 
high proton concentration (acidic erythrocyte) into an area of low proton concentration 
(parasite cytosol) and this would be difficult without the presence of a permease on the 
parasite membrane (Warhurst, 1986). However, the above hypothesis has been opposed 
and the compartmental pH values used scrutinised (Ginsburg and Geary, 1987). 
Furthermore, the pH of the parasite cytosol has been recently re-assessed by a variety of 
groups using pH-sensitive fluorescent indicators and estimated to be -7.3 (Bosia et al., 
1993; Wunsch et al., 1998; Saliba and Kirk, 1999; Hayashi et al., 2000); although the pH 
in the region of the infected RBC cytoplasm immediately adjacent to the parasite has 
been estimated to be -6.9 (Hayashi et al., 2000) which points to a small but significant 
inward H+ electrochemical gradient (Saliba and Kirk, 2001). 
Recent work by Sanchez et al. (1997) and Wiinsch et al. (1998) pointed to a 
plasmodial Na + /H+ exchanger (NHE) mediating the import of CQ. They demonstrated 
that there were altered saturation kinetics between CQS and chloroquine-resistant (CQR) 
parasites and that CQ uptake was inhibited competitively by specific inhibitors of the 
NHE. The P. Jalciparum NHE resides in the plasma membrane of the parasite and plays 
an essential role in maintaining the cytosolic pH and regulating the cell volume by 
exchanging excess protons for sodium ions (Bosia et al., 1993). The amiloride analogue, 
EIP A, is a specific and reversible inhibitor of eukaryotic NHE (Wunsch et al., 1998) and 
has been shown to inhibit the plasmodial NHE, resulting in intracellular acidification 
(Bosia et al., 1993). EIP A was observed to reduce CQ uptake in a dose dependent 
manner (Sanchez et al., 1997) allowing the authors to conclude that CQ import is 
mediated by a NHE, and both CQ and EIP A compete for the binding domain on the NHE 
(Sanchez et al., 1997). It was initially suggested that CQ is directly transported by the 
NHE in place of sodium in exchange for protons (Sanchez et al., 1997), but the 
hypothesis was modified to suggest that CQ is carried through the NHE in a burst of self-
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stimulated exchange between sodium and protons (WUnsch et al., 1998). 
Electrophysiological studies by these authors lends support to this proposal as CQ import 
is associated with cytoplasmic alkalisation inhibitable by EIPA (WUnsch et al., 1998). 
Bray and co-workers (Bray et al., 1998; Raynes et al., 1999; Bray et al., 1999a; 
Bray et al., 1999b) found that drug uptake was the same in sodium-deficient medium 
which questioned the NHE model. Bray et al. (1999a) suggested that the amiloride 
analogue inhibition of CQ uptake occurs because they compete for the binding of CQ to 
FPIX rather than due to NHE inhibition. This leads us to the further role of CQ binding 
to FPIX. 
1.2.1.1.5 Chloroquine-ferriprotoporphyrin IX binding 
The proton trapping mechanism probably does not account for the full extent of 
CQ or AQ accumulation by P. [alciparum as other eukaryotic cells with large acidic 
compartments accumulate lower amounts ofCQ (Warhurst, 1985; Krogstad et al., 1992; 
MacIntyre and Cutler, 1993). The work of Slater and Cerami (1992) lent support to the 
CQ-FPIX binding hypothesis. The authors showed that in vitro polymerisation of FPIX 
was inhibited by CQ at concentrations in the high micromolar to low millimolar range. 
The ability of CQ to inhibit FPIX polymerisation in both synthetic and parasite cell-free 
systems has since been confirmed by a number of groups (Chou and Fitch, 1993; Egan et 
al., 1994; Dom et al., 1995). 
It was initially thought that the amount and rate of FPIX production by the 
parasite were insufficient to account for total CQ uptake by the infected RBC (Raynes et 
al., 1999). Bray et al. (1998) reported that a large proportion of the total CQ uptake is 
non-saturable and only the saturable portion of uptake is relevant to the antimalarial 
properties of the drug. Thus, the saturable component of drug uptake is relevant to FPIX 
production, as reviewed by Raynes et al. (1999): 
1) The kinetics of FPIX production and CQ-FPIX binding agree with the measured 
rates of CQ uptake (Bray et al., 1998) based on accepted kinetics of Hb 
degradation (Goldberg et al., 1990). 
2) Saturable CQ accumulation is retained in cell debris of lysed infected cells pre-
loaded with CQ. This accumulated CQ could only be displaced with other FPIX-
binding drugs (Bray et al., 1998; Bray et al., 1999a). As there is no membrane 
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integrity, saturation has to be explained without the use of proton-trapping, 
diffusion or active transport. Furthermore, purified digestive vacuole extracts can 
generate CQ binding sites in a cell-free system using Hb as a substrate, and this 
process can be inhibited by plasmepsin inhibitors (Bray et al., 1999a). 
3) Plasmepsin inhibitors reversibly inhibit the saturable uptake of CQ into infected 
RBC (Bray et al., 1999a). Two aspartic proteases, plasmepsins I and II, and one 
cysteine protease, have been purified from P. Jalciparum digestive vacuoles. Both 
plasmepsin enzymes have been shown to cleave Hb at the domain responsible for 
holding the tetramer together, and hence unravel Hb allowing further degradation 
by other proteases. This is the same site of initial cleavage as digestive vacuole 
extracts, alluding to the suggestion that these enzymes playa major role in the 
ultimate production of FPIX (Francis et al., 1997). These inhibitors antagonised 
CQ uptake and antiplasmodial activity indicating the importance of CQ-FPIX 
binding to the antimalarial effect of CQ (Mungthin et al., 1998; Bray et al .. 
1999a). 
4) The local pH at the binding site is important as the plasmepsins have pH optima 
near 5. The proton pump inhibitor, bafilomycin AI, prevents Hb digestion in the 
intact cell which suggests that acid conditions are necessary to reveal the drug 
target (Francis et al., 1997). CQ accumulation is, in addition, inhibited by 
lysosomotropic compounds including high concentrations of ammonium chloride, 
due to the ability of these compounds to elevate vacuolar pH. This could decrease 
plasmepsin activity, ultimately resulting in reduced CQ-FPIX binding (Raynes et 
al.. 1999) 
1.2.1.2 Mode of action of chloroquine 
There are many different hypotheses and proposals to explain how chloroquine 
exerts its antimalarial activity. Many of the hypotheses are directly related to 
accumulation of the drug, but others have no correlation at all. A clear and proven 
hypothesis on the mode of action of CQ would allow further research into identifying 
and inhibiting the vulnerable target(s} within the parasite. 
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1.2.1.2.1 DNA and RNA damage 
Early studies by Parker and Irvin (1952) showed that a number of quinolines 
inhibited DNA replication and RNA synthesis by interacting with DNA in vitro, and thus 
inhibit essential cellular functions (Cohen and Yielding, 1965). Additionally, the drug 
was also shown to inhibit both RNA and DNA synthesis in bacterial cells (Cohen and 
Yielding, 1965). Subsequent studies (Hahn et al., 1966; O'Brien et al., 1966a; O'Brien et 
al., 1966b; Kwakye-Berko and Meshnick, 1990) revealed similar effects. However, the 
CQ-induced ribosomal RNA degradation in P. knowlesi did not occur until the pigment 
clumping was complete (Warhurst and Williamson, 1970). The binding of CQ to 
bacterial DNA and RNA, inhibits DNA and RNA polymerases at concentrations above 
100 ~M (Cohen and Yielding, 1965; Slater, 1993). However, the unexplained specificity 
for the parasite DNA over the host DNA was a concern since CQ also interacts well with 
mammalian DNA (Cohen and Yielding, 1965). There is an enormous difference (over a 
thousand fold) in external CQ concentration which exerts toxic effects on malarial 
parasites and those which damage DNA replication machinery (Slater, 1993; Foley and 
Tilley, 1998). In view of the AT-richness of the plasmodial DNA, parasites would be 
expected to be less susceptible to CQ since CQ has been shown to interact more strongly 
with GC-rich DNA (Kwakye-Berko and Meshnick, 1990; Foley and Tilley, 1998). 
Further work (Kwakye-Berko and Meshnick, 1989; Kwakye-Berko and Meshnick, 1990) 
confirmed that CQ binding to DNA is highly dependent on salt concentrations and that 
there are enough binding sites on plasmodial DNA to support the CQ-DNA intercalation 
antimalarial activity ofCQ, but the affinity is low. 
More recent studies on plasmodial enzymes involved in DNA replication have 
not shown any evidence of being direct targets of CQ (Foley and Tilley, 1998). Other 
quinolines such as QN can interact with DNA (albeit at a lower affinity than CQ) 
although MQ does not measurably bind to DNA (Davidson et al., 1975). It is commonly 
thought that all the quinoline-derivatives have a common mechanism of action which is 
supported by biological data. The varying affinity of the quinolines to bind to DNA 
questions DNA binding as their main mode of action (Slater, 1993). 
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1.2.1.2.2 Inhibition of haemoglobin degradation 
CQ is active against the stages of the malaria parasite which are degrading Hb 
and the drug accumulates in the digestive vacuole - the same site for the RBC Hb 
degradation (see Section 1.2.1.1). Zarchin et al. (1986) originally observed that the 
quinoline drugs, CQ, MQ and QN, inhibit amino acid release from infected RBC at the 
same concentrations at which they inhibit parasite growth. Additionally, the rate of CQ 
accumulation was shown to be directly related to the rate of amino acid production which 
increases with parasite age; and both these rates were inversely related to the inhibitory 
effects of the drug. Furthermore, it was noted that the lysosomotropic agents 
methylamine and ammonium chloride also inhibited amino acid production. The authors 
suggested that this degradation process is pH dependent, localised in the digestive 
vacuole and that metabolically dependent acidification of the vacuole is imperative. CQ 
accumulates to a high concentration within the parasite digestive vacuole (see Section 
1.2.1.1.1). The protonation of CQ depletes the vacuole of protons and raises the pH from 
around 5.2 to above 6.0. pH values exceeding 6.2 will be inhibitory to vacuolar proteases 
resulting in the parasite's inability to degrade Hb and hence will be starved of amino 
acids (Homewood et al., 1972; Slater, 1993). 
The quinolines have also been reported to have phospholipase inhibiting 
properties (Slater, 1993). As the endocytic vesicles accumulate in the digestive vacuole 
following CQ exposure (see Section 1.2.1.1.1), it is possible that CQ inhibits the 
phospholipase enzymes responsible for degrading the inner membrane of the endocytic 
vesicle. In mammalian cells in vitro, CQ reduced the uptake of acid hydro lases into the 
lysosome by impairing binding at the cell surface and also impaired the recycling of the 
putative receptors necessary for lysosomal enzyme uptake (Gonzalez-Noriega et al., 
1980). For malaria parasites, this would result in the inhibition of endocytosis and amino 
acid deprivation (Ginsburg and Geary, 1987). It has also been suggested that CQ can 
inhibit Hb degradation directly by blocking vacuolar proteases such as an aspartic 
protease (Slater, 1993). 
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1.2.1.2.3 The role of chloroquine in detoxification of FPIX or haem 
Free haem released from the digestion ofHb - either in the form ofFPIX or haem 
(Fell) - has at least four potential outcomes in the infected RBC: 1) dimerisation into 
haemozoin; 2) further degradation within the digestive vacuole; 3) translocation across 
the lysosome membrane and detoxification within the parasite cytosol; or 4) remaining 
bound to serum albumin or haemopexin (Ginsburg et al., 1998; Loria et al., 1999). 
Ginsburg et al. (1998; 1999) have proposed an alternative model of the 
antimalarial action of CQ based on its ability to inhibit FPIX degradation by glutathione. 
The model is based on the assumption that if the rate ofhaemozoin production is smaller 
than the rate of FPIX production, there must be an alternative mechanism for the 
detoxification of FPIX. A previous report has indicated that only 50% of the FPIX was 
polymerised into haemozoin in P. berghei (Wood and Eaton, 1993). Ginsburg and co-
workers (Ginsburg et al., 1998; Zhang et al., 1999) analysed the decline in Hb content 
with the amount of haemozoin produced in P. falciparum and could only show about 
30% of the FPIX was converted into haemozoin at the mid-term trophozoite stage. They 
suggested that non-polymerised FPIX exists in the digestive vacuole, translocates the 
vacuole membrane and is subsequently degraded by reduced glutathione in the parasite 
cytosol (Ginsburg et al., 1998; Zhang et al., 1999). Atamna and Ginsburg (1995) 
previously demonstrated that FPIX can be very rapidly degraded by reduced glutathione 
at an optimum pH 7 and that this degradation can proceed even when FPIX was 
dissolved in RBC membranes (Famin et al., 1999). Later, it was reported that both CQ 
and AQ were able to competitively inhibit FPIX degradation by reduced glutathione, 
whether the FPIX is in solution, non-specifically bound to protein, or dissolved in 
parasite membranes; and this inhibition resulted in the increase of membrane-associated 
FPIX in a dose- and time-dependent manner. A direct relationship between the 
membrane accumulation of FPIX and the extent of parasite killing was shown at 
concentrations of CQ and AQ equivalent to the ICso values (Ginsburg et al., 1998; Famin 
et al., 1999). The hypothesis therefore states that CQ would inhibit the ability of reduced 
glutathione to degrade cytosolic FPIX and this would result in the accumulation of FPIX 
in the membranes of infected RBC leading to ion homeostasis, disruption and cell death. 
According to the hypothesis of Loria et al. (1999), only about one third of the 
haem produced by the maturing parasite is polymerised into haemozoin and the 
remainder appears to be degraded in the digestive vacuole by a non-enzymatic process. 
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This process is possibly through the action of H202 which leads to an accumulation of 
high levels of iron within the parasite. The H20 2 is produced by the autoxidation of haem 
(FeU) released from Hb, to FPIX (FeUI) at the acidic pH of the digestive vacuole, 
producing a superoxide anion. The H20 2 reacts with and degrades the protoporphyrin 
ring and decomposes itself. CQ forms a complex with the FPIX inhibiting the 
peroxidative decomposition of FPIX and this enhances the accumulation of toxic FPIX 
and CQ-FPIX complexes. 
Using chemical analysis, Mossbauer spectroscopy, electron spectroscopic 
imaging and transmission electron microscopy, Egan et al. (2002) recently reported that 
at least 95% of the iron observed within the trophozoite is incorporated into haemozoin. 
This is strong evidence demonstrating that the formation of haemozoin represents the 
major haem-detoxification pathway of P. Jalciparum. 
1.2.1.2.4 Inhibition of haem polymerisation and related enzymes 
Early observations suggested that the mode of action of CQ somehow interferes 
with the parasite's digestive process (Macomber and Sprinz, 1967; Warhurst and 
Hockley, 1967a). It had been shown earlier that CQ can form a tight complex with FPIX, 
the affinity is high, and stoichiometrically the complex contained 2 FPIX to 1 CQ 
molecule (Cohen et al., 1964; Chou et al., 1980). QN alternatively forms a complex with 
FPIX with a stoichiometry of 1 to 1 whilst epiquinine, the antimalarially inactive epimer 
of quinine, does not form a complex with FPIX (Warhurst, 1981). 
Slater and Cerami (1992) demonstrated, using a trophozoite extract, that the 
polymerisation of FPIX was inhibited by CQ and QN in vitro in the high micromolar to 
low millimolar range - in addition AQ, MQ and PPQ have also been shown to inhibit 
polymerisation (Slater, 1993). This strengthened the suggestion that the CQ-induced 
inhibition of FPIX polymerisation into haemozoin leads to a toxic build-up of CQ-FPIX 
complexes and FPIX within the parasite (Fitch, 1986; Foley and Tilley, 1998). 
Subsequently, Chou and Fitch (1992; 1993) confirmed the inhibition of FPIX 
polymerisation by CQ in P. berghei and observed a decrease in the amount ofhaemozoin 
formed when these infected RBC were treated with CQ. However, these effects were 
relatively small and it has been argued that the inhibition of FPIX polymerisation is 
secondary to parasite killing (Asawamabasakda et al., 1994b). Furthermore, the 
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concentration ofCQ needed to inhibit haemozoin polymerisation is several thousand-fold 
greater than the ICso of the drug, although the drug does accumulate to a high 
concentration within the digestive vacuole (Slater, 1993; Foley and Tilley, 1998). 
There are three proposed mechanisms for the inhibitory effect of CQ (Pagola et 
ai., 2000): 1) direct binding of the drug to FPIX in solution thereby interfering with the 
crystallisation of haemozoin (Egan et ai., 1994; Dorn et ai., 1998); 2) chemi-absorption 
of the drug onto crystallised haemozoin, leading to inhibition of further FPIX 
aggregation (Sullivan et ai., 1998); and 3) enzymatic inhibition of a protein that catalyses 
haemozoin crystallisation (Slater and Cerami, 1992). 
Hypotheses in the first category originally proposed that CQ exerts its action by 
binding to the FPIX within the digestive vacuole thereby capping the FPIX molecule, 
preventing polymerisation and hence haemozoin formation (Slater, 1993; Sullivan et ai., 
1996b; Sullivan et ai., 1998; Dorn et ai., 1998). It was also shown that CQ does not bind 
to isolated haemozoin and will only bind measurably to haemozoin in the presence of 
haem (Sullivan et al., 1996b). Pagola et al. (2000) established that haemozoin is not a 
coordination polymer but a series of dimers linked by hydrogen bonds, and that the 
dimerisation cannot be stopped at a single site as if it were a continuous polymer. 
However, the binding of CQ to FPIX molecules in order to prevent dimserisation would 
require many CQ molecules. Sullivan et al. (1996b; 1998) have emphasised that the 
origin of antimalarial activity of CQ lies within the ability of forming a surface-drug 
interaction in the CQ-FPIX complex. Pagola et ai. (2000) have proposed that since both 
natural and synthetic malaria pigment crystallize as long thin needles, these relatively 
small, fast-growing faces could be the site of CQ surface adsorption and hence action. 
The surface area of the growing faces of haemozoin crystallites is entirely consistent 
with the estimate of surface area coverage for the final crystallites. Therefore, for 
crystallites formed and growing in the young trophozoites, there will be more than 
sufficient chloroquine to ensure complete surface coverage. This hypothesis of a surface 
adsorption process limiting new haem uptake has not yet been tested experimentally. 
The third category of models suggests that a protein or haem polymerase 
mediates FPIX polymerisation into haemozoin, and that the action of CQ is to inhibit this 
process (Slater and Cerami, 1992). Other workers have showed that CQ inhibits the 
growth of haemozoin in vitro and argued against the enzyme-mediated FPIX 
polymerisation model. Egan et ai. (1994) demonstrated the spontaneous polymerisation 
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of FPIX into /3-haematin (synthetic haemozoin) in vitro between 6°C and 65°C, in 0.1 -
4.5 M acetate and pH 4.2 - 5.0; and CQ, QN and AQ were found to block the /3-haematin 
formation. These authors concluded that the formation of haemozoin does not require a 
haem polymerase, but suggested that spontaneous polymerisation of FPIX might be the 
main target for these antimalarial drugs. Their observations were subsequently confirmed 
by Dom et al. (1995) showing that CQ inhibition ofhaemozoin or /3-haematin production 
was identical in trophozoite lysate, and in artificial systems with no protein or parasite 
material. Exposure of the parasite lysates to a variety of proteases had no effect; and the 
parasite extracts retained their activity at 4 °C for several weeks - even after boiling. 
Dom et al. (1998) later suggested that the binding of CQ inhibits polymerisation by 
shifting the FPIX dimerisation equilibrium to the Jl-oxo dimer, thus reducing the 
availability of monomeric FPIX for incorporation into haemozoin. However, the 
isolation of the parasite extract fractions with unambiguous activity to form haemozoin 
has been disputed, and the role of enzymes is uncertain (Pagola et al., 2000). Raynes et 
al. (1996) have argued that the rate of polymerisation under assumed intravacuolar 
conditions was too slow to account for the known efficiency of FPIX disposal and an 
extra polymerising component is required in vivo. It has also been reported that P. 
falciparum histidine-rich protein II is capable of binding to FPIX and has also been 
shown to initiate polymer formation (Sullivan et al., 1996a), although strains which 
cannot produce these proteins still produce haemozoin (Francis et al., 1997). 
1.2.2 The other quinolines and related compounds 
1.2.2.1 Mode of action of the 4-aminoquinoline amodiaquine 
AQ is closely related to CQ, differing only by having a p-hydroxyanilino 
aromatic ring in its side chain (Figure 1.3). AQ has similar blood schizontocidal 
properties to CQ and was widely used in the past to treat and prevent malaria. AQ has 
been shown to be at least two-fold more active than CQ in vitro against growing P. 
falciparum (Spencer et al., 1983; Ekweozor et al., 1987); however, it is rapidly 
metabolised in vivo to desethylamodiaquine which has been estimated to be over three-
fold less active in vitro than AQ (Childs et al., 1989). One of the major advantages of 
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AQ over CQ is the greater efficacy in the treatment of cases involving CQR strains 
(Spencer et a/., 1983; Looareesuwan et a/., 1985); and it has retained its potency in some 
areas of Africa where there is CQ resistance, but efficacy does vary (Olliaro et a/., 1996). 
However, due to the toxic side effects during treatments and the adverse drug reactions 
reported by travellers using AQ as a prophylaxis, the WHO advised against using the 
drug in malaria control programmes (Olliaro et a/., 1996). This has caused much 
confusion over the safety of the drug, but more recent reports claimed that the drug is 
safe, tolerable and highly effective (Adjuik et a/., 2002) As a treatment regimen the drug 
seems to be no more toxic than CQ or SP when used as a treatment (Olliaro et a/., 1996). 
Hawley et at. (1996) demonstrated that AQ is accumulated more efficiently than 
CQ and this uptake is similar to that reported for CQ viz.: biphasic pattern of 
accumulation; energy, temperature and pH dependent; saturable low-capacity, high-
affinity (initial uptake) component; and reduction by ammonium chloride and other 
lysosomotropic agents. These observations supported Fitch's (1973) initial findings of 
AQ competitively inhibiting CQ accumulation and suggestion that these compounds 
share a similar uptake mechanism. In contrast, AQ does have significant differences to 
CQ. Like CQ, it is a weak base but it has lower pKa values (PKa\ = 7.1 for quinoline ring 
nitrogen, pKa2 = 8.1 for side chain terminal nitrogen) so that according to the proton-
trapping mechanism, the drug might be expected to be accumulated less efficiently in the 
parasite vacuole (Hawley et a/., 1996; Foley and Tilley, 1998). At physiological pH, 
unlike CQ, AQ is -52% monoprotonated and only -32% diprotonated; although both 
drugs are essentially diprotonated at the vacuolar pH. This indicates that absolute AQ 
accumulation levels cannot be fully explained by the proton-trapping mechanism alone 
and there has to be another accumulating factor (Hawley et a/., 1996). The accumulation 
of AQ has been shown to be 2- to 3-fold greater than CQ in a CQS parasite (Hawley et 
a/., 1996), and this could be related to the 2- to 4-fold lower AQ ICso seen in CQS 
parasites compared to their CQ ICso (Spencer et al., 1983; Ekweozor et a/., 1987; 
Hawley et a/., 1996). Binding to FPIX seems the likely target accounting for the 
additional accumulation by AQ (Hawley et al., 1996); and the role of CQ binding to 
FPIX thereby influencing its uptake, has been reported in detail (see Section 1.2.1.1.5; 
Bray et a/., 1999a). At the digestive vacuolar pH -5, the proportion of molecules of AQ 
with unprotonated quinoline ring nitrogen is over 10-fold greater than for CQ. Bray, 
Chapter 1: General Introduction 40 
Ward and colleagues proposed an increased affinity of AQ for FPIX due to additional 11"-
11" interactions. 
1.2.2.2 The bisquinolines 
The bisquinolines are compounds that contain two quinoline nuclei combined 
through an aliphatic or aromatic linker. Piperaquine (PPQ; Figure 1.3) and its analogues 
have been shown to be potent against CQS and CQR parasites in vitro (Chen et al., 1982; 
Le Bras et al., 1983; Chen, 1991; Raynes, 1999). Certain unique bisquinolines are toxic 
in mice, but analogues have shown longer duration of action and few signs of toxicity 
(Vennerstrom et al., 1992). PPQ and its derivative hydroxypiperaquine have shown very 
little toxicity at the curative doses and clinical trials have proved the drugs to be tolerable 
and successful candidates for further studies (Chen, 1991; Raynes, 1999). 
1.2.2.3 The arylaminoalcohols: quinine, mefloquine, halofantrine and 
lumefantrine 
On the basis of structure (which includes only one electronegative nitrogen atom; 
Figure 1.3) and their effect on the parasite, the more lipophilic arylaminoalcohols differ 
from the 4-aminoquinolines (Warhurst and Thomas, 1975; Warhurst, 1987). At 
physiological pH, the ring nitrogen and tertiary amine nitrogen of CQ are both 
protonated giving a net charge of +2. With MQ, as an example, the pKa of the aromatic 
nitrogen is below 2, so that only the secondary amine is protonated at pH 7.4 giving a net 
charge of +1 for the molecule (Vanderkooi et al., 1988). The arylaminoalcohols are 
lipophilic drugs which bind tightly to serum components, including high-density 
lipoproteins (Mu et al., 1975; Desneves et al., 1996; Colussi et al., 1999; Go and Feng, 
2001). These drugs do not cause pigment clumping in P. berghei trophozoites but 
competitively inhibit the CQ induced pigment clumping. The drugs also cause swelling 
of digestive vesicles and parasite membranes, cytoplasmic degeneration, and a decrease 
in the pigment density (Davies et al., 1975; Peters et al., 1977). Additionally, 
arylaminoa1cohols display an inverse relationship with 4-aminoquinolines in their 
antimalarial activity against CQR parasite lines (Olliaro, 2001). 
QN acts primarily as a blood schizontocide and has little effect on sporozoites or 
pre-erythrocytic stages of the parasite. Over the last 50 years the use of QN has been 
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declining due to the development of the more potent 4-aminoquinolines (Raynes, 1999). 
Worldwide, QN is used mainly as a parenteral first-line treatment for severe falciparum 
malaria. It can be used as an oral treatment for uncomplicated malaria, but its efficacy in 
the treatment of uncomplicated malaria in parts of Thailand and Cambodia when used 
alone has declined in the last few years to only -50% (Price et al., 1999). It has low 
potency, a small therapeutic index and a range of side effects. It is relatively safe, but 
overdoses can be serious. In combination with either tetracycline or doxycycline it is an 
excellent drug for the treatment of uncomplicated malaria (Winstanley, 2001). 
MQ is used as a prophylactic and treatment agent but is very expensive and thus 
not widely used in Africa. It is highly effective against multidrug-resistant strains. 
Serious adverse reactions are rare, although dose-dependent symptomatic reactions, such 
as upset stomach and dizziness, are common. Other side effects of the drug are its ability 
to precipitate fonns of psychosis, e.g. delirium, hallucinations in non-predisposed 
patients taking prophylactic doses ofthe drug (Winstanley, 2001). 
HAL is highly effective against multidrug-resistant strains. A senous 
shortcoming of the drug is poor and variable absorption after oral treatment which 
compromises its clinical efficacy. There have been concerns that low serum 
concentrations could lead to the emergence of drug-resistant strains (Go and Feng, 2001). 
The drug is said to be cardio-toxic and has been associated with some cases of sudden 
death (Nosten et a/., 1993; Winstanley, 2001; Bindschedler et al., 2002). 
Lumefantrine (LM) or benflumeto1 is exclusively used in combination with 
artemether (as coartemether) to treat uncomplicated falciparum malaria. It is well-
tolerated, eliminated very slowly and has a similar phannacokinetic profile to HAL, but 
little is known about its mode of action or drug reactions (Ezzet et al., 2000; Winstanley, 
2001). LM has some similar chemical and biological similarities to HAL, such as similar 
variable absorption, but does not share any similar cardiac adverse reactions (Ezzet et al., 
2000; Bindschedler et a/., 2002). 
1.2.2.4 Mode of action of the arylaminoalcohols 
The interaction of both QN and MQ with FPIX appears to be different to that of 
CQ. The affinity of these drugs for FPIX is 103_ to 104-fold lower than CQ (Chou et al., 
1980) however, they are active at the 10 to 100 nM external concentration which 
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questions Fitch's (1969; 1970) proposal that drug-FPIX complex fonnation drives their 
accumulation (Slater, 1993). According to the weak base effect or proton-trapping 
proposal, the monobasic drugs, QN and MQ, would not accumulate sufficiently within 
the food vacuole to reach concentrations required for the inhibition of FPIX 
polymerisation. Calculating the level of accumulation using the charge on the drug, the 
monobasic drugs are only predicted to be concentrated in the digestive vacuole about 
200-fold (Yayon et al., 1984; Ginsburg et at., 1989; Foley and Tilley, 1998). Conversely, 
MQ is more potent an antimalarial than CQ, and the distribution ratio of the pH-
dependent MQ uptake between the medium and parasitised RBC has been shown to be 
-3-fold greater than for CQ, leading to the suggestion that the accumulation of these 
drugs is enhanced by a secondary active transport system (Vanderkooi et al., 1988), MQ-
binding parasite proteins (Desneves et al., 1996) or that these drugs have additional sites 
of action within the parasite (Geary et al., 1986a). Ginsburg et al. (1989) proposed that 
the monoprotic drugs MQ and QN mostly exert their effect of raising the digestive 
vacuole pH (see Section 1.2.1.1.3) by crossing the membrane into the vacuole as a 
protonated molecule (i.e. translocating protons across the vacuolar membrane) as 
opposed to diprotic CQ which raises the pH by proton-trapping. Both QN and MQ 
competitively inhibit CQ uptake, and vice versa, suggesting a similar mode of 
accumulation (Fitch et al., 1979). 
As with both QN and MQ, HAL does not induce pigment clumping; but competes 
with CQ inhibiting the CQ-induced pigment clumping and reverses the process (Einheber 
et al., 1976). Ultrastructural changes after HAL exposure in P. berghei include: 
mitochondrial swelling, pigment changes, damage to digestive vacuole, and damage to 
the haemozoin and cytoplasm (Peters et al., 1987). Based on these points, Peters and co-
workers have suggested that HAL could have a similar mode of action as MQ or QN. 
It has been suggested that the mode of action of MQ relates to its ability of both 
membrane impainnent and pH gradient dissipation observed in Escherichia coli cells 
(Brown et at., 1979) and membranes (Nissani and Ginsburg, 1989), respectively. The 
unprotonated fonn of MQ has been shown to destabilise phospholipids within parasite 
membranes and the drug can cause RBC lysis at relatively low concentrations, while QN 
has no lysing ability even at millimolar concentrations (Ginsburg and Krugliak, 1988). 
MQ binds with high affinity to membranes (Chevli and Fitch, 1982) and uninfected RBC 
(Mu et at., 1975; Fitch et al., 1979; Chevli and Fitch, 1982; San George et al., 1984). By 
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contrast, CQ is only taken up to a very limited degree by RBC (Fitch et al., 1979). This 
high-affinity binding of the drug to many proteins probably contributes to the slow 
metabolism and long half-life of the drug (Mu et al., 1975). Along with its ability to bind 
to serum proteins (Mu et al., 1975), it has been suggested that this may facilitate the 
delivery ofMQ (Foley and Tilley, 1998) and HAL (Go and Feng, 2001) to the parasite, 
as P. falciparum has been shown to accumulate lipids and other hydrophobic molecules 
from the serum (Grellier et al., 1991; Berman et al., 1994). Using a photoreactive 
quinolinemethanol analogue which closely mimics the action of MQ, Desneves et al. 
(1996) studied MQ-interacting proteins and showed that MQ specifically interacts with 
apo-A1, the major protein of high density lipoproteins. In addition, MQ was reported to 
interact with RBC membrane protein 7.2b (stomatin) and two other proteins with a 
molecular mass of22 kDa and 36 kDa. It was suggested that these proteins may be either 
involved in MQ uptake or targets of the antimalarial mechanism ofMQ in the parasites. 
In conclusion, Foley and Tilley (1997) have postulated that the quinolinemethanols may 
exert their action on the parasite by disrupting the membrane trafficking events involved 
in the uptake of metabolites and that the drugs could target proteins which playa role in 
trafficking pathways. 
1.2.3 Antifolates 
The antifolate drugs (Figure 1.4) inhibit enzymes of the protozoan folic acid 
biosynthetic pathway. Folate synthesis is essential to malaria parasites as they are unable 
to obtain pyrimidines from their host. Folate is an essential cofactor in substitutions of a 
single carbon. Two stages of the pathway leading to tetrahydrofolate are targeted. The 
precursor p-aminobenzoic acid (PABA) reacts with pteridine in the formation of 
dihydropteroate which is catalysed by dihydropteroate synthase (DHPS). This IS 
subsequently condensed with glutamate to form dihydrofolate. Tetrahydrofolate IS 
ultimately produced from dihydrofolate and NADPH by the enzyme dihydrofolate 
reductase (DHFR). Blocking the biosynthesis of folate results in decreased synthesis of 
pyrimidines and blockage of DNA replication, as well as decreased methionine synthesis, 
and reduced conversion of serine to glycine (Foote and Cowman, 1994; Cowman, 1995; 
Warhurst, 1998). The antifolates (particularly in combination with DHPS antagonists) 
are effective against all growing stages ofthe parasite: on liver pre-erythrocytic schizonts 
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(causal prophylactic action), on blood schizonts, and on oocysts in the mosquito vector 
(sporontocidal action; Warhurst, 1999). 
The sulfonamide drugs act on the pathway by mimicking PABA and therefore 
inhibit the production of dihydropteroate by DHPS. Sulfadoxine (SDX) is the most 
frequently used sulfonamide in the treatment of malaria (Foote and Cowman, 1994; 
Cowman, 1995). These drugs are usually used in combination with DHFR inhibitors to 
achieve a synergistic blockade of sequential enzymes in the same metabolic pathway and 
to delay the onset of resistance. A combination of sulfadoxine with pyrimethamine 
(Fansidar®; SP) is commonly used as a second-line treatment in areas with chloroquine 
resistance (Warhurst, 1999). The combination is now replacing CQ as a first-line 
treatment regimen in countries where CQ usage has been withdrawn, e.g. Kenya (Omar 
et al., 2001b). 
The DHFR inhibitors pyrimethamine (PYR) and proguanil (PG) are the most 
commonly used antifolate drugs in malaria treatment, but resistance to both is now 
widespread. PG by itself has weak antimalarial activity and is often referred to as a 
prodrug which is converted to the active triazine metabolite cyc10guanil in the liver. PG 
is a highly protein-bound molecule which is concentrated in RBC, with intracellular 
concentrations exceeding five times the plasma concentrations (Ramanaiah and 
Gajanana, 1988; Baggish and Hill, 2002). PYR or cyc10guanil binds to the hydrophobic 
groove of the active site of DHFR and competitively inhibits the binding of 
dihydrofolate, thus preventing the fonnation oftetrahydrofolate (Warhurst, 1998). 
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Figure 1.4: Structures of the folate antagonists and atovaguone. 
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Atovaquone (ATV; Figure 1.4) is a hydroxynaphthoquinone with broad-spectrum 
antiprotozoal activity. It is a highly lipophilic molecule and structural analogue of 
protozoan ubiquinone (also known as co-enzyme Q), a mitochondrial quinone involved 
in electron transport. ATV is protein bound (> 99%) and there have been problems with 
the drug due to poor and unreliable bioavailability, but it causes no significant 
displacement of other highly protein-bound drugs. ATV is also used against 
Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS (Baggish and 
Hill, 2002). Unfortunately, in clinical trials alone against P. falciparum malaria, ATV 
displayed -30% treatment failures and there are reports of rapid emergence of resistant 
parasites (Chiodini et al., 1995; Looareesuwan et al., 1996). Recrudescent parasites show 
approximately lOOO-fold resistance to ATV (Looareesuwan et ai. , 1996) leading to the 
suggestion of using ATV in combination with a synergistic agent such as PG (Canfield et 
ai. , 1995). Clinical trials of the combined drugs have been very encouraging with cure 
rates approaching 100% with few cases of resistance (Looareesuwan et ai. , 1996; Radloff 
et al.. 1996a; Srivastava and Vaidya, 1999). This has led to the recent introduction of 
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Malarone® (GlaxoSmithKline; atovaquone and proguanil hydrochloride) as a new drug 
combination for the treatment (Looareesuwan et al., 1999; Llanos-Cuentas et al., 2001) 
and prophylaxis (Hogh et al., 2000; Overbosch et al., 2001) of uncomplicated falciparum 
malaria. 
1.2.4.1 Mode of action of atovaquone 
The mitochondrion in the malaria parasite is the site of many important 
physiological activities such as oxidative phosphorylation and the metabolism of 
molecules such as amino acids and lipids. Mitochondria also act as an electron disposal 
site for the many electrons produced by dihydroorotate dehydrogenase - an enzyme 
located in mitochondria essential for pyrimidine biosynthesis. This enzyme could be said 
to bridge pyrimidine synthesis and the mitochondrial electron transport system. Proteins 
involved in the above functions are encoded by genes on both mitochondrial and nuclear 
genomes. Because most of the mitochondrial proteins are encoded by the nuclear genome 
and imported into the mitochondria, an active protein transport network is present in the 
organelle. Both metabolites and protein transport require a membrane potential across the 
inner mitochondrial membrane, and the mitochondrial electron transport chain generates 
this potential. The maintenance of this potential is critical, not only for ATP synthesis, 
but for vital mitochondrial metabolic activities (Srivastava et al., 1997; Vaidya and 
Mather, 2000). 
Fry and Pudney (1992) showed that ATV inhibited mitochondrial electron 
transport at the cytochrome bc 1 complex in P. falciparum and P. yoelii at 100-fold lower 
concentrations than mammalian mitochondria. The specific site of inhibition was 
suggested to lie between cytochromes b and Cl of this complex as the drug inhibited 
cytochrome C reductase activity. ATV shares structural similarity to the natural quinone 
substrate of the cytochrome bCI complex, ubiquinol or Ubiquinone, and it has been 
postulated that like Ubiquinone, ATV binds to the parasite cytochrome b (CYT b; Vaidya 
et al., 1993). Yeast mitochondrial inhibitors such as stigmatellin and myxothiazole, 
which are structurally similar to ATV, have been shown to bind at or around the 
ubiquinol oxidation-reduction (Qo)-(Qi) sites of CYT b and inhibit electron transport (di 
Rago et al., 1989; Korsinczky et al., 2000). In addition, further studies by Srivastava et 
al. (1997) reported that ATV also collapsed the potential across the inner mitochondrial 
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membrane in live P. yoe/ii parasites but had no effect on mammalian mitochondrial 
membrane potential. This depolarisation of the malarial mitochondria is profoundly 
detrimental to the mitochondrial functioning (Srivastava et al., 1997; Vaidya and Mather, 
2000). Further studies have shown ATV to reduce the parasite oxygen consumption rate 
in a concentration-dependent manner supporting its role as a cytochrome bel inhibitor 
(Murphy and Lang-Unnasch, 1999). Overall, ATV targets two areas of mitochondrial 
function which are intimately linked, the mitochondrial electron transport chain and the 
membrane potential (Srivastava et al., 1997). 
1.2.4.2 Mechanism and role for the synergy between atovaquone and proguanil 
The effectiveness of the ATV -PG combination was initially puzzling. The initial 
combination trials were conducted in Thailand, where about 90% of the patients with 
falciparum malaria failed to respond to PG alone and a third of those on ATV 
recrudesced. Cure rates close to 100% were seen with the combination (Looareesuwan et 
al., 1996). The PG failures were thought to be due to widespread mutations in the 
parasite dhfr gene (Srivastava and Vaidya, 1999). Other trials in Africa have shown 
similar success with the combination (Radloff et al., 1996a). It was originally suggested 
that the in vitro synergy seen by the combination of the two drugs is due to proguanil 
somehow interacting with DHFR or another enzyme of the pathway ultimately inhibiting 
pyrimidine synthesis (Canfield et al., 1995). However, PG alone has very little effect on 
the parasite and needs to be metabolised by the host into the antifolate cycloguanil. This 
conversion is controlled by certain isoforms of cytochrome P450 of which about 20% of 
the African and Asian popUlation are deficient in. It was therefore hypothesised that this 
synergy involved mechanisms other than DHFR inhibition (Srivastava and Vaidya, 
1999). Srivastava et al. (1999) demonstrated that PG significantly enhanced the ability 
ATV to collapse the mitochondrial membrane potential. PG by itself had no effect on 
electron transport or mitochondrial membrane potential. It was also demonstrated that 
cycloguanil and other DHFR inhibitors had no effect on ATV-mediated electropotential 
collapse, and that DHFR inhibition was not responsible for synergism. Surprisingly, PG 
had no effect on the ability of ATV to inhibit mitochondrial electron transport 
(Srivastava and Vaidya, 1999) and PG failed to potentiate ATV by direct inhibition of 
the parasite respiratory chain (Murphy and Lang-Unnasch, 1999). 
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The parasite mitochondrial DNA (mtDNA) is only 6 kb in length and encodes 
only three proteins (cytochrome e oxidase subunits I and II, and CYT b). Sequence 
analysis of hydroxynaphthoquinone-resistant strains and strains with varying 
susceptibilities highlighted defined regions of cytb gene in which mutations occurred 
(Korsinczky et al., 2000). This pointed to a role of the CYT b complex in the mode of 
action of these drugs (Vaidya and Mather, 2000). The mtDNA in malaria parasites is 
extremely well conserved across a large number of geographically distinct P. falciparum 
isolates and many highly divergent Plasmodium species (McIntosh et al., 1998). 
However, CYT b gene mutations leading to ATV resistance arise quickly and spread 
rapidly. It has been hypothesised that the mode of action of the drug might contribute to 
its own resistance (Srivastava et al., 1999; Vaidya and Mather, 2000). Of the 12 
nucleotide changes seen in nine independently derived mutants of P. yoelii reported by 
Srivastava et al. (1999), 11 replaced A:T base-pairs with G:C base-pairs which is often a 
consequence of free radical mutagenesis. The authors speculated that during ATV-
inhibited electron transport at the cytochrome be J complex, the accumulated reduced 
ubiquinol (or the half-reduced ubi semiquinone free radical) could readily donate 
electrons to molecular oxygen, resulting in the formation of reactive oxygen species 
(ROS). These ROS could then act as locally active mutagens and may induce mutations 
in the replicating mtDNA. The parasites bearing the advantageous mutations will be 
selected and spread through the population (Vaidya and Mather, 2000). As previously 
mentioned, PG synergises ATV by lowering the concentration at which ATV is able to 
collapse the mitochondrial membrane potential. In the absence of the electropotential 
gradient, mtDNA replication will be inhibited, thus avoiding the possibility of mutations 
occurring. Thus, the combination of PG and ATV would not only have the beneficial 
effect of increased atovaquone activity, but would reduce the chances of mutations 
arising in the mtDNA (Vaidya and Mather, 2000). 
1.2.5 Artemisinin derivatives 
The herb Artemisia annua L. (qing haD, sweet wormwood, annual wormwood) 
has been used in Chinese traditional medicine for more than 2000 years as a treatment for 
fever and malaria. The antimalarial activity of A. annua L. was rediscovered in China in 
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1971, when a low-temperature ethyl ether extraction of the leafy portions of the plant 
was shown to have antimalarial activity. In 1972, Chinese scientists isolated a crystalline 
substance from the plant which was found to contain the principal antimalarial activity. 
This compound was named qinghaosu (chemical name now artemisinin) which literally 
means the active ingredient of qing hao (Hien and White, 1993). The first clinical studies 
conducted in 1972 showed excellent activity against both vivax and falciparum malaria. 
By 1979 the Qinghaosu Antimalarial Co-ordinating Research Group reported that over 
2000 patients had been cured with artemisinin (QHS; Figure 1.5) derivatives (Klayman, 
1985). 
Subsequently, Chinese scientists experimented with semi-synthetic derivatives of 
QHS in an attempt to develop a more water-soluble and potent active compound. Two 
derivatives, artesunate and artemether, with greater antimalarial activity were 
synthesised, from the reduction product dihydroartemisinin (DHA; Klayman, 1985; 
Haynes and Vonwiller, 1994). The drugs were shown to elicit a rapid parasitological and 
clinical response in human falciparum malaria, including severe and complicated cases 
and multidrug-resistant infections (WHO, 1993). Since these impressive results over a 
million people have been treated with the compounds. Reports from Asia, South America 
and Africa have all confirmed that QHS or its derivatives are to date the most rapidly 
acting of all antimalarial drugs (White, 1994). 
QHS is a sesquiterpene lactone with a novel peroxide bridge linkage (empirical 
formula ClsH220S ; molecular weight 282) and, unlike the quinolines, lacks a nitrogen-
containing heterocyclic ring system (Klayman, 1985). Complete chemical synthesis was 
reported in 1983, but this approach would be too expensive for commercial 
pharmaceutical production. Instead, the QHS in current use is derived from cultivated A. 
annua L. (Hien and White, 1993). Structure and activity relations have suggested that the 
endoperoxide bridge is essential for antimalarial activity (Meshnick, 1994). QHS and its 
derivatives have been shown to be effective against blood-stage parasites in nanomolar 
concentrations, and have displayed a unique stage-specific profile in preventing parasite 
development. Late ring-stage parasites and developing schizonts are more susceptible to 
QHS than trophozoites. The drug also inhibits early gametocyte formation that could be 
important for blocking transmission of the disease (Mehra and Bhasin, 1993; Skinner et 
a/., 1996; Price et a/., 1996). QHS is available for oral and rectal use (WHO, 1993) and it 
is about five times less potent than the derivatives and must therefore be given in a 
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higher dosage (White, 1994). There is little data available on the absolute bioavailability 
of the drug, and, as with the other derivatives, absorption after oral intake is incomplete 
(de Vries and Dien, 1996). Unfortunately, QHS-derivatives cannot be used for 
prophylaxis since they have a short half-life (Kamchonwongpaisan and Meshnick, 1996). 
High recrudescence rates are an unfortunate characteristic of these antimalarials and are 
probably due to their short elimination time (Radloff et al., 1996b). Unlike other QHS-
derivatives, QHS is not metabolised in the host into more active compounds such as 
DHA (Skinner et al., 1996). 
Figure 1.5: The structure of artemisinin and common semi-synthetic derivatives. 
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1.2.5.1 Mechanisms of uptake and antiparasitic activity 
1.2.5.1.1 Accumulation of artemisinin derivatives 
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P. falciparum infected red cells accumulate eH]-DHA (Gu et al., 1984) and 
C4C]-QHS (Meshnick et al., 1991; Kamchonwongpaisan et al., 1994) to a much higher 
intracellular concentration than uninfected red cells. Estimates range from 8-fold 
(Meshnick et al., 1991), through 300-fold (Gu et al., 1984), to as high as 5500-fold 
(Janneh, 2000). The mechanism of QHS accumulation is not known. All quinoline and 
QHS antimalarials bind to FPIX with varying affinities (Chou et al., 1980; Meshnick et 
al., 1991; Sullivan et al., 1998), although there are conflicting views on whether QHS-
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derivatives inhibit (Pandey et al., 1999; Janneh, 2000) or do not inhibit 
(Asawamahasakda et al., 1994b; Hawley et al., 1998) FPIX polymerisation into 
haemozoin. It has been proposed that binding to FPIX will lead to the accumulation of 
drugs within the parasite, as the FPIX-drug complex is unable to cross the vacuolar 
membranes (Chou et al., 1980; Meshnick et al., 1991; Bray et al., 1998). It has been 
demonstrated that a chemically synthesised FPIX-QHS adduct can inhibit all FPIX 
polymerisation. The adduct mimics FPIX in binding to histidine-rich protein II but 
cannot self-polymerise. The authors concluded that the intravacuolar formation of these 
adducts inhibits FPIX polymerisation and this is critical for the action QHS-derivatives 
(Kannan et al., 2002). Pandey et al. (1999) suggested that this binding of the 
endoperoxides to FPIX and to haemozoin is sufficient to explain uptake into cells. 
Numerous other workers have implicated a role for FPIX in the mode of action of QHS-
derivatives (Meshnick et al., 1991; Zhang et al., 1992; Meshnick, 1994; Hong et al., 
1994; Wei and Sadrzadeh, 1994; Shukla et al., 1995; Berman and Adams, 1997; 
Meshnick, 1998; Kapetanaki and Varotsis, 2000). On the contrary, Janneh (2000) 
concluded that only a marginal contribution of drug uptake can be accounted for by 
binding to FPIX, and that the major contributor to QHS uptake is intracellular free iron. 
1.2.5.1.2 Iron-mediated cleavage 
Earlier Meshnick et al. (1994) proposed that the antimalarial action of QHS is 
dependent on two sequential steps (Figure 1.6). The first step, activation, involves the 
iron-mediated cleavage of the endoperoxide bridge to generate an unstable organic free 
radical and/or other electrophilic species. The second step, alkylation, involves the 
reactive species forming covalent adducts between the drug and malarial proteins. 
There is considerable evidence suggesting that iron is required for the 
antimalarial activation ofQHS and its derivatives (Meshnick, 1994; Olliaro et al., 2001; 
Robert et al., 2002). However, the transient source of iron in this mechanism has not 
been clearly described. There are several sources of iron within the parasite-infected red 
cell, i.e. Hb, iron in haemoproteins (e.g. catalase and cytochrome c), haem (Fell), FPIX, 
haemozoin, and free iron. Haem (Fell) is released from Hb in the digestive vacuole after 
the parasite has digested the globin component. It spontaneously oxidises to FPIX and 
subsequently is converted in the parasite vacuole into insoluble haemozoin (Gabay et al., 
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1994; Paitayatat et al., 1997). The iron-catalysed reduction of the peroxide moiety results 
in more cytotoxic compounds, such as free radicals, being produced that subsequently 
kill malarial parasites (Zhang et al., 1992; Meshnick et al., 1993). A free radical is a 
short-lived and highly reactive molecule that contains an unpaired electron and is often a 
partially reduced form of molecular oxygen (Meshnick, 1994). A high-valent iron-
oxygen intermediate, Fe(IV)=O +-+ -O-Fe(III), is proposed to also be involved in parasite 
damage (Cumming et al., 1997; Kapetanaki and Varotsis, 2000), but this has been 
disputed (Wu et al., 1998). The importance of the peroxide group was evident when it 
was discovered that deoxyartemisinin - a QHS analogue with a single oxygen replacing 
the endoperoxide bridge -lacked any antimalarial activity (China Cooperative Research 
Group, 1982; Brossi et al., 1988). 
The effect of oxidant related compounds on the antimalarial activity of QHS-
derivatives lent support to the theory of these endoperoxides exerting their effects 
through oxygen-mediated toxicity. High oxygen tension and compounds that promote 
free radical generation (increased oxidant stress), such as doxorubicin and miconazole, 
exert a synergistic interaction with artesunate (Krungkrai and Yuthavong, 1987). 
Conversely, free radical scavengers, e.g. a-tocopherol (vitamin E), catalase, 
dithiothreitol (Krungkrai and Yuthavong, 1987), retinol (Skinner-Adams et al., 1999), 
reduced glutathione and ascorbate (Meshnick et al., 1989), antagonise antimalarial 
activity of QHS-derivatives. Deficiency in vitamin E (an antioxidant) was shown to 
enhance QHS antimalarial action against P. yoelii in mice (Levander et al., 1989). In 
addition, inhibitors of endogenous parasite antioxidants, e.g. buthionine sulfoximine or 
diethyldithiocarbamate, promote QHS action (Kamchonwongpaisan et al., 1992). 
Evidence is accumulating implicating the role of haem in the mode of action of 
QHS and its derivatives (Meshnick et al., 1991; Zhang et al., 1992; Meshnick, 1994; 
Hong et al., 1994; Pandey et al., 1999; Kapetanaki and Varotsis, 2000). The haem-rich 
internal environment of the parasites is assumed to explain why QHS is selectively toxic 
to malaria parasites (Meshnick et al., 1993). The importance of haem is suggested by the 
observation that a CQR strain of P. berghei lacking haemozoin is extremely resistant to 
QHS (Peters et al., 1986). QHS has been reported to alkylate haemoproteins but not 
haem-free proteins, suggesting haem plays a role in the activation of these drugs (Yang et 
ai., 1994). Recently, new evidence has become available suggesting other sources of 
activation. Wu et al. (1999) showed that non-haem Fell (FeS04) may cleave the peroxy 
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bond and the transient carbon-centred radical can attack the sulfhydryl (SH) group of 
cysteine. As an example, a P. falciparum protein containing a single cysteine was shown 
to bind to eH]-DHA. This interaction was reduced by two-thirds when the cysteine 
moiety was blocked by a thiol-blocking reagent (Bhisutthibhan et al., 1998). This 
protein, of unknown function, with a molecular mass of 25 kDa was isolated, sequenced 
and found to have a high degree of homology to members of the translation-controlled 
tumour protein (TCTP) gene family. The TCTP protein was shown to bind to FPIX and 
calcium and it is located in cytoplasm, food vacuolar membrane, and in parasite limiting 
membranes (Bhisutthibhan et al., 1998; Bhisutthibhan et al., 1999). Furthermore, QHS-
derivatives have been demonstrated to alkyl ate specific malaria proteins 
(Asawamahasakda et al., 1994c) which adds further support to the hypothesis of the 
radical attack point on the Fe-S or haem-containing proteins being somewhere in peptide 
chains in close proximity to the metal centre (Wu, 2002). 
Pandey et al. (1999) showed that QHS antimalarials interrupt the Hb catabolic 
pathway using in vitro and ex vivo studies. The authors suggested that endoperoxides 
cause inhibition of haem polymerisation to haemozoin by interacting with catalyst 
proteins; and are powerful inhibitors of malarial digestive vacuole proteases responsible 
for Hb degradation. Additionally, these drugs initiate the breakdown of the haemozoin 
already present in the digestive vacuole. Previously, QHS has been shown to react with 
FPIX to form covalent adducts (Meshnick et al., 1991; Hong et al., 1994) and eH]-DHA 
has been reported concentrated in haemozoin (Hong et al., 1994). The endoperoxide 
antimalarials are fast acting drugs and cause rapid parasite damage (Ellis et al., 1985; 
Maeno et al., 1993). This combination of several possible actions aimed at haem related 
processes might be an explanation for the rapid efficacy of the drugs. 
However, it has also been reported that in vitro, the QHS-FPIX complex has 
diminished antimalarial activity with an ICso raised from 10 nM to 42 nM (Meshnick et 
al., 1991) as opposed to the CQ-FPIX complex, which is lytic for both erythrocytes and 
the infecting parasites (Chou et aI., 1980). These data supported the suggestion that the 
formation of the QHS-FPIX complex in the vacuole could be accompanied by other 
reactions such as free radical generation (Pandey et al., 1999). 
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Figure 1.6: The proposed mechanism of action of artemisinin. Adapted from 
Meshnick(1994). 
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Free radicals and reactive intermediates are thought to be formed from QHS 
rapidly reacting with nearby molecules, and protein alkylation has been reported when 
[14c]-QHS or eH]-DHA was incubated with human serum albumin (Yang et aI., 1993). 
The binding appears to be via a covalent linkage and this could explain why QHS is 
rapidly eliminated from the circulation (Yang et al., 1993; de Vries and Dien, 1996). No 
binding between DNA and QHS has been found (Yang et al., 1994) and QHS has been 
demonstrated to have no effect on mRNA coded protein synthesis (Ferreras et aI., 2002). 
Accumulation studies of eH]-DHA and [14c]_QHS reported that these drugs 
accumulate in the digestive vacuoles and mitochondria (Maeno et aI., 1993). 
Ultrastructural changes induced in P. Jalciparum in vitro and in vivo by QHS and DHA 
have been studied using autoradiographic and electron microscopic techniques. These 
studies showed that eH]-DHA associates with the parasite limiting membranes (Ellis et 
al., 1985), digestive vacuole membranes, haemozoin (Ellis et al., 1985; Maeno et al., 
1993) and mitochondria (Maeno et al., 1993). Ultrastructural studies of parasites exposed 
to QHS or artemether indicate early damage to parasite mitochondria, nuclear envelope, 
and the rough endoplasmic reticulum, followed by changes in the ribosomes, nuclei, and 
digestive vacuole (Ellis et al., 1985; Jiang et al., 1985; Maeno et al., 1993; Kawai et al., 
1993). In vivo studies have reported parasite damage within three hours after QHS 
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administration, and these findings correlate well with the rapid and effective action of 
QHS and its derivatives demonstrated in human clinical trials (Jiang et al., 1985; Kawai 
et aI., 1993). The QHS induced membrane damage has been further investigated in vitro. 
Berman and Adams (1997) demonstrated that the addition ofQHS to FPIX enhanced the 
peroxidase activity ofFPIX by 2- to 3-fold, while the FPIX-catalysed oxidation ofRBC 
membrane lipid was increased -6-fold. These functional changes were paralleled by the 
presence of a long-lived FPIX-QHS adduct - possibly a covalent linkage via an iron-
oxygen-carbon bond. Additionally, QHS has been shown to reduce the membrane 
fluidity of infected RBC and this was suggested to be due to the drug damaging the 
infected RBC membrane (Sibmooh et al., 2000). 
[14C]_QHS was observed to alkyl ate proteins of isolated red cell membranes, but 
not of intact red cells (Asawamahasakda et al., 1994a). Initial studies suggested that QHS 
alkylated haem and parasite proteins, but no structures were proposed (Hong et al., 
1994). It was also shown that QHS and its derivatives react with specific malarial 
proteins. In P. !alciparum-infected red cells, eH]-DHA and [3H]-arteether were noted to 
alkyl ate several parasite specific membrane-associated proteins. The labelled proteins 
were neither strain- nor stage-specific (Asawamahasakda et al., 1994c). It was therefore 
concluded that the drugs reacted with specific proteins rather than random free-radical 
attack as was initially thought. Although cleavage of the endoperoxide bridge of QHS by 
intraparasitic free haem might not cause any fatal effects, the reactions of QHS with 
haem-containing proteins or enzymes could be completely different from the usual non-
covalent blockage of enzymes or receptors through the binding of a reversible antagonist. 
Intramolecular alkylation within a protein or enzyme may change accessibility of the 
protein and interrupt its normal functioning. The irreversible covalent bonding probably 
could have effects at lower concentrations, because the active centre is irreversibly 
destroyed (Wu, 2002). 
An additional hypothesis of accumulation and action by QHS-derivatives has 
been suggested. Akompong et al. (1999) have proposed that the PVM-TVM (see Section 
1.1.2.2) is a major pathway for the transport ofDHA to the parasite in the infected RBC, 
and that QHS-derivatives affect protein organisation in the PVM-TVM complex leading 
to inhibition of in vitro cell growth. 
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1.3 The basis of drug resistance 
In the 1940s when CQ was introduced as a powerful new chemotherapeutic, it 
was thought that falciparum malaria would be completely eliminated, or at least 
contained to the point that the disease was of no major threat to health. However, in the 
early 1960s, resistance to CQ was first reported in parts of Thailand and South America 
(Bustos et aI., 1994). This then spread from these initial foci to other parts of the world 
reaching Africa (Kenya and Tanzania in 1979), and later South Africa in 1985 (Sharp 
and Le Sueur, 1996). CQ resistance has now spread to most tropical areas of the world, 
and in some locations parasites are resistant to most clinically useful drugs (Figure 1.7). 
Increasing drug resistance in many parts of the world has aggravated the problem 
of formulating drug policies deciding which anti-malarial should be used in treatment, 
and prevention of the disease. According to the WHO, resistance to SP is present in 
South-East Asia, South America and focally in Africa, while sensitivity to QN, 
particularly in the treatment of uncomplicated malaria, is also diminishing. MQ 
resistance is more sporadic, except in certain border areas of Thailand and adjacent 
countries, where MQ and multidrug resistance is now widespread. MQ resistance is on 
the increase in the African malarious areas where SP resistance prevails (Barradell and 
Fitton, 1995; Olliaro and Trigg, 1995), In the multidrug resistant phenotype displayed by 
some parasites, there is cross-resistance between even dissimilar drugs (Basco and Le 
Bras, 1993; Pradines et ai" 1998a; Wongsrichanalai et al., 1999), Biochemical and 
genetic basis of this resistance is discussed in the following sections. 
1.3.1 Chloroquine Resistance 
The last five decades have witnessed the rise and fall of the most efficacious, 
relatively non-toxic and widely used antimalarial CQ. The success and importance of this 
drug in malaria chemotherapy stimulated diverse investigative experimentation all 
geared towards a better understanding of the drug's mode of action and mechanism of 
resistance development. It is anticipated that this understanding will reveal biological 
details of the parasite that can he utilised to prevent or retard the development of drug 
resistance to existing or newer agents. 
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Figure 1.7: Global status of resistance to CQ and SP and multidrug-resistant areas. Data 
are from the WHO. Picture from Wongsrichanalai et at. (2002). 
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Currently, it is thought that the concentration of CQ at its site of action within the 
acidic digestive vacuole of the parasite, is essential for its toxicity (Homewood et al., 
1972; Kaschula et a/., 2002). Reduced CQ accumulation seen in CQR parasites (Fitch, 
1970) has been suggested to form the basis for CQ resistance, and this resistance was 
demonstrated to be partially reversed by verapamil (VP), a calcium-channel blocker 
which reverses resistance of mammalian cells to anti-cancer drugs (Martin et ai., 1987). 
More recently, this hypothesis was confirmed when isolated vacuoles from CQR 
parasites were observed to have reduced CQ accumulation compared to CQS parasites 
(Saliba et at., 1998). 
Evidence is accumulating in favour of the proposed multigenic nature of CQ 
resistance (Brockelman et al. , 1989; Foote et ai., 1990b; Adagu and Warhurst, 1997; von 
Seidlein et ai., 1997; Su et at., 1997; Reed et al., 2000; Warhurst, 2001; Djimde et al., 
2001; Sidhu et ai. , 2002). Although mechanisms have been proposed to account for CQ 
resistance, many of these reviewed in the following sections are conflicting. 
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1.3.1.1.1 Increased efflux of chloroquine 
Early studies suggested that CQ resistance was based on an enhanced drug efflux 
system in CQR cells. Krogstad et al. (1987) found that CQR parasites release pre-
accumulated CQ almost 50 times more rapidly than CQS isolates. This efflux was shown 
to be energy dependent because it could be inhibited by energy depletion and ATP 
blockers (Krogstad et al., 1992). It has been demonstrated that CQ resistance could be 
partially reversed by the calcium-channel blocker VP (Martin et al., 1987) and other 
compounds (Kyle et al., 1990; Taylor et al., 2000; van Schalkwyk et al., 2001). These 
observations suggested a similar mechanism of resistance as seen in the mammalian 
multi drug resistant (MDR) phenotype in tumour cells. These MDR cells are 
characterised by the ability to pump out a wide range of chemically dissimilar 
compounds, via an efflux pump on the cell membrane. The efflux pump is a p-
glycoprotein (Pgp) - an ATP-dependent transporter encoded by mdr genes (Slater et al., 
1982; Rogan et al., 1984; Fojo et al., 1985). The diverse range of drugs such as VP, 
dilitiazem, vinblastine and daunomycin are thought to increase the concentration of CQ 
in the digestive vacuole through inhibition of an efflux pump (Martin et al., 1987). 
although the level of CQ accumulation obtained on reversal is never equivalent to the 
level seen in CQS strains (Bray et al., 1996a). This suggests that there is another 
component of CQ resistance not affected by VP and CQ resistance could be multigenic 
(Ward et al., 1995). However, a number of other studies have suggested that the 
decreased steady-state levels of CQ are due to reduced drug accumulation rather than a 
drug export mechanism (Geary et al., 1990; Ginsburg and Stein, 1991; Bray et al., 
1992a; Bray et al., 1994). 
Bray et al. (1999a) later argued that VP is one of many diverse compounds which 
disrupt lysosomal pH, and it can overcome CQ resistance by increasing the lysosomal pH 
thereby increasing affinity ofCQ to FPIX. 
1.3.1.1.2 Decreased influx of chloroquine due to changes in vacuolar pH 
Several enzymes responsible for the degradation of Hb have been isolated from 
the digestive vacuole. These enzymes have been shown to function optimally at pH 4.5 -
5.0 and it has been argued that the vacuole would need to be acidic in order for the 
breakdown of Hb to occur (Francis et al., 1997). CQ would concentrate in the acidic 
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parasite digestive vacuole most probably due to its weak base properties (see Section 
1.2.1.1.3). Yayon et al. (1985) proposed that due to the transmembrane proton gradient 
being the driving force behind CQ accumulation, changes to this gradient could alter the 
susceptibility of the parasite to CQ. This implied that a small rise in vacuolar pH (in the 
order of 0.2 to 0.5 pH unit) could result in lower CQ accumulation, leading to CQ 
resistance. Since CQR parasites accumulate less CQ than CQS (Verdier et al., 1985), it 
was proposed that CQ resistance might be explained by an elevation of the vacuolar pH 
in CQR compared to CQS parasites (Geary et al., 1990). This hypothesis was favoured 
by many workers, although it has never been conclusively demonstrated in vitro due to 
difficulties in measuring vacuolar pH (Spiller et al., 2002). Subsequently, a mathematical 
kinetic model lent support to this hypothesis (Ginsburg and Stein, 1991). An increased 
digestive vacuolar pH in resistant parasites may be either due to an increased proton leak 
or reduced ATPase proton pump activity. This model was used to analyse the time-
course of CQ uptake and the steady-state levels of drug accumulation in strains of P. 
falciparum that displayed variable drug resistance. Using fractional fill analysis to 
differentiate forces of uptake from forces of efflux, the authors found that CQ resistance 
was compatible with the existence of a weakened proton pump in CQR parasites. 
However, their analysis failed to detect any link between CQ resistance and multidrug 
efflux pump activity; and concluded that the difference in accumulation between CQR 
and CQS parasites could be explained purely in terms of differential uptake forces (Ward 
et al., 1997). In addition, the extracellular pH can affect CQ accumulation (Yayon et al., 
1984; Yayon et al., 1985; Geary et al., 1990), further supporting the theory that CQ 
resistance could be due to decreased acidification of the whole parasite or the digestive 
vacuole (Ginsburg and Stein, 1991). Supporting evidence by Bray et al. (1996a; 1996b) 
showed that the initial uptake rate in CQR parasites is reduced and VP increases this 
initial uptake rate selectively in CQR strains. However, Bray, Ward and colleagues point 
out that there may be a small but measurable efflux component to CQ transport in CQR 
parasites (Ward et aI., 1997). 
The vacuolar ATPase or proton pump is responsible for the regulation of the pH 
of the lysosome or digestive vacuole. It achieves this by translocating H+ into the 
lysosome. The H+-ATPase is a complex of eight subunits and only one component is 
necessary for pH regulation (Bowman et al.. 1988). Two subunit genes of the P. 
falciparum H+-ATPase have been analysed and no differences were observed between 
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CQR and CQS parasites (Karcz et aI., 1993; Karcz et al., 1994). However, Bray et al. 
(1 992b ) showed that CQR strains were more sensitive to inhibition with the vacuolar 
ATPase inhibitor bafilomycin AI; and testing CQ in combination with bafilomycin Al 
showed that they both became less sensitive to CQ. 
There have been attempts to directly measure the intravacuolar pH of CQR and 
CQS parasites. Two early studies estimated the pH at around 5.2 (Yayon et al., 1984; 
Krogstad et al., 1985). An early study of digitonin-permeabilised infected RBC using pH 
dependent fluorescin-dextran probes did not reveal any large differences between the 
vacuole pH of CQS and CQR parasites (Krogstad et al., 1985); however, a later study 
showed a significant difference in CQ accumulation between isolated digestive vacuoles 
from CQS and CQR parasites (Saliba et al., 1998). Further studies using intact infected 
RBC may be needed to detect small pH changes that may occur (Foley and Tilley, 1998). 
More recently, Dzekunov et al. (2000) measured the intravacuolar pH of CQS HB3 and 
CQR Dd2 using acridine orange (AO) as a vacuolar pH probe in intact parasites. The 
estimated pH values were 5.64 and 5.21 for HB3 and Dd2, respectively, a contradiction 
to earlier theories. It was suggested that at the lower pH of the CQR strain there is less 
soluble FPIX. Since CQ only binds to soluble FPIX, the parasite, by altering pH, can 
manipulate the interaction of FPIX with the drug without altering the total net amount of 
target (Dzekunov et al., 2000). At this lower pH, majority of the FPIX was insoluble and 
not available for CQ binding. Using the same AO method, Ursos et al. (2000) later 
reported that VP normalised the vacuolar pH (i.e. raised the pH) for the CQR strain to a 
value close to that of the CQS strain, but no pH change was seen in the CQS strain. The 
intracellular VP in the CQR parasite would presumably increase the amount of soluble 
FPIX available for CQ binding as a type of resistance reversal mechanism (Spiller et al., 
2002). Using the above method, further evidence in support of the link between digestive 
vacuole pH and CQ resistance was reported (Fidock et al., 2000b; Mehlotra et al., 2001). 
However, the use of AO as an accurate compartment selective marker for the 
measurement of the digestive vacuole pH was questioned. AO is a fluorescent weak base 
known to stain DNA, RNA and enter lysosomes (Bray et al., 2002a), however it does not 
have a well-documented property of staining the digestive vacuole and is not clearly 
visible in the vacuole (Ginsburg et al., 1989; Bray et al., 2002a). In other acidic vesicles 
it has a red shifted emission spectrum, in contrast bound to DNA or double-stranded 
RNA it exhibits a green fluorescence only (Spiller et al., 2002; Bray et al., 2002b). Bray 
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and co-workers (Spiller et al., 2002; Bray et aI., 2002a; Bray et al., 2002b) have 
concluded that the methods used by Roepe and colleagues (Dzekunov et al., 2000; Ursos 
et al., 2000) which focus on the green fluorescence of AO which is detected in the 
parasite cytosol and not the digestive vacuole, thereby invalidating conclusions drawn 
from this work on the pH of digestive vacuoles. Additionally, AO does also share some 
structural homology with the antimalarial quinicrine (Zhang et al., 2002) and resembles 
AQ closely in its charge and hydrophobicity (Warhurst et al., 2002) further questioning 
the use of this compound as an accurate pH probe. Roepe and colleagues recently added 
further support to their hypothesis demonstrating increased acidity in membrane vesicles 
prepared from yeast cells expressing mutant PfCRT (Zhang et al., 2002). 
Pgh-l protein is primarily localised to the membrane of the digestive vacuole 
(Cowman et al., 1991), and its role in pH regulation and/or drug uptake was uncertain. 
Wild-type pfmdrl-encoded protein was expressed in Chinese Hamster Ovary (CHO) 
cells which demonstrated a VP-insensitive, ATP-dependent, increased susceptibility to 
CQ. The Pghl-mediated increased accumulation of the antimalarial was found to be due 
to decreased lysosomal pH. The cells showed no change in susceptibility to primaquine, 
quinine, adriamycin, or colchicine. Similar increase in CQ susceptibility was not 
observed in cells carrying mutated Pgh-l protein (1034cys and 1042asP) and decreased 
lysosomal pH was not seen. The wild-type, Pgh-l mediated CQ accumulation was non-
stereoselective. It was noted that both bafilomycin Al and ammonium chloride almost 
completely inhibited CQ uptake. It was concluded that wild-type Pgh-l does not 
transport CQ, but instead influences CQ accumulation by modulating the pH of the 
digestive vacuole (van Es et al., 1994a; van Es et al., 1994b). 
1.3.1.1.3 Decreased influx of chloroquine due to changes in chloroquine importer 
While it is generally argued that a decreased level of CQ in the parasite digestive 
vacuole is vital for CQ resistance, the underlying biochemical mechanisms remained 
unclear. Following a demonstration by Moreau's group that a CQ analogue accumulated 
in digestive vacuoles of CQS P. berghei parasites while the drug accumulated in the 
cytoplasm of CQR parasites (Moreau et al., 1986), a permease theory was proposed. A 
CQ importer pump was proposed on the parasite outer membrane and the drug was 
assumed to diffuse into the lysosome becoming trapped inside the acid vacuole. In CQR 
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parasites, the pump would be produced in higher quantities, and localise also to the 
lysosome membrane, where, orientated in reverse, it would export the drug into the 
parasite cytoplasm (Warhurst, 1986; Warhurst, 1988). Alternatively, lower levels of this 
carrier protein or a decreased affinity for CQ, could lead to less of the drug in the 
digestive vacuole and hence the parasite displaying a resistant phenotype. The proposal 
that the weak base effect was insufficient to explain entry of CQ into the parasite 
cytoplasm and received support from other workers (Krogstad et al., 1992). Sanchez et 
al. (1997) demonstrated that CQ uptake was temperature-dependent, saturable and could 
be inhibited by EIPA, a specific inhibitor of the parasite Na+lH+ exchanger (NHE). This 
lead to the suggestion that CQ was imported by binding to the Na+ binding domain of the 
NHE and transported into the parasite in exchange for protons. However, using the 
progeny of a genetic cross between P. Jalciparum CQS HB3 and CQR Dd2 (Well ems et 
al., 1991), Sanchez and workers suggested that the differences in the kinetics of CQ 
uptake between CQS and CQR parasites were due to an import mechanism with reduced 
affinity for CQ. Their analysis of the 16 recombinants indicated that these differences 
were similar to one or the other of the parent clones. The authors concluded that the 
calcium-channel blocker VP could act on CQ transport by modulating the NHE activity 
through the Ca2+/calmodulin regulatory pathway. Supporting evidence from this group 
(WUnsch et al., 1998) was provided linking CQ resistance to an elevated cytoplasmic pH 
due to a constitutively activated NHE in CQR parasites. CQ activates the NHE of CQS 
parasites, resulting in the CQ uptake during a Na+lH+ exchange. This differential 
stimulation of the NHE would result in lower accumulation of CQ within the digestive 
vacuole. 
This view was questioned by Bray et al. (l999a) who reported that CQ uptake 
into isolated parasites occurs at normal rates when sodium was replaced by choline, and 
under these conditions the NHE should not function. The NHE inhibitors (e.g. ami lori de) 
used by WUnsch et al. (1998) could have functioned in lowering CQ accumulation by 
competitive binding to FPIX (Bray et al., 1999a). Furthermore, Bray et al. (1999a) 
demonstrated that the VP effect is unrelated to NHE activity as the ability of VP and 
other resistance modifiers to increase the CQ uptake is retained in sodium-free 
conditions. 
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1.3.1.1.4 Reduced drug binding 
Hb digestion is a precondition for CQ susceptibility of malaria parasites as the 
blood schizontocides are only effective on the parasite during Hb digestion, and parasites 
that do not either produce haemozoin or do not produce haemozoin when exposed to CQ, 
are CQR (Fitch et al., 1986). FPIX within the digestive vacuole has been identified as a 
high affinity drug receptor of CQ (Chou et al., 1980) and it has been suggested that both 
the activity and saturable uptake of CQ is due to the binding of the drug to FPIX (Bray et 
al., 1999a). Fitch (1983) suggested that CQR parasites might have lower levels of CQ-
FPIX complex or possibly lower levels of soluble FPIX (Dzekunov et al., 2000). This 
was supported by the observation that CQR P. berghei parasites contained less 
haemozoin. Taking all these into account, CQ susceptibility could be determined by the 
amount of free FPIX available within the vacuole. A parasite could therefore become 
CQR by reducing the amount or affinity of drug binding sites (Fitch, 1983), or by 
reducing the accessibility of the drug to FPIX (Bray et al., 1998). Bray et ale (1998; 
1999a) have argued that saturable CQ uptake at equilibrium is due solely to the 
formation of the CQ-FPIX complex and that VP, ammonium chloride and other 
lysosomotropic agents increase do not alter the cytosolic pH at the low concentrations 
required to reverse resistance. They argue that the ability of these compounds to increase 
the affinity of CQ for FPIX is unlikely to be caused by any interaction with cytosolic pH 
regulators such as the NHE. However, Bray and colleagues do admit that these agents 
might be expected to produce a significant alkalisation of the lysosome as seen in cancer 
cell endosomes (Millot et al., 1997). The authors conclude that CQ resistance is 
associated with reduced CQ-FPIX binding affinity rather than changes to the capacity of 
binding sites or changes in CQ transport across membranes. In addition, Ginsburg et ale 
(1999) showed that CQ and related drugs inhibited FPIX degradation by glutathione and 
proposed that glutathione may be responsible for the majority of FPIX detoxification 
within the parasite cytosol and CQ or AQ could exert antimalarial activity by inhibiting 
this degradation by binding to FPIX. Hence, parasites could become CQR by raising 
cellular levels of glutathione, as higher levels of drug would be required to inhibit the 
FPIX degradation. A higher level of intracellular glutathione has been observed in some 
CQR rodent malaria strains (Dubois et al., 1995). 
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1.3.1.2 Genetic Changes 
The links between CQ resistance and MDR cancer cells stimulated researchers to 
investigate changes seen in the parasite at the molecular level. At present, three genetic 
detenninants have been ide~tified which may contribute to the CQR phenotype. 
Interestingly, as well as a role in variations in CQ susceptibility, mutations in both 
pfmdr 1 and pfert have increasingly been shown to playa role in the susceptibility of P. 
falciparum to a range of other structurally diverse and related antimalarials. 
Figure 1.8: An illustrated model of the Pgh-1 protein showing amino acid substitution 
sites. Picture by Prof. D.C. Warhurst. 
asnsstyr 
tyr184phe 
ser1034cys 
asn1042asp 
aSP1246tyr 
link: 642·661 
1.3.1.2.1 pfmdrl gene 
Pgh-l 
1246 
CYTOPLASM 
The gene pfmdrl on chromosome 5 encodes for the P·falciparum P-glycoprotein 
(Pgh-l) which is structurally similar to the Pgh of other members of the A TP binding 
cassette (ABC) family of transport proteins. The -160 kDa protein product shows 54% 
similarity to mammalian P-glycoprotein (Wilson et al., 1989; Foote et al. , 1989). The 
protein is expressed throughout the asexual erythrocytic stages on the digestive vacuole 
membrane of the parasite (Cowman et aI., 1991; Cremer et ai., 1995). In eukaryotes, 
these proteins are defined by the presence of two A TP binding domains, two 
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hydrophobic domains each containing 5 - 8 transmembrane regions, and a 120 - 250 
amino acid conserved peptide motif. These proteins translocate a variety of substrates 
including sugars, amino acids, peptides, proteins and inorganic ions across cellular 
membranes (peel, 2001). P. faleiparum parasites resistant to multiple drugs display 
several, but not all, characteristics of mammalian MDR. Some chemosensitising agents 
commonly used to reverse mammalian MDR can reverse CQR parasites to CQ 
susceptibility levels close to that of CQS parasites, whereas in mammalian MDR, 
reversers like VP completely restore sensitivity (Martin et al., 1987; Peel, 2001). Other 
compounds such as oxaprotiline, citalopram, chlorpromazine, desipramine have similar 
effects in P. falciparum but similarly do not completely restore sensitivity (Kyle et al., 
1990; Taylor et al., 2000; van Schalkwyk et al., 2001). This reversal effect ofVP etc. in 
P. falciparum extends to structurally related quinine and quinidine (Kyle et al., 1990), as 
well as desethyl forms of AQ and CQ (Bray et al., 1996a). The arylaminoalcohols MQ 
and HAL fail chemosensitisation with VP, yet can be restored by the neuroleptic drug 
penfluridol (PEN), a compound which does not affect CQR parasites (Oduola et al., 
1993; Peel, 2001). The role of Pgh-l in mediating antimalarial drug resistance to the 
quinolines, arylaminoalcohols and artemisinin drugs has been controversial. More 
recently, accumulating evidence suggests a role for Pgh-l in a MDR phenotype in P. 
falciparum (price et al., 1999; Reed et al., 2000; Peel, 2001). 
Changes to the regulation of mdr genes and/or their proteins can lead to drug-
resistant phenotypes in many different organisms. At the level of gene expression, the 
gene can be amplified due to multiple copies of the gene present in the genome, or there 
can be an increased gene transcription due to an induction model (Prof. David Warhurst, 
personal communication). This has been demonstrated in Candida albieans where 
antifolate sulfadiazine induces the expression of a multidrug exporter for the unrelated 
antifungal drug fluconazole by inducing RNA transcription (Henry et al., 1999). Earlier 
studies hinted that amplification of the pfmdr 1 was associated with the CQR phenotype 
(Foote et al., 1989), but subsequent studies failed to link overexpression and CQ 
resistance (Cowman et al., 1991; Cowman et al., 1994). In one study, in vitro selection 
for increased CQ resistance in a P. falciparum clone carrying amplified pfmdr 1 resulted 
in a cell line resistant to a 10-fold higher concentration ofCQ. The resulting parasite line 
had deamplified pfmdr 1 and displayed increased susceptibility to MQ, HAL and QN 
(Barnes et al., 1992; Peel et al., 1994). Some strains, with more than one copy of the 
Chapter 1: General Introduction 66 
pfmdrl gene usually have higher pfmdrl transcript levels (Foote et al., 1989; Wilson et 
al., 1993). In the case of MDR strain W2Mef, it has been suggested that increased 
pfmdrl expression could mediate MQ resistance (see Section 1.3.2.2; Wilson et al., 
1993; Volkman et al., 1993). 
The search for sequence variations in the pfmdr 1 gene concentrated on point 
mutations thought to be associated with CQ resistance (Foote et al., 1990b). These 
polymorphisms resulted in the following amino acid substitutions asn86tyr, tyr184phe, 
ser1034cys, asn1042asp and aSP1246tyr (Figure 1.8). Changes in codon 184 have been reported 
to have no correlation with CQ resistance in laboratory strains (Foote et al., 1990b) and 
this has been verified in the field (e.g. Omar et al., 200Ia). A single asn86tyr mutation (K1 
allele) has been associated with CQ resistance in Africa and Asia (Foote et al., 1990b; 
Basco et al., 1995; Adagu et al., 1996; P6voa et al., 1998). In contrast, other studies have 
shown no link with codon 86tyr and reported other mutations (e.g. pfmdr 1 codons 184, 
1034, 1042 and 1246) in Thailand (Wilson et al., 1993), South America (P6voa et al., 
1998; Durand et al., 2001) and Africa (Awad-el-Kariem et al., 1992; Basco and 
Ringwald, 1998). Other polymorphisms, particularly the codon 1246 change which is 
found mainly in South America, are thought to be rare in Africa (Omar et al., 2001a); but 
recent reports show this may not be the case for much longer (Basco and Ringwald, 
1998; McCutcheon et al., 1999; Omar et al., 2001a). 
It was thought that a genetic cross between CQR Dd2 and CQS HB3 would 
clearly display a linkage betweenpfmdrl and CQ resistance, but the CQR phenotype was 
shown not to be linked to chromosome 5 (Wellems et al., 1990; Wellems et al., 1991). 
However, recent studies show direct evidence for the involvement ofPgh-1 in enhancing 
CQ resistance. Allelic replacement experiments replacing the wild-type allele with a 
mutant allele of the pfmdrl gene (codons ser1034cys, asn1042asp and aSP1246tY) was a mile-
stone study clearly showing pfmdrl involvement in CQ resistance (Reed et al., 2000). 
Introduction of pfmdr 1 polymorphisms into CQS parasites had no effect on CQ 
sensitivity, but replacement of mutant with wild-type pfmdr 1 sequence in a CQR parasite 
line halved the resistance. Increased CQ accumulation was seen in resistant parasites 
transfected with wild-type pfmdr 1 alleles and this increase in sensitivity could be further 
enhanced by the addition of VP, indicating that VP was working on a different target. 
Conversely, no change in CQ accumulation was observed in CQS parasites transfected 
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with mutant pfmdr 1 alleles. These results support the hypothesis that the CQR phenotype 
is multigenic (Foote et a/. J 1990b; Ward et a/. J 1995). 
1.3.1.2.2 cg2 gene 
Analysis of the progeny of a genetic cross between CQS HB3 and CQR Dd2 
parasite lines revealed that the rapid effiux phenotype (in CQR parasite lines) was 
controlled by a single gene or a closely linked group of genes on chromosome 7 which 
did not map to pfmdrl on chromosome 5 (Wellems et a/. J 1990; Well ems et a/. J 1991). 
The progeny of the cross demonstrated phenotypic characteristics of either of the parents 
and no intermediates, so it was thought that a single genetic locus could be responsible. 
Polymorphisms in a -330 kDa protein (cg2 gene) in this region were later identified. The 
protein is expressed in erythrocytic asexual stages and localised to the digestive vacuole 
and 'peripheral membranes' i.e. surrounding the parasitophorous vacuolar space. The 
polymorphisms in the cg2 gene included variations in three repetitive sequences (K, y, 0», 
changes in the length of a central poly-asparagine tract, and 12 individual point 
mutations outside the repetitive sequence (Su et a/. J 1997). 
These changes were associated with CQ resistance although the association was 
not 100% in isolates from Africa (Su et a/. J 1997; Basco and Ringwald. 1999; Adagu and 
Warhurst, 1999b) and South-East Asia (Su et a/. J 1997) suggesting yet another genetic 
variation. Subsequently, the Cg2 protein was suggested to be a NHE (Wiinsch et a/. J 
1998) as it has some motifs common to other NHE proteins. Wellems et a/. (1998), 
however, have argued otherwise and claim the cg2 gene is not a NHE. In transfection 
studies, Fidock et al. (2000a) used allelic exchange of cgl and cg2 polymorphisms and 
drug susceptibility assays of the transfectants showed no change in CQ sensitivity and 
VP had no reversal effect. The authors therefore suggested that CQ resistance mechanism 
may not be dependent on these polymorphisms alone, although these changes may have a 
role in CQ resistance, possibly complementing changes in a nearby gene. 
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Figure 1.9: A model illustrating the PfCRT protein showing amino acid substitutions. 
specifically the IY576thr mutation. Picture by Prof. D.C. Warhurst. 
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Further analysis of the 36 kb segment on chromosome 7 (Su et al.. 1997) 
identified a highly interrupted and previously undetected gene, plcrt, 10 kb from cg2 
(Fidock et al.. 2000b). Translation of the Dd2 plcrt gene predicted a 48.6 kDa 
transmembrane protein with ten transmembrane segments which was shown to be mainly 
located in the digestive vacuole (Fidock et ai. . 2000b; Cooper et ai. . 2002). Patterns of 
point mutations were associated with one of the CQR progeny from the HB3 and Dd2 
genetic cross (Wellems et al .. 1990) and CQR laboratory lines from Africa, South-East 
Asia and South America. One amino acid substitution, lys76thr located in the first 
transmembrane segment (Figure 1.9), was present in all resistant isolates and absent from 
all sensitive isolates tested in vitro. Other mutations in codons 72, 74, 75, 97, 220, 271, 
326, 356 and 371 are thought to complement the 76 mutation. The CQS Sudanese strain, 
106/1, carried all six plert mutations associated with resistance in Africa and Asia except 
the amino acid change at 76, adding further support to the role of codon 76 in CQ 
resistance. Episomal transformation of CQS parasite line 10611 with a plasmid 
containing mutant plcrt from CQR Dd2 resulted in transformed lines that grew in CQ 
concentrations only normally tolerated by CQR parasites. These lines still harboured the 
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mutant plert plasmid and there was little change in the CQ ICso. Stepwise CQ pressure 
on the transformed lines resulted in the loss of the plasmid and the selection of a highly 
CQR line, 34-11E, with a novel single (lys76ile) codon change. This CQR line displayed an 
ICso greater than Dd2 which was VP-reversible. Comparison of the nucleotide sequences 
of 106/1 and 34-11E demonstrated that these lines all carried plmdr 1 wild type residues 
tyr184, serl034, aso1042, aSP1246 and mutated codon 86tyr (Fidock et al., 2000b) -
associated with CQ resistance in Africa. 
Subsequently, the 106/1 strain was cultured under CQ pressure lethal to CQS 
parasites for 28 to 42 days (Cooper et al., 2002). Sequence analysis of the selected 
parasite lines revealed novellYS76aso and lys76i1e mutations and had CQ ICso values of 8- to 
12-fold higher, respectively, than that of 106/1. Compared to 106/1, the lys76ile (K76I) 
line was significantly susceptible to QN, but showed reduced susceptibility to its 
diastereomer quinidine - a stereoselective sensitivity not previously seen in CQR 
parasites. In addition, VP combinations in the K76I line with QN showed an antagonistic 
interaction, whilst the quinidine combination was synergistic. The authors concluded that 
this further highlighted the importance of the residue 76 of PfCRT in determining 
sensitivity to CQ and other drugs. Subsequent experiments showed that parasite lines 34-
lIE and K76I have identical antimalarial drug responses including the stereoselective 
sensitivity seen with QN and quinidine (Prof. David Fidock, personal communication) 
The PfCRT lys76thr substitution, has shown a marked association with CQ 
resistance in clinical studies and field isolates (Djimde et al., 2001; Adagu and Warhurst, 
2001). Further conclusive evidence linking the role of point mutations in plert and CQ 
resistance has been recently published. Sidhu et al. (2002) implemented an allelic 
exchange approach and replaced the CQS plcrt allele of a CQS line with alleles from 
CQR lines of African (K76I), South-East Asian (Dd2) or South American (7G8) origin. 
Recombinant CQS clones expressing PfCRT from CQR lines demonstrated ICso values 
in the range of 100 - 150 nM and these ICso values were 70 - 90% of non-transformed 
CQR lines. The authors suggested that lower CQ ICso values observed in the plcrt-
modified clones may be either due to lack of additional genetic factors such as mutated 
pfmdrl, or reduced PfCRT expression which was significantly lower in two of the 
clones. The recombinants also showed a significantly reduced eH]-CQ accumulation 
supporting reduced CQ accumulation in CQR P.lalciparum parasites (Verdier et al., 
1985; Krogstad et al., 1992; Bray et al., 1992b). The decreased CQ susceptibility in the 
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pfcrt-modified clones was VP-reversible. The ICso values of VP chemosensitised lines 
were still significantly higher than the CQ ICso values in the CQS lines, but equivalent to 
the CQ + VP ICso values of the CQR control parasite lines. The VP reversibility was 
noted to be more pronounced in the recombinants expressing pfcrt of 'Old World' (Dd2 
or K76I) origins than of 'New World' (7G8) origins. It is thought that the VP-reversible 
phenotype may reflect a physical association between VP and mutant PfCRT and/or 
mutant PfCRT -mediated physiological changes within the digestive vacuole that alter the 
activity ofVP on haem binding and drug-FPIX formation (Sidhu et al., 2002). 
The function of pfert is still unknown, although it has been suggested that it 
normally operates in facilitated diffusion of positively charged amino acids (such as 
histidine) from the digestive vacuole into the cytoplasm (Figure 1.10). When mutated 
from lysine to threonine 76 the side chain positive charge is lost. This loss of positivity 
applies to most of the changes in the resistant pfcrt sequence. The protein therefore could 
have an enhanced transport capability to transport the positive CQ molecule (Warhurst, 
2001). While PfCRT as well as Pgh-1 have been associated with in vitro CQ resistance 
(e.g. Fidock et al., 2000b; Cooper et al., 2002; Sidhu et al., 2002), it has been suggested 
that at least one other gene may be involved in highly resistant CQ phenotypes (Basco 
and Ringwald, 2001; Chen et al., 2002; Sidhu et al., 2002; Thomas et al., 2002). 
1.3.2 Resistance to other quinolines and related compounds 
1.3.2.1 4-Aminoquinolines and bisquinolines 
Cross-resistance between CQ and AQ has been reported (Misra et al., 1995; 
Pradines et al., 1998a; Basco et al., 2002) but other reports show that clinically important 
cross-resistance may be between CQ and the metabolite of AQ (Childs et al., 1989). 
Supporting the last point, Ringwald et al. (1998) noted that the level of sensitivity of 
African isolates to mono-desethylamodiaquine in vitro is dependent on the level of CQ 
resistance in vitro than AQ; although 'moderately' CQR isolates were sensitive in vitro 
to mono-desethylamodiaquine and highly CQR parasite lines showed appreciable AQ 
resistance. Geary et al. (1987) reported that CQR parasites show reduced sensitivity to 
AQ in vitro. Cross-resistance between AQ and CQ in CQR parasites was shown by Bray 
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et al. (1996b) and these parasites displayed a reduced accumulation of eH]-AQ. Time 
course studies highlighted a reduced initial rate of AQ accumulation in CQR compared 
with CQS parasites. Sidhu et al. (2002) demonstrated a slightly lower AQ susceptibility 
in CQR pfert-modified clones, although these transfectants remained sensitive to the 
drug with ICso values of 22 - 35 nM. Cross-resistance was seen between CQ and mono-
desethylamodiaquine. 
Depending on the chemical modifications to the structure, piperaquine (PPQ) and 
other bisquinolines are highly active against CQR parasites. It is thought that some 
bisquinolines have the same mode of action as the 4-aminoquinolines (Raynes, 1999). 
This is a worry as the parasite could therefore adopt a similar mechanism of resistance 
against these drugs as cross-resistance between CQ and PPQ has already been seen in P. 
falciparum both in vitro (Go and Feng, 2001) and in the field (Fan et al., 1998). One 
report showed up to 20% cross resistance with CQ and PPQ in P. berghei (Basco et aI., 
1994a). 
1.3.2.2 Arylaminoalcohols 
Cross-resistance has been reported between MQ, HAL and QN in a number of 
different studies from a range of geographical areas (Gay et al., 1997; Duraisingh et al., 
1999; Brockman et al., 2000) leading the authors to suggest these drugs could have a 
similar mechanism of resistance. MQ resistance strongly correlates with amplification 
and overexpression of pfmdr 1 in both field and laboratory isolates placed under drug 
pressure; has shown cross-resistance to HAL, and sometimes QN; and has been 
associated with increased sensitivity to CQ (Wilson et al., 1989; Peel et aI., 1993; 
Nateghpour et al., 1993; Wilson et al., 1993; Cowman et al., 1994; Peel et al., 1994; 
Price et al., 1999). Overexpression or amplification of wild-type pfmdrl and 
overexpression of its protein product is thought to be associated to efflux of the 
hydrophobic drug from the parasite digestive vacuole (see Section 1.3.1.2.1). In one 
study, CQR clone FAC8 which carries three copies of pfmdrl, was selected for high-
level CQ resistance, resulting in a cell line resistant to a lO-fold higher CQ concentration. 
These cell lines lost the amplified pfmdrl and showed an increased susceptibility to MQ, 
HAL and QN. No sequence changes in the pfmdr 1 gene were seen and it was suggested 
that over-expression of the wild-type Pgh-l is incompatible with high level CQ 
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resistance - fitting with the observation of an inverse relationship existing between MQ 
and CQ resistance (Barnes et al., 1992). Certainly this inverse relationship has been seen 
in Africa (Duraisingh et al., 2000a). In another study, two CQR clones, Kl and W2Mef, 
were placed under MQ pressure. The resultant MQ-resistant lines had an amplified 
pfmdr 1 leading to overexpressed Pgh-l, and increased level of resistance to HAL and 
QN. They both displayed reduced CQ ICso values (Cowman et al., 1994). These in vitro 
studies seem to suggest the pfmdr 1 locus is under selective pressure from the quinolines 
(Peel, 2001). 
However, some studies (Lim et al., 1996; Ritchie et al., 1996; Chaiyaroj et at., 
1999) demonstrate no link between arylaminoalcohol resistance and the amplification 
and overexpression of pfmdrl. Selection for HAL resistance in CQR Kl resulted in 
reduced sensitivity to both HAL and MQ and an increased sensitivity to CQ. These 
sensitivity changes were reflected by changes in drug accumulation. The HAL-resistant 
strain showed no evidence of pfmdr 1 amplification, increased Pgh-l expression, or the 
loss of the mutated 86tyr residue in pfmdrl. The loss of high-level CQ resistance was 
associated with the inability of VP to reduce the CQ ICso, whereas VP was still able to 
increase QN sensitivity. Changes in pfcrt, however, were not analysed (Ritchie et al., 
1996). South American clone FAC8 was selected under MQ pressure to be 3-fold more 
resistant to MQ with increased resistance to HAL and QN. No changes in copy number, 
level of expression, or sequence polymorphisms in pfmdr 1 were displayed in the resistant 
clones. A small increase in the CQ ICso was noted (Lim et al., 1996). A more recent 
analysis of multidrug-resistant P. falciparum isolates from Thailand failed to show any 
amplification of pfmdrl in moderate to high levels of MQ resistance. The authors 
suggested that there must be other mechanisms that mediate MQ resistance (Chaiyaroj et 
al., 1999). This is consistent with the results of the CQR genetic cross which suggested 
that MQ resistance may not be necessarily linked to pfmdrl (Well ems et al., 1990). 
However, CQS HB3 used in the cross has an atypical pfmdr 1 with codon 1042asp 
mutation. It would appear therefore that arylaminoalcohol resistance is a complex 
phenotype involving multiple genetic determinants that may be geographically distinct 
(Peel, 2001). 
In an allelic exchange experiment, Reed et al. (2000) examined the effects of 
pfmdrl mutations on MQ, HAL and QN sensitivities (see Section 1.3.1.2.1). The 
introduction of the three mutations (in codons 1034, 1042 and 1246) conferred resistance 
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to QN in a CQS strain to levels seen in a CQR strain. Conversely, these mutations 
increased the sensitivity of the strain to MQ and HAL. The pfmdr 1 asnS6tyr mutation -
which to date has not been investigated using transfectants - has been shown to confer 
increased sensitivity to both MQ and HAL, but not to CQ and QN (price et al., 1999; 
Duraisingh et aZ., 2000a). These differences suggest that QN resistance could be 
dependent on certain mutations in pfmdr 1 alone and could account for the cross-
resistance reported between CQ and QN (Basco and Le Bras, 1993; Duraisingh et al., 
2000a). However, a recent study failed to demonstrate the association between pfmdrl 
asnS6 and decreased MQ sensitivity (Mawili-Mboumba et al., 2002). Other studies in 
Brazil (P6voa et aZ., 1998; Zalis et aZ., 1998) reported sensitivity to MQ and HAL in all 
CQR isolates which carried pfmdrl codons 1034cys 1042asP and 1246tyr but the wild-type 
asnS6. In one of these studies, although no increase in pfmdr 1 copy number was noted, the 
isolates had reduced QN susceptibility (Zalis et al.. 1998). 
Sidhu et aZ. (2002) revealed a 2- to 4-fold increased sensitivity to QN, MQ, QHS 
and DHA in transfected CQR clones expressing mutated PfCRT. The introduction of the 
CQR Dd2 pfert mutations into the GC03 clone (which carries a HB3-like pfmdrl with a 
codon 1042asP mutation) increased QN susceptibility to -so nM, although control Dd2 
and GC03 had values of over 220 nM. As previously demonstrated with K76I line 
(Cooper et aZ., 2002), the increased susceptibility to QN was accompanied with a 
decreased susceptibility to quinidine indicating the stereospecificity of the PfCRT-
mediated drug effect. However, unlike the K76I line which also carried mutated pfmdrl 
86tyr (Cooper et aZ., 2002), both QN and quinidine were chemosensitised (i.e. 'reversed') 
by VP in the pfert-modified transfectants each containing the pfert Dd2, K76I and 7G8 
alleles (Sidhu et aZ., 2002). These data provide the first direct evidence of the gene 
product playing a role in susceptibility to these antimalarials. 
1.3.3 Antifo/ate resistance 
Resistance to both PYR and SDX develops through point mutations in the dhfr 
(e.g. Warhurst, 1998) or dhps (Brooks et aZ .• 1994) genes, respectively. Mutations are 
thought to occur in a stepwise fashion with every supplementary mutation conferring a 
higher level of resistance (Plowe et aZ., 1997 ; Warhurst. 1998). A single point mutation 
in dhfr codon serl08asn confers PYR resistance and the addition of asnSI ile and cYSS9arg is 
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linked to higher-level PYR resistance. The mutation ile1641eu in combination with ser108asn 
and one or both asnS1 ile or cysS9arg confers high-level resistance to both PYR and 
cyc10guanil (Peterson et al., 1990; Foote et al., 1990a). These six modifications are the 
only PYR resistance mutations seen frequently in the field (Plowe et al., 1997). Further 
evidence of the role of codons ser108asn, asn51 i1e and cys59arg in PYR resistance was 
confirmed by transformation of PYR-sensitive parasites with plasmids containing the 
polymorphisms (Wu et al., 1996). These polymorphisms are found in or around the 
active site pocket ofDHFR and appear to have arisen in response to the different ways in 
which PYR and cyc10guanil bind to the enzyme (Peterson et al., 1990). Amino acid 
changes can cause the active site to change shape (e.g. replacement of amino acid with a 
more bulky side-chain) or properties (e.g. disruption of hydrogen-bonding). The 
conserved hydrophobic active site accommodates the heterocyclic ring system of the 
drug and rigid DHFR inhibitors such as PYR and cyc10guanil are particularly susceptible 
to changes at this site (Warhurst, 1998). The effect of ser108asn on PYR resistance was 
further highlighted in a recent study which showed an increase in the prevalence of the 
mutation from 13% to 100% on prophylaxis in Mali emphasising the need to combine 
PYR with another antifolate or antimalarial (Doumbo et al., 2000). 
Point mutations in five positions in dhps have been identified and shown to be 
associated with SDX resistance. Parasite lines exhibiting decreased susceptibility 
harbour alaS81 gly, or the combination of ser436phe/alallys and ala613thrlser. Using transfection 
methods Triglia et al. (1998) introduced specific mutations in the dhps gene and found 
that the ala437gly substitution increased the SDX ICso 5-fold and the addition of further 
mutations raised the level of resistance 24-fold. A mutation resulting in lys540glu has been 
reported which correlates strongly with ala437gly (Plowe et al., 1997). Highly resistant 
strains in the field have been reported with triple mutations (Nzila et al., 2000). 
1.3.4 Resistance to atovaquone 
The rapidity of drug resistance emergence when ATV is used as a single agent 
has led to the hypothesis that the drug can induce its own resistance via production of 
ROS (see Section 1.2.4.2). ATV-resistant P. Jalciparum parasites are about 1000-fold 
less sensitive to ATV in vitro (Looareesuwan et al., 1996; Korsinczky et al., 2000; 
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Fivelman et al., 2002). The decreased susceptibility of Plasmodium parasites is 
associated with single point mutations in the parasite cytb gene resulting in amino acid 
changes in the ubiquinone binding site (Syafruddin et al., 1999; Srivastava et al., 1999; 
Korsinczky et al., 2000). Single point mutations within the ubiquinone binding site 
confer resistance to mitochondrial electron inhibitors in a variety of micro-organisms (di 
Rago et al., 1989). Korsinczky et al. (2000) placed the P. falciparum Kl strain under 
ATV drug pressure and cloned a series of parasite lines with decreased susceptibility to 
ATV. The single point mutation in cytb gene leading to a met133ile codon change only 
showed a 25-fold increase of the ATV ICso. The addition ofpro275thr, lys272arg, or glY280asp 
codon changes resulted in an approximate decrease of ATV susceptibility by 200-,500-, 
or 900-fold respectively. Surprisingly, a clone with double mutations, leu281 ile and 
val284lys, only showed a 75-fold decrease in ATV susceptibility - this anomaly may not 
be so surprising since the residues are very close to one another. However, mutations in 
the 268 codon were associated with the most profound decrease in ATV susceptibility. 
The single change tyr268asn (seen in a parasite line from West Africa isolated from a 
patient who failed Malarone® treatment), showed an increased ATV ICso of almost 1000-
fold (Fivelman et al., 2002). A change in this codon, tyr268ser, was seen in an isolate 
obtained from a Thai patient who failed combined ATV + PYR treatment. The ATV ICso 
of the parasite line was almost 10 OOO-fold higher than an ATV-sensitive strain 
(Korsinczky et al., 2000). 
The codons 133, 268 and 284 mutations occur at putative contact residues with 
CYT b. These residues were all within hydrophobic or H-bond interaction distance of 
ATV when ATV was modelled into the putative binding site and could therefore affect 
the drug binding (Korsinczky et al., 2000; Fivelman et al., 2002). Mutations resulting in 
amino acid substitutions at residues 271,272,258,267 and 268 in P. yoelii (Srivastava et 
al., 1999) and 133, 144 and 284 in P. berghei (Syafruddin et al., 1999) have been linked 
with a decrease in ATV susceptibility. Mutations in the cytb gene are said to be 
associated with a loss of 'fitness' in P. falciparum. The double amino acid change, 
met133ile and glY280asp have been shown to impede parasite growth 5 to 9%. It was 
suggested that the mutations weaken the CYT b-ubiquinone complex causing the 
electron transport chain to become less efficient. However, lack of fitness in vitro does 
not necessarily mean lack of fitness in vivo (Peters et al., 2002). 
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In P. yoelii the combination of PG + ATV does not affect the mitochondrial 
membrane potential collapse in ATV -resistant parasites (with altered residues leu271 val 
and lys272arg) unlike ATV -sensitive parasites. This suggested that the addition of PG may 
not be synergistic with ATV once ATV resistance has developed (Srivastava et al., 
1999). Conversely, it was shown in P. Jalciparum that the synergistic effect of the 
combination in the ATV -resistant line C2B was unaffected and this interaction was of an 
equal potency (Le. equivalent mean FIC values) to that seen in the ATV-sensitive strains 
W2 and D6. The C2B line, isolated from a patient displaying an Rl-type treatment 
failure, had ATV resistance 95-fold that of the pre-treatment isolate but the mutation(s) 
in the cytochrome b DNA from this line were not reported (Canfield et al., 1995). 
1.3.5 Artemisinin Resistance 
There have been attempts to select for resistance to QHS and its derivatives 
mainly by exposing parasites to increasing drug concentrations in vivo or in vitro. There 
has been little success with P. Jalciparum strains. Strains apparently adapt to drug 
pressure but lose their apparent resistance when drug pressure is removed or after a 
period of frozen storage (Prof. Steven Meshnick, personal communication). 
1.3.5.1 Experimental 
Jiang (1992) obtained a 3-fold increase in the artesunate ICso of a CQS P. 
Jalciparum strain under increasing concentrations of artesunate over 130 days. The 
resistance decreased significantly once the strain was grown in drug-free medium. QHS-
resistant mutants of P. Jalciparum have been reported in vitro after mutagenic treatment 
with N-methyl-N-nitro-nitrosoguanidine (MNNG), demonstrating a 3- to 10-fold 
increase in QHS resistance (Inselburg, 1985). QHS-resistant clones of Toxoplasma 
gondii were selected with approximately 65-fold lower sensitivity to QHS using 
increasing selective pressure. Chemical mutagenesis was also attempted using MNNG 
and ethylmethane sulfonate, but neither mutagen resulted in QHS-resistant mutants. 
However, cross-resistance to DHA and ATM was observed (Berens et al., 1998). 
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1.3.5.2 Mouse Model 
QHS-resistant strains have been developed in vivo from a naturally CQR P. yoelii 
strain. Chawira et ala (1986) reported a 40-fold decrease in QHS sensitivity. Some 
resistance was lost when the drug pressure was removed, but rapidly regained when the 
pressure was reapplied. Cross-resistance was observed with DHA and artemether, but not 
with artesunate. Cross-resistance with CQ, AQ, QN and MQ was also observed. The 
authors suggested that changes in membrane composition could confer resistance to other 
antimalarials due to a possible multidrug resistance mechanism. The above P. yoelii 
strain was revived a few years later, but the level of resistance had dropped from 40- to 
16-fold (Peters et al., 1993; Peters and Robinson, 1999), with a further drop to 4-fold 
(Peters and Robinson, 1997); although more recent studies show that there are clear 
biochemical and molecular differences to the parent strain (Peters and Robinson, 1999). 
In the original study, a P. berghei CQS strain was concurrently subjected to the same 
drug pressure, but little resistance to QHS was obtained (Chawira et al., 1986). A recent 
re-analysis of the original data has shown that a 16.3-fold increased QHS resistance was 
obtained in the CQS strain (Peters and Robinson, 1999). The above parent strains of 
CQR P. yoelii and CQS P. berghei were recently exposed to a range of natural (QHS and 
artesunate) and synthetic (Ro 41-3823 and Fenozan B07) endoperoxides. QHS resistance 
developed to a moderate level in both strains, but it was not retained once the drug 
pressure was withdrawn. Little or no resistance developed to the other endoperoxides. It 
was further suggested that endoperoxide resistance may develop more readily in CQS 
than CQR parasites (peters and Robinson, 1999). 
Walker et ala (2000) made an attempt in determining the mechanism of resistance 
in the above Chawira et ala (1986) P. yoelii strain which was 4-fold less susceptible to 
QHS at the time of the study. A comparison of uptake studies between the sensitive and 
resistant strains showed that the resistant strain accumulated significantly less eH]-DHA 
than the sensitive strain, but the difference in accumulation was less than 2-fold. A large 
difference in accumulations would be thought to account for a 16.5-fold difference in 
sensitivity. Drug target alterations were also studied, but no changes in the TCTP 
sequence or drug-binding receptors were reported. It could be possible that the resistant 
strain over-expresses one of the target proteins or has an increased drug detoxification 
mechanism possibly due to cytochrome P-450 (Meshnick, 1998). 
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Liu and Ren (1987) reported a strain of P. berghei selected with a 29.3-fold 
higher resistance to artesunate. There was about a 2-fold decrease in the sensitivity to 
QHS and artemether, but no cross-resistance to CQ was found. The resistance was 
gradually lost in the absence of drug pressure. Cheng et al. (1988) selected an ATM-
resistant line of P. berghei that showed a 139-fold increase in resistance to ATM. The 
parasites reverted to normal sensitivity after 38 untreated passages. Cross-resistance to 
artesunate, QHS and CQ (a 16-fold increase) was interestingly noted although the 
parental strain was CQS. 
1.3.5.3 Field Situation 
1.3.5.3.1 Reported cases 
There have been few reports of QHS resistance. A P. Jalciparom strain, 
originating in West Africa, was isolated from a French traveller and found to have 
significantly reduced sensitivity in vitro to many drugs including QHS, ATM and 
artesunate (Gay et aI., 1994). 
An interesting strain of multi drug-resistant P. vivax malaria in India was reported 
to recrudesce twenty days later after a six day course of injectable artemether (Kshirsagar 
et al., 2000). Three other cases in India of treatment failure to parenteral artemether 
might, as the authors suggest, indicate low-level resistance to the QHS-derivatives or 
insufficient treatment (Gogtay et al., 2000). Four cases in Sierra Leone showed 
artesunate treatment failure which the authors suggested was due to indiscriminate use of 
the drug among the population (Sahr et al., 2001). None of the three reports can indeed 
confirm field QHS resistance as there were no DNA analyses or ICso values reported. 
1.3.5.3.2 Field trials 
Oduola et al. (1992) identified multidrug-resistant strains of P. Jalciparom from 
Nigerians which also had reduced sensitivity to QHS. This was a disturbing observation 
of spontaneous resistance since QHS-derivatives had never been used in West Africa. 
This was a classical example of innate resistance as was seen with MQ in areas of West 
Africa (Oduola et al., 1987). There have been reports of artesunate treatment failures in 
an area of Thailand with highly MQ-resistant malaria (Luxemburger et al., 1998). In 
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vitro drug assays, however, demonstrated no decrease in sensitivity in parasites obtained 
from patients who failed artesunate treatment (Looareesuwan et al., 1992). In contrast, a 
decrease in sensitivity to arteflene in vitro was seen in 2 out of 6 recrudescent parasites 
from arteflene-treated patients (Radloff et al., 1996b). With highly hydrophobic drugs 
the inoculum effect may affect the ICso levels obtained from in vitro drug assays. It is 
important when testing strains in vitro, to control for this (Duraisingh et al., 1999). 
1.3.5.3.3 Cross-resistance 
Studies from many different geographical areas have observed cross-resistance 
between QHS-based drugs, MQ and HAL (Doury et al., 1992; Basco and Le Bras, 1993; 
Bustos et al., 1994; Gay et al., 1997; Le Bras, 1998; Pradines et al., 1998b; Brockman et 
at., 2000; Duraisingh et al., 2000a). Other studies have shown a weak correlation 
between the endoperoxides and CQ resistance (Yang et al., 1992; Hassan Alin et al., 
1995; von Seidlein et at., 1997; Pradines et al., 1998a). Conversely, there have been 
reports that CQR isolates are more susceptible to the endoperoxides (Basco and Le Bras, 
1993; Le Bras, 1998; Duraisingh et al., 1999), although the derivatives were shown to be 
highly effective against CQS and CQR parasites. These discrepancies may be due to the 
inoculum effect. Hydrophobic antimalarials (particularly MQ and QHS-derivatives), are 
susceptible to the inoculum effect; and studies that did not control for this effect (e.g. von 
Seidlein et al., 1997) could show cross-resistance between the endoperoxides and CQ 
(Duraisingh et al., 1999). In a more recent study in Thailand, it was reported that in areas 
with decreased MQ sensitivities there is a strong correlation with lower QHS 
sensitivities. Along the Myanmar border the sensitivity to artesunate and MQ decreased 
from 1991 to 1994, a time when endoperoxides were not freely available. However, this 
was attributed to the migration of people from Myanmar, a region where QHS-
derivatives have been widely available for many years (Wongsrichanalai et al., 1999). 
1.3.5.4 Genetic determinants 
The Pgh-l protein has been implicated in playing a major role in resistance to the 
endoperoxides. Studies in vitro on field isolates (Price et al., 1999; Duraisingh et al., 
2000a) and an experimental cross (Duraisingh et al., 2000b) have indicated an 
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association between decreased sensitivity to artemisinin and the presence of the 'wild-
type' asn86 codon of Pgh-l protein. However, a recent study of clinical isolates from 
Cameroon failed to show any link between in vitro responses to QHS and presence of 
mutations in codons 86 or 184 of Pgh-l (Basco and Ringwald, 2002). Two studies have 
revealed a link between a decrease in QHS susceptibility and amplification of the 'wild-
type' asnS6 coded by the pfmdrl gene (Peel et al., 1994; Price et al., 1999) - as 
demonstrated for both MQ and HAL resistance (see Section 1.3.2.2). Furthermore, in co-
artemether clinical trials carried out in children, Duraisingh (1999) reported a 
significantly reduced prevalence of mutated pfmdr 1 86tyr in recurring infections. In both 
the Gambian and Tanzanian trial areas 'wild-type' pfmdrl asn86, was selected; while in 
the control group on CQ only, prevalence of pfmdr 1 asnS6 recurrences was significantly 
reduced. This highlighted the difference in allele selection between the two drugs. Reed 
et al. (2000) experimented with the transfection of various pfmdr 1 alleles into CQS and 
CQR strains (see Sections 1.3.1.2.1 and 1.3.2.2). Replacement of the CQS allele of the 
pfmdrl gene with a CQR allele was shown to increase the sensitivity of the strain to 
QHS, MQ and HAL. Conversely, the replacement of the CQR with a CQS allele 
exhibited an increase in the QHS ICso. In both transfectants, the QHS sensitivity was not 
at the level of either of the original or control parent strains, which suggests other factors 
may play an important role in QHS susceptibility. 
QHS sensitivity has been linked to pfcrt changes. A 2- to 3-fold increased 
susceptibility to QHS compared to control is associated with pfcrt mutations lys76asn or 
lys76i1e (Cooper et al., 2002). In the allelic replacement experiment of the pfcrt gene, a 2-
to 3-fold increased sensitivity to QHS and DHA was seen in two of the three CQRpfcrt-
modified clones expressing mutated PfCRT (Sidhu et al., 2002). In both these 
transfection studies a similar trend was seen with HAL and MQ thus supporting previous 
reports of cross-resistance. 
1.3.6 Multigenic basis of multidrug resistance 
The recent papers of Reed et al. (2000), Fidock et al. (2000b), Warhurst (2001), 
and Sidhu et aZ. (2002) present further evidence on the proposed nature of CQ resistance 
in P. faZciparum being multi genic with overlapping resistance mechanisms. There is 
increasing support from the field showing a strong correlation between CQ resistance 
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and mutations in bothpfmdrl andpfcrt genes (Djimde et al., 2001; Adagu and Warhurst, 
2001; Babiker et al., 2001). 
1.3.6.1 Multigenic multidrug resistance phenotypes 
It was first shown that resistance and accumulation of CQ could be reversed by 
VP (Martin et al., 1987), although the level of CQ sensitivity obtained was never 
equivalent to the level in CQS strains (Bray et al., 1996a). This suggested that there was 
a component of CQ resistance which was not affected by VP and supported the theory of 
the multigenic nature of CQ resistance (Foote et al., 1990b; Ward et al., 1995; Adagu 
and Warhurst, 1997). The discovery of the pfcrt gene (Fidock et al., 2000b) and its 
transfection (Sidhu et al., 2002) confirmed this hypothesis, as the CQ resistance in 
transfectants expressing the mutated protein was VP-reversible. Warhurst (2001) 
suggests that as polymorphisms of pfcrt show a 100% negative predictive value for 
decreased CQ sensitivity, mutations in the gene probably initiate the cellular changes 
towards the multigenic CQR phenotype. The mutated PfCRT protein could be inefficient 
in exporting protonated amino acids and small peptides (Figure 1.10), which could cause 
the vacuolar pH to decrease (Fidock et al., 2000b). Wild-type Pgh-l makes mammalian 
lysosomes more acidic (van Es et al., 1994b), so this combined effect would require 
mutated Pgh-l to raise the pH close to normal levels. Other mutations (in pfmdr 1 and 
possibly eg2) may have complementary effects permitting a move to a more dangerous 
level of resistance (Prof. David Warhurst, personal communication). 
Cross-resistance among MQ, HAL and QHS-derivatives has been widely 
reported (Pradines et al., 1998b; Duraisingh et al., 1999; Ringwald et al., 1999a). 
Resistance to MQ and HAL is reported to be associated with pfmdrl amplification and 
the wild-type allele (see Section 1.3.2.2). Decreased QHS sensitivity, similarly, has been 
reported to be associated with the wild-type pfmdrl allele (see Section 1.3.5.4). Both 
Reed et al. (2000) and Sidhu et al. (2002) have demonstrated sensitivity changes for all 
these drugs in their allelic replacement experiments with pfmdr 1 and pferl, respectively. 
Consequently, there is concern that multidrug resistance to all three drugs could develop. 
The inverse relationship between CQ and MQIHAL - also seen with these transfectants -
correlates with the difficulties in producing a MQ-resistant and CQRP.falciparum strain 
in vitro (Cowman et al., 1994). As antifolate resistance is associated with an unrelated 
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group of genes, SP resistance can occur concurrently with any other drug resistance (see 
Section 1.3.3). 
1.3.6.2 Accelerated resistance to multiple drugs (ARM D) phenotype 
It has been hypothesised that continual exposure of malarial parasite populations 
to different drugs could have selected not only for resistance to individual drugs but also 
for genetic traits that select for the initiation of resistance to novel unrelated 
antimalarials. This phenomenon was investigated by culturing five different P. 
Jalciparum clones, with varying numbers of pre-existing drug resistance mutations, in the 
presence of two new antimalarial agents to which all the clones were equally susceptible 
(Rathod et al., 1997). The two antimalarials, 5-fluoroorotate and ATV are structurally 
and mechanistically unrelated. The Indochina strain W2, which is resistant to a range of 
antimalarials, independently developed resistance to both antimalarials about 1000-fold 
more frequently than the African strain D6. All the strains except W2 failed to yield to 5-
fluoroorotate resistance even after 2 months of culture. In contrast, ATV resistance was 
acquired in two additional strains, although the initial parasite popUlation was of a larger 
size than W2. The authors proposed that W2, which is resistant to many antimalarials, 
could carry genetic traits that may greatly facilitate the independent acquisition of 
resistance to new and unrelated compounds. On the other hand, drug sensitive strains 
such as D6, which are susceptible to many antimalarials, may lack these traits. These so 
called 'mutator' phenotypes could have molecular metabolic systems highly prone to 
cause mutations within the parasite genome. Examples of altered polymerases and 
altered DNA repair enzymes have been reported in bacteria and cancer cell lines leading 
to 'mutator' genotypes. With time, the range of mutant genotypes will be tested for 
fitness against environmental challenges, and phenotypes displaying advantageous 
mutations would be selected (Miller, 1996; Rathod et al., 1997; Hyde, 2002). 
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Figure 1.10: The effect of CO on FPIX detoxification in the digestive vacuole of a cas P. 
fa/ciparum parasite (A) and a COR parasite (B). Picture from Warhurst (2001). ; 
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t A: The pH 5.5 of the vacuole is thought to be regulated by the Pgh-1 protein by transporting 
anions into the vacuole to optimise the acidification by the proton pump. During the digestion of 
Hb, protonated basic amino acids (AAH+) are released together with toxic FPIX (Fp9) which is 
detoxified into haemozoin. CQH+ binds to FPIX and thus inhibits its polymerisation, which leads to 
the accumulation of FPIX and CO-FPIX, causing membrane damage. It is thought that the 
protonated basic amino acids are transported out the vacuole by PfCRT. The PfCRT protein 
probably has a limited affinity for CQH+ and exports some of the drug from chloroquine-sensitive 
parasites. 
B: Shows COR parasite vacuole with mutations in pfcrl and pfmdr1. The mutant PfCRT probably 
has an increased affinity for COH+ and a reduced affinity for AAH+ resulting in increased exports 
of the drug, enabling haemozoin formation to proceed normally. The presence of mutant Pgh-1 
may increase the fitness of parasites by further optimising the pH for the damaged PfCRT. The 
mutated pfmdr1 also increases the sensitivity of the parasite to MO and OHS, probably as a 
result of the partial inactivation of the ability of mutant Pgh-1 to export these drugs. 
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1.4 Combination chemotherapy 
Combination drug regimens in cancer, AIDS and tuberculosis often achieve a 
therapeutic efficacy greater than monotherapy. Other benefits may include decreased 
toxicity, delay or prevention of drug resistance development, and favourable effects of 
synergistic drug interactions. Antimalarial drug resistance is becoming a major public 
health disaster in many areas of the tropical world (White et al., 1999). In the search for 
effective combination regimens, Malarone®, LapDap and Coartem® have recently 
become available or are in development. It is hoped that combination chemotherapy will 
delay the onset of resistance to new agents and reduce the effects of resistance to existing 
agents (White, 1998; Peters, 1999). 
Although the outcomes of in vitro interactions between antiplasmodials are open 
to modulation in the more stringent area of host pharmacokinetics, they provide an 
essential background for pre-clinical and clinical studies. Synergism (supra-additivity), 
additivism (summation) and antagonism (sub-additivity) are the expected outcomes of 
drug-drug interactions. The interaction is said to be additive when the combined effect is 
no more than the expected sum of the effects of the individual drugs, while a synergistic 
effect describes a combined effect that is more than the sum of the effects of the 
individual drugs. An effect is antagonistic when a combined effect is less than the sum of 
the effects of the individual drugs (Rideout and Chou, 1991). 
1.4.1 Rationale for malaria drug combinations 
The rationale for malaria combination chemotherapy has been recently reviewed 
(Nosten and Brasseur, 2002). Ideally, combination chemotherapy in malaria should take 
advantage of synergistic interactions, as these would enhance therapeutic efficacy and 
lower the risk of resistance emerging. If drugs in combination are antagonistic, the 
efficacy of such regimens might be compromised and the chances of resistance 
developing and spreading are increased, as less-effective drugs may be allowing weakly 
resistant clones to survive and be transmitted. It is difficult to predict in vivo drug 
interactions in humans based on in vitro findings, though animal model studies may be 
more predictive (Chawira et al., 1987). Although certain drug combinations show 
antagonism in vitro, the effects are not usually apparent in vivo. 
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The triple combination of sulfadoxine/pyrimethamine with mefloquine (MSP) 
was initially introduced in Thailand from late 1984 but by 1990 it was replaced by high-
dose MQ monotherapy due to a large drop in cure rates (Nosten et al., 2000). Previous 
researchers had demonstrated that these three drugs in combination could slow down the 
development of MQ resistance both in vitro (Brockelman et al., 1989) and in vivo 
(Merkli et al., 1980). The combination has also been shown to have high cure rates in 
two studies in Burma (Tin et al., 1985) and Gabon (LeU et al., 1998). The failure of the 
MSP combination was thought to be due to high levels of SP resistance already present 
in Thailand when the combination was first introduced (Nosten et al., 1991; Nosten et 
al., 2000), as well as pharmacokinetic incompatibilities between the three antimalarials 
(White, 1998). Antifolates have been shown here to be antagonistic in vitro with MQ 
(Figure A2.4; Appendix 2). From mid-1994 onwards MQ in Thailand was then generally 
deployed in combination with artesunate and the efficacy vastly improved to nearly 
100% (Nosten et aI., 2000). QHS-derivatives are synergistic or additive with MQ in 
animal experiments and in vitro (Chawira et al., 1987; Chawira and Warhurst, 1987; 
Fivelman et aI., 1999). In the five years since the introduction of this combination, it has 
proven to be highly effective with a cure rate approaching 100% (Nosten et al., 2000). 
This high efficacy rate was seen despite the presence of a high level of MQ resistance 
when this combination was initially deployed. However, since the introduction of this 
combination, MQ (Fevre et al., 1999; Nosten et al., 2000; Brockman et al., 2000) and 
artesunate (Brockman et al., 2000) susceptibility has been reported to improve, although 
MQ has been reported to be cross-resistant with QHS-derivatives (see Section 1.3.5.3.3). 
An 8-year Chinese field study by Chen et al. (1997) revealed a drop in the cure 
rate from an original 100% to as low as 87% with the addition of SP to pyronaridine -
reported to be an antagonistic interaction (Ringwald et al., 1999b). Although this was 
still superior to pyronaridine alone, the drug combination did not protect either of the two 
drugs and resistance could have developed. A clinical trial combining artesunate and CQ 
showed a reduction of fever within 6 hours after administration and cleared parasitaemia 
within 31 hours, but all patients experienced recrudescence. The authors suggested that 
the high recrudescence was due to antagonism of the two drugs (Bunnag et al., 1991). 
Another possible example of antagonism already exists in the new SP-artesunate 
combination, which has previously reported to be antagonistic (Chawira et al., 1987; 
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Fivelman et a/., 1999), and has not yet satisfied expectations in the field (von Seidlein et 
a/., 2000). 
1.4.2 Interaction of the Artemisinins with Other Drugs 
Methoxylated flavones (artemetin and casticin) that occur in Artemisia annua 
have been shown to be synergistic with QHS in vitro, but they did not possess any 
antimalarial activity when tested alone (Elford et a/., 1987). Tetrandrine and berbamine 
are principal alkaloids of traditional Chinese herbal remedies for rheumatic diseases. 
Both compounds showed antimalarial activity and potentiation of QHS activity was seen 
in P.ja/ciparum CQS strains in vitro (Ye et a/., 1989; Ye et a/., 1993). 
Combinations of standard antimalarials with QHS in vivo in mice revealed 
synergism with MQ, tetracycline and primaquine. Antagonism was shown with dapsone, 
SDX, PYR, SP and cycloguanil; whilst CQ and QHS showed an additive interaction 
(Chawira et a/., 1987). Interactions between pyronaridine and QHS were tested on drug-
resistant P. yoe/ii strains in vivo. The cOf!1bination proved to be additive in a CQR strain, 
but synergistic in QHS- and pyronaridine-resistant strains (Peters and Robinson, 1997). 
Chawira and Warhurst (1987) tested QHS in combinations with some commonly 
used antimalarial drugs in vitro against CQR and CQS P. Ja/ciparum strains. Synergism 
was seen with MQ, tetracycline and primaquine combinations, and antagonism was seen 
with PYR and CQ. Synergism in vitro has also been reported between arteether and QN 
or MQ (Ekong and Warhurst, 1990), and between ATM and LM (Hassan Alin et a/., 
1999). 
Fivelman et al. (1999) combined artesunate with some common antimalarials in 
two P. ja/ciparum strains. Synergy was also seen in the MQ and QN combinations and 
antagonism in the PYR combination. The CQ combination was reported to be additive in 
the CQS strain but antagonistic in the CQR strain. The authors suggest that CQS strains 
of P. Jalciparum may be less susceptible to antagonistic interactions between artesunate 
andCQ. 
Peters and Robinson (2000) studied the effects of delaying the selection of drug 
resistance by combining QHS or artesunate with long acting blood schizontocides in 
rodent malaria. It was reported that the combination of QHS with MQ significantly 
impeded the selection of drug resistance, although resistance was eventually seen in both 
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CQS and CQR strains. The QHS and pyronaridine combination reported greater success 
in the prevention of resistance, although a very low level of resistance was observed. The 
relevance of these results to the human model is hard to ascertain. The ratio of the two 
drugs in combination and the dosage size seems to have varying effects in impeding 
resistance. 
In vitro combinations of QHS with ATV, QN, MQ, AQ, CQ and pyronaridine 
were tested by Gupta et al. (2002a; 2002b) in CQR Kl and FCR3, and CQS F32 P. 
falciparum strains. In the two studies, the checkerboard method was used to ascertain the 
interaction between QHS and each of the six other antimalarials. The mean FIC values of 
the drug combinations were calculated for three different degrees of inhibition using the 
ICso, IC90 and IC99 values. Using the FICso values averaged over the three strains, the 
interaction of QHS with QN, MQ or ATV was additive, additive and antagonistic, 
respectively. However, using the FIC90 and FIC99 values synergism was shown for all 
three drugs. In the case of the combinations of QHS with CQ or pyronaridine, an additive 
to synergistic interaction was seen; and the interaction with AQ indicated a consistent 
synergistic interaction. 
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1.5 Summary of chloroquine drug action and resistance 
Many different hypotheses and proposals explaining how chloroquine exerts its 
antimalarial activity were discussed in this chapter. This is a summary of the most 
relevant hypotheses on chloroquine drug action and resistance. 
1.5.1 Drug Action 
• Evidence of CQ exerting its effects in the vacuole has been observed using 
ultrastructural studies of malaria parasites in the presence of CQ. Damage to the 
lysosomal system is the first morphological change detected after exposure to 
CQ. 
• More CQ accumulates inside an infected RBC as opposed to an uninfected RBC 
and CQ activity depends on high level accumulation within the parasite - CQ 
resistance is characterised by reduced intracellular concentration of the drug. 
• It was suggested that the antimalarial effect of CQ was due to its weak base 
properties which allowed it to accumulate to high levels in the acid digestive 
vacuole. The pH gradient is thought to be produced by a vacuolar membrane-
based ATP-dependent proton pump proposed to be similar to that of mammalian 
lysosomes and both are inhibited by bafilomycin Al - which also leads to a 
reduction in CQ accumulation. 
• As an addition to the proton-trapping theory the presence of a CQ importer pump 
or permease on the plasma or digestive vacuole membrane was suggested. 
However, conclusive evidence demonstrating the existence of a transporter has 
been controversial or lacking. 
• The proton trapping mechanism probably does not account for the full extent of 
CQ or AQ accumulation by P. Jalciparum as other eukaryotic cells with large 
acidic compartments accumulate lower amounts of CQ. 
• It has been proposed that the binding of CQ to a specific receptor was driving the 
selective concentration of the drug and that this receptor was FPIX - the 
degradation product ofHb. 
• In vitro polymerisation of FPIX was shown to be inhibited by CQ at 
concentrations in the high micromolar to low millimolar range. The ability of CQ 
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to inhibit FPIX polymerisation in both synthetic and parasite cell-free systems 
has been confirmed by a number of groups. 
• It was initially thought that the amount and rate of FPIX production by the 
parasite were insufficient to account for total CQ uptake by the infected RBC. It 
has been suggested that a large proportion of the total CQ uptake is non-saturable 
and only the saturable portion of uptake is relevant to the antimalarial properties 
of the drug. 
• The demonstration of saturable CQ accumulation being retained in cell debris of 
lysed infected cells pre-loaded with CQ, FPIX production kinetics are equal to 
CQ uptake rates and the effect of plasmepsin inhibitors has added weight to this 
argument. 
• There are three proposed mechanisms for CQ's inhibitory effect on FPIX 
polymerisation: 1) direct binding of the drug to FPIX in solution thereby 
interfering with the crystallisation of haemozoin; 2) chemi-absorption of the drug 
onto crystallised haemozoin, leading to inhibition of further FPIX aggregation; 
and 3) enzymatic inhibition of a protein that catalyses haemozoin crystallisation. 
1.5.2 Drug resistance 
• Reduced CQ accumulation seen in CQR parasites has been suggested to form the 
basis for CQ resistance - partially reversed by verapamil (VP), a calcium-channel 
blocker which reverses resistance of mammalian cells to anti-cancer drugs. 
• It has been shown that the initial uptake rate of CQ in CQR parasites is reduced 
and VP increases this initial uptake rate selectively in CQR strains. 
• Early studies suggested that CQ resistance was based on an enhanced drug efflux 
system in CQR cells. Later studies linked CQ resistance to changes in a CQ 
importer, but these two arguments have been controversial. 
• It was proposed that CQ resistance might be explained by an elevation of the 
vacuolar pH in CQR compared to CQS parasites. This hypothesis was favoured 
by many workers, although it has never been conclusively demonstrated in vitro 
due to difficulties in measuring vacuolar pH. 
• It suggested that CQR parasites might have lower levels of CQ-FPIX complex or 
possibly lower levels of soluble FPIX. CQ susceptibility could be determined by 
Chapter J: Genera/Introduction 90 
the amount of free FPIX available within the vacuole. A parasite could therefore 
become CQR by reducing the amount or affinity of drug binding sites. 
• There is further evidence that CQ resistance is associated with reduced CQ-FPIX 
binding affinity rather than changes to the capacity of binding sites or changes in 
CQ transport across membranes, but the results are not conclusive. 
• There is increasing support from the field showing a strong correlation between 
CQ resistance and mutations in both pfmdr 1 and pfcr! genes. Mutations in the 
pfcr! gene (in particular codon 76) show a 100% correlation to CQ resistance. 
Evidence is accumulating in favour of the proposed multigenic nature of CQ 
resistance and other genes may be involved in highly CQR phenotypes. 
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1.6 Aims of the thesis 
Resistance of P. falciparum to clinically useful antimalarials is widespread and 
the search for alternatives identifies artemisinin and its derivatives as valuable 
replacements. These derivatives and other antimalarial drug combinations are in the 
process of being released world-wide as combination regimens to treat multidrug 
resistant P. falciparum infections. However, the exact mechanisms of the interactions 
between artemisinin-derivatives and other antimalarials, or between individual 
components of other drug combinations (e.g. Malarone®, LapDap) are not completely 
understood in drug resistant strains. 
Therefore the aims of this project are to examine the antimalarial drug 
susceptibilities of a range of P. falciparum lines to establish baseline ICso values and to 
assess the responses of the parasite lines to in vitro drug combinations. It is hoped that 
this will provide insight into the interactions that exist between potentially clinically 
useful drug combinations which will be useful in the selection of appropriate combined 
regimens. The study also aims to investigate drug uptake and its role on drug resistance. 
The findings of this investigation will expand our knowledge of the mechanisms of 
antimalarial drug resistance. The specific objectives of this project will therefore focus 
on: 
• Investigating antimalarial susceptibilities of a range of P. falciparum 
lines and in particular pfmdrl transfectants, 106/1 and K76I lines carrying 
unique pfert mutations and a parasite isolated from a Malarone® treatment 
failure 
• The characterisation of pfmdr 1 and pfert polymorphisms of the parasite 
lines as well as assessing the cytochrome b profile of the Malarone® 
treatment failure isolate and strain-typing of the parasites 
• Drug interaction studies of artemisinin-derivatives with structurally 
diverse antimalarials as well as drug interaction studies of Malarone® 
components (atovaquone and proguanil) 
• Uptake studies of eH]-CQ and eH]-DHA and in combination with other 
antimalarials 
CHAPTER 2 
MATERIALS AND METHODS 
2. 1 Parasite Lines 
92 
Plasmodium falciparum laboratory lines K1, FC27, T996, 307, 7G8 and B303 
used in this study were obtained from LSHTM malaria parasite bank with the kind 
permission of Prof. David Warhurst. Parasite line RSAII was kindly donated by Prof. 
Pete Smith of the Department of Pharmacology, University of Cape Town, South Africa. 
Lines 7G8_mdr7G8, 7G8-mdrDlO, DI0-mdrP1o and DlO_mdr7G8/3 were used with the kind 
permission of Prof. Alan Cowman of The Walter and Eliza Hall Institute of Medical 
Research, Melbourne, Australia, and were kindly donated by Prof. Steve Ward of the 
University of Liverpool, UK. Lines 106/1 and K76I (also referred to as 34-11E) were 
kindly donated by Prof. Dave Fidock of the Albert Einstein College of Medicine, New 
York, USA. See Appendix I-A for more details about the parasite lines used. 
2.1.1 106/1 and K761 parasite lines 
The CQR K76I parasite line used in these studies was selected from the 106/1 
line after an unsuccessful transformation. The line was selected during the transformation 
process using CQ 230 nM and harboured a novel pfcrt mutation encoding mutated pfcrt 
codon 76i1e - the parasite line is also referred to as 34-11E (Fidock et al., 2000b). The 34-
lIE parasite line was shown to have the same pfcrt and pfmdr 1 polymorphisms and has 
an identical antimalarial profile as a similar K76I line isolated by Cooper et al. (2002; 
Prof. David Fidock, personal communication) and was therefore named K76I for clarity. 
2.2 Parasite Cultivation 
Malaria parasites were continuously cultured according to the method of Trager 
and Jensen (1976), with slight modifications (Fairlamb et al., 1985), in a class II 
Microbiological Safety Cabinet under aseptic conditions. The parasites were maintained 
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with A + erythrocytes suspended in complete culture medium (CM). The incomplete 
culture medium (1M) was prepared with RPMI-1640 (Appendix I-B), filter sterilised and 
stored at -20°C until needed. Before use, the 1M was made complete supplementing it 
with 5% sterile sodium bicarbonate solution (AnalaR, BDH) and pooled AB+ human 
serum (The National Blood Service, Bristol; see Appendix I-C). CM was maintained at 
pH 7.3. Incubation was at 37°C under a gas phase of3% 02, 4% C02 and 93% N2 (BOC 
Gases). In order to obtain higher parasite counts or parasitaemia, flasks were sometimes 
placed on a plate shaker and gently shaken overnight at 37°C. The DI0_mdrD10 and DI0-
mdr7G8 transfectants were placed under drug pressure with 0.1 J.lM PYR once 
successfully retrieved from liquid nitrogen. The transfectants 7G8_mdr7G8 and 7G8-
mdrDIO were placed under drug pressure using 5 nM WR99210 (kindly supplied by Dr. 
David Baker). The cultures were kept between 2 - 20% parasitaemia at 5% haematocrit. 
2.2.1 Preparation of erythrocytes 
Human A+ erythrocytes (with buffy coat removed) obtained from the National 
Blood Service South Thames BTC, London, were washed free of plasma and remaining 
components before use in culture. 20 ml of the erythrocyte suspension was spun at 600 g 
for 20 min at room temperature. The plasma was discarded, and the cells were then 
washed 2 - 3 times in wash medium (CM without serum). Packed cells were resuspended 
in an equal volume of wash medium (WM) to obtain a haematocrit of 50%. This was 
stored at 4 °C until expired. 
2.2.2 Synchronisation of culture 
Culture synchronisation was carried out (using predominately ring stage) by 
incubating the parasite pellet at 37°C with 3.5 volumes of 15% D-sorbitol solution 
(Sigma Chemical Co, UK) in WM for 5 minutes (Lambros and Vanderberg, 1979). The 
culture was then vortexed for 1 minute, and washed twice with CM. This technique 
targets the erythrocytes containing the mature forms of the parasite, which are more 
permeable to sorbitol, causing them to burst, and leaves ring-stage parasites unaffected. 
After synchronisation, the culture was maintained at 37°C as described above. 
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2.2.3 Cryopreservation 
Cultures with predominantly nng stages (Wilson et al., 1977) and with a 
parasitaemia of more than 5% were frozen using the filter-sterilised cryopreservative 
mixture (Rowe et al., 1968) stored at -20°C (Appendix I-H). The selected cultures were 
transferred to 15 ml sterile plastic tubes, spun at 600 g for 5 minutes and the spent 
medium discarded. Packed cells were mixed with an equal volume of the 
cryopreservative (warmed to 37°C) and 0.5 ml to 1.0 ml aliquot was transferred to a 
sterile screw-capped cryotube (Nalge Nunc International, Denmark). Tubes were placed 
in the -80°C overnight and then transferred to cryobank tanks containing liquid nitrogen 
(-196°C). 
Cryopreserved parasites were removed from liquid nitrogen storage and vials 
quickly thawed at 37°C in a water bath. The contents were transferred to a 15 ml sterile 
centrifuge tube and centrifuged at 500 g for 2 min and the supernatant discarded. To 
prevent osmotic lysis, equal volume of filter sterilised 3.5% sodium chloride (AnalaR, 
BDH) in WM was added, and cells centrifuged as described and supernatant discarded. 5 
ml of WM was added and cells centrifuged as before. This washing was repeated twice. 
Finally, parasite pellet was suspended in CM, at 5% haematocrit and transferred to 
culture flask which was gassed with gas mixture described above. Cultures were 
maintained at 37°C. 
2.2.4 Parasite subculturing 
Giemsa-stained thin blood films were prepared daily to monitor the growth of the 
cultures. These were prepared from each culture flask by spreading approximately 10 III 
of 50% haematocrit culture onto a clean glass microscopic slide. Blood films were 
methanol-fixed for approximately 20 sec before staining in 10% Giemsa stain (BDH, 
UK) solution (Appendix I-D) for 20 min. Slides were then removed and briefly rinsed 
under tap water, dried and examined by oil immersion under a light microscope at a total 
magnification of x1200. Thin blood films showing healthy uncontaminated cells were 
then counted (using a 3x3 graticule) until ~ 50 parasitised or > 200 erythrocytes in one 
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of the nine squares had been reached. The percentage parasitaemia was determined as 
follows: 
% Parasitaema = number of !nfected cells x 100 
number of unlfected cells x 9 
2.3 In vitro dose-response assay 
2.3.1 Drug preparation 
Stock solutions of the drugs were prepared at 20 mg/ml or 10 mg/ml 
concentrations in the appropriate solvents e.g.: ddH20, ethanol, methanol and DMSO. 
Ethanol, methanol and DMSO - used at a final concentration of < 0.05% - had no effect 
on parasite growth. Dilutions were prepared from stock solutions on the day of the 
experiment, using CM. Top concentration per well was prepared at twice the desired 
final concentration in a 96-well sterile flat-bottomed microtitre plate (TPP, Switzerland). 
2.3.2 Parasite preparation 
The zero or blank of the drug assay was unparasitised erythrocytes (RBC) 
without drug and the control was parasitised erythrocytes (pRBC) without drug. The 
parasitaemia of the culture was determined at early ring stage as in Section 2.2.4. If the 
lactate dehydrogenase assay was to be used to determine parasite viability, the 
parasitaemia was assessed at early trophozoite stage. For the initial ICso dose-response 
assays, a final 1 % parasitaemia at 2.5% haematocrit was used in a total volume of 200 III 
per well. The controls were similarly prepared. 
2.3.3 Plate preparation 
One hundred microlitres of eM was added to all wells except those in column 3A 
to H. Two hundred microlitres of the top concentration for each drug was placed in 
duplicate in wells 3A:3B, 3C:3D, 3E:3F, and 3G:3H of a 96-well microtitre plate. Two-
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fold dilutions of drugs was made by transferring 100 III from column 3A to H through 
column 4A to H to column 12A to H, using a multichannel pipette, discarding the last 
100 III from wells in column 12. Thorough mixing was ensured at each transfer. All 
wells, except those in column lA to H, received 100 III of a pRBC suspension. The 
remaining wells received 100 III of RBC suspension which was used as a blank control. 
Column 2A to 2H was used as a pRBC control without drug. Plates were stacked in a 
sterile modular chamber, gassed for 3 minutes with the gas mixture mentioned above and 
incubated humidified at 37 °C. In the case of assessing parasite viability using the 
radio labelled hypoxanthine assay, incubation was briefly halted after 20 - 24 hours to 
allow dosing of each test well 10 III eH]-hypoxanthine (Amersham, U.K.) to a final 
concentration of 0.2 IlCi (Desjardins et al., 1979). Then plates were regassed and 
incubated for another 24 hours, after which they were either stored at -80 °c until 
harvested. In the case of the lactate dehydrogenase assay, the plates were incubated 
uninterrupted for 48 hours, after which the LDH assay was immediately carried out (see 
Section 2.3.4). Each combination experiment was repeated at least twice. 
2.3.4 Lactate dehydrogenase assay of paraSite viability 
The lactate dehydrogenase (LDH) assay was adapted from Makler et al. (1993). 
The Malstat plate was prepared as a replica of the drug assay plate. Wells in the 96-well 
Malstat plate corresponding to the control and drugged wells of the assay plate were 
aliquoted with 100 III of Malstat Reagent (Appendix I-E) and 25 III of NBTIPES 
(Appendix I-F) solution. A multichannel pipette was used to gently resuspend the 
erythrocytes in drug assay plates and transfer 20 III of the cells to corresponding wells in 
the Malstat plate. The LDH reaction (Figure 2.1) was thus initiated and the progress of 
the reaction was monitored by the appearance of purple colour. Optical density reading at 
630 nm was obtained using a MRX II microplate reader (Dynex Technologies, USA) 
with Revel software by Dynex Technologies. 
The above reaction, catalysed by the cytosolic enzyme LDH, involves the 
conversion of lactate to pyruvate (Figure 2.1). The reaction is dependent on the co-
enzyme NAD+ which is reduced to NADH by the transfer of a hydride anion (H") from 
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lactate to NAD+. Makler (1993) confinned that 3-acetyl pyrimidine NAD (APAD) can 
also be used by LDH as a coenzyme in this reaction. LDH is a ubiquitous enzyme and 
can be found in human red blood cells. Human red blood cell LDH perfonns this reaction 
at a very slow rate in the presence of APAD. The enzyme activity is thus measured by 
monitoring the fonnation of APADH from APAD in the above reaction. The production 
of APADH converts the NBTIPES solution to coloured product by reduction. 
Figure 2.1: Lactate is converted to pyruvate by the enzyme lactate dehydrogenase. In the 
LDH reaction. NAD is a coenzyme in the reaction and Is reduced to NADH. 
OH 
I . CH-C-COO 
3 I 
H 
'-Lactate 
NAD+ NADH \,,/.. R CH3-C-COO' + H+ 
Pyruvate 
2.3.5 Radiolabelled uptake of hypoxanthine as a measure of parasite 
viability 
Frozen plates were thawed at room temperature and the contents of each well 
were harvested onto Wallac printed glassfibre filter mats (perkin-Elmer, UK) using a 96-
well cell harvester (Tomtec, USA) and filter mats were dried for 1 hour at 55°C. Each 
filter mat was placed in a sample bag containing 4.5 ml of Wallac Betaplate liquid 
scintillation fluid (Perkin-Elmer, UK) and bag was heat-sealed. The radioactivity of the 
eH]-hypoxanthine incorporated into parasite nucleic acid was detennined relative to the 
untreated controls using a Wallac 1450 Microbeta® scintillation ~-counter (Perkin-Elmer, 
UK). 
2.3.6 Calculation of dose-response curves 
The radioactivity data obtained above were incorporated into Microsoft Excel 
(Microsoft Inc.) and ICso values calculated using the XLFit (lD Business Solutions Ltd., 
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UK) add-on. The inhibitory concentrations were calculated by converting either the cpm 
or absorbance readings to percentage inhibition values. The ICso values were then 
derived from the curve-fitting analysis of the sigmoidal log drug concentration/response 
curves along with the standard error of the mean. 
2.4 Drug Combination Assay 
The interaction between two antimalarial drugs was assessed using a modification 
of the method ofBerenbaum (1978). The assay was first carried out to obtain the ICso of 
the individual drugs, e.g. drug A and drug B. For the combination assay, drug dilution 
was made to allow the ICso of the individual drugs to fall around the 4th two-fold serial 
dilution. The dilutions for each of the 2 drugs were then prepared in fixed ratios as in 
Table 2.1. 
Table 2.1: The fixed ratio combinations used in the Interaction studies 
Drug A DrugB 
5 0 
4 1 
3 2 
2 3 
1 4 
0 5 
The preparation of combination plates was as described in Section 2.3, with a 
modified layout (Figure 2.2). The combination assay was carried out in triplicate with the 
RBC blank control in column lA-H of a 96-well flat-bottomed microtitre plate (Figure 
2.2). A final 1 % parasitaemia at 1 % haematocrit was used for all combination assays, 
unless otherwise stated, in a total volume of 200 III per well. Outer wells in rows 2A to 
llA and columns 12A to 12H contained pRBC controls. Two hundred microlitres of the 
top concentration for each drug or drug combination was placed, in triplicate, in row 3H 
to I1H. One hundred microlitres of CM was added to all wells except those in row 3H to 
IIH. The combination solutions were serially diluted, using a multichannel pipette, from 
row H to row B, transferring 100 III each time after a thorough mixing and discarding the 
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last 100 J.lI from wells in row B. Wells in column I A to I H received 100 )ll of RBC 
suspension and the remaining wells were dosed with 100 J.ll of a pRBC suspension. Two 
plates were used for testing the six drug solutions. The combination assay, viz. , 
incubation, eH]-hypoxanthine or LDH assay and ICso calculations were as in Section 
2.3 .6. Each combination experiment was repeated at least twice. 
Figure 2.2: A microtitre plate layout of a combination experiment.* 
l When prepared as described. blue wells (. ) serve as an erythrocyte control (blank - no drug 
and no parasites). red wells (. ) serve as a parasite control (no drug). green wells (. ). yellow wells 
( ) and purple wells (. ) serve as drug wells for three drug combinations. in triplicate. with wells in 
row H holding the highest drug concentration. 
The combination assay produced six dose-response curves each with two ICso 
components relating to each of the two drugs used (see Figure 4.3). As assay of 
individual drug was carried out in parallel with the combination assay, two ICso values 
for each drug alone (e.g. the 5:0 and 0:5 combinations) were calculated. The fractional 
inhibitory concentration (FIC) of each drug in the combinations was calculated (see 
below) and the resulting six pairs of FIC values were used to obtain isobolograms 
(Berenbaum, 1978): 
FIC of drug ICso of drug in combinatio n ICso of drug alone 
Chapter 2: Materials and Methods 100 
Interaction between two drugs could have three types of effects: additive, 
synergistic and antagonistic (see Section 4.1). For each data point, a value for the sum of 
the component FIe values can be calculated (IFIC) and hence an overall mean value 
computed for each drug combination. This overall mean can be plotted on a scatter-graph 
(Figure 2.3) which allows direct comparison of the different effects of combined drug 
interaction. The unpaired Student's t-test in SigmaPlot 2000 was used to compare the 
mean FIC values between two parasites. If P < 0.05, the results were considered 
significant. If one parasite's mean FIC value is compared to a group of parasites, the 
highest or largest P value of the group is quoted for comparison. A framework for 
understanding drug interactions is presented in Figure 2.3. 
Figure 2.3: Framework for understanding the interaction scatter-graphs demonstrating the 
possible in vitro interactions of antimalarials t. 
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Parasite 
to Parasites in section A demonstrate CO sensitivity seen in cas parasites and carried PfCRT 
lys76 codon. Parasites in section B demonstrate decreased CO sensitivity or CO resistance and 
carried mutated PfCRT codon 76. The effect of combined drugs on a parasite is antagonistic if 
the mean FIC is > 1, additive if it is equal to 1, and synergistic if it is < 1 (see Section 4.1.1). 
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2.5 Nucleic acid techniques 
2.5.1 DNA isolation 
Parasite culture (mainly schizonts) was placed in a 15 ml sterile plastic tube, spun 
at 600 g for 5 minutes and the spent medium discarded. The packed cells were either 
stored at -20°C or immediately subjected to saponin lysis to free the parasites from their 
host cells. The packed cells were incubated for 30 min at 4 °C with 0.1 % saponin 
solution in PBS to a ratio of 1.5 volumes saponin solution to 1 volume packed cells. The 
lysed material was then diluted in 5 to 10 volumes of PBS and spun at 500 g for 10 min. 
The supernatant was discarded and the grey pellet was washed in 10 volumes PBS twice 
or until pellet was clean. 
The parasite pellets (100 J.lI) were suspended in 200 J.lI of proteinase K sterile 
lysis buffer (10 mM tris HCI pH 8.0, 10 mM EDTA) and 1 J.lI of20 mg/ml proteinase K 
was added to a final concentration of 100 J.lg/ml. The pellet was vortexed thoroughly and 
then incubated overnight at 55°C. 
After incubation, the parasite suspension was transferred to microtubes and an 
equal volume of phenol solution (phenol: chlorofonn: isoamyl alcohol in a 25:24:1 (v/v) 
ratio) was added. The tubes were vortexed for 30 sec, centrifuged at 13 000 g for 3 min 
and the top aqueous phase was transferred to clean microtubes. The extract was either 
subjected to another phenol extraction, or an equal volume of chlorofonn was added 
followed by vortexing and centrifugation. A 1I10th volume of sodium acetate (3.0 mM 
pH 5.2) was added to the extract followed by 2 volumes of ice-cold absolute ethanol. The 
tubes were place at -20°C and left overnight. The precipitated DNA was sedimented by 
centrifugation and washed in 70% ice-cold ethanol in order to desalt the DNA. The 
alcohol was poured off and the DNA residue allowed to air dry. The DNA was dissolved 
in ddHzO and the approximate concentration estimated using 1.0 OD260 = 50 J.lglml 
(Sambrook et al., 1989). 
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2.5.2 Polymerase chain reaction 
Relevant segments of the putative resistant associated genes or other genes of 
interest were amplified by PCR in a Hybaid OmniGene Thennal Cycler. Reactions were 
carried out in 50 J.lI volumes containing standard PCR buffer (1.5 mM MgCh, 50 mM 
KCI, 10 mM Tris-HCI, pH 8.3, 0.01% (w/v) gelatine) and 1.25 U BioTaq DNA 
polymerase (Bioline, UK), unless otherwise stated. Mixture was overlaid with a drop of 
mineral oil and centrifuged briefly and then placed in the thennal cycler. 
To avoid contamination all PCR reagents, tips and pipettes were kept in a 
dedicated PCR area which was kept separate from the parasite DNA handling area and 
the area where PCR products were analysed. Positive and negative (ddH20 instead of 
DNA) controls were simultaneously run to check for successful amplification and for 
contamination. 
2.5.2.1 Verification of peR products 
Horizontal gel electrophoresis of PCR or RFLP products was perfonned in a 1 x 
TAE buffer pH 7.8 (0.04 M Tris-acetate EDTA pH 8.0). The reaction products were size 
fractionated through a 1.5% agarose gel. Eight microlitres of the reaction product was 
added to 2 J.lI of loading solution (orange G; Sigma, UK) and carefully loaded into gel 
wells. The samples and the HyperLadder IV (Bioline, UK) 100bp size marker were 
electrophoresed at 100 Volts for 1 - 1.5 hours. Gels were visualised on an ultraviolet 
transilluminator following ethidium bromide staining (final concentration 0.5 J.lglml in 
TAE buffer) and photographed using a Gel Documentation System (Grabit). 
2.5.3 Gene sequencing 
2.5.3.1 Sequencing reaction 
PCR products were purified into a final volume of 30 J.lI in ddH20 using Qiagen 
spin columns (Qiagen, UK) according to the manufacturer's instructions. The purified 
products were stored at -20°C or used immediately in sequencing reactions. Purified 
PCR products were sequenced using internal sequencing primers (see Appendix I-I) by 
cycle sequencing with 3' BIG DYETM tenninator cycle sequencing pre-mix kit (PE 
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Applied Biosystems, UK). Reactions were carried out in 20 JII volumes containing: 8 JII 
BIG DYETM terminator cycle sequencing mix (PE Applied Biosystems, UK), 1 JII of 
either the forward or reverse primer (final conc. 1 JIM), 5 JII ofPCR product and 10 JII of 
ddH20. The samples were placed in a MJ Research PTC 225/200 Peltier Thermal Cycler 
and run through the following cycles: 94°C (15 sec), 55°C (15 sec), 60°C (3 min) for 
25 cycles. 
Sequencing products were then transferred to 1.5 ml microtubes, made up to 20 
JII with 10 JII ddH20 and the DNA was precipitated with 2 JII sodium acetate (3.0 mM 
pH 5.2) and 50 JII 100% ethanol. The tubes containing the mixtures were left on ice for 
-15 min. The precipitated DNA was sedimented by centrifugation at 13 000 g for 30 min 
at 4 °c and then washed with 250 JII ice-cold 70% ethanol. The alcohol was poured off 
and the DNA residue allowed to air dry. The DNA was re-suspended in 3 JII of 5:1 
formamide:blue-dextran EDT A loading buffer for sequencing. Samples were stored at 4 
°C and 0.5 JII loaded onto a Perkin Elmer ABI Prism™ 377 DNA Sequencer (PE 
Applied Biosystems, UK). 
2.5.3.2 Alignment and verification of sequence 
Sequences were assembled and checked using published reference sequences 
using Sequence Navigator version 1.0.1 (PE Applied Biosystems, UK). DNA sequences 
were translated to protein sequences usmg the ExP ASy programme 
(http://ca.expasy.org/tools/dna.html). DNA and protein sequences were aligned and 
compared usmg the ClustalW multiple sequence alignment programme 
(http://www.ebi.ac.uklclustalwD. 
2.6 Uptake of (H}-dihydroarlemisinin and (H}-chloroquine 
2.6.1 Reagents 
eH]-DHA was originally purchased from Moravek Biochemicals (California, 
USA) with a specific activity of 1.4 Cilmmol. The eH]-DHA was later purified and 
kindly donated by Dr. Pat Bray of the University of Liverpool. eH]-CQ was from 
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DuPont NEN (Massachusetts, USA) with a specific activity of 50.4 Cilmmol. Silicon oil 
(specific gravity 1.07 glml) was purchased from AnalaR, BDH. 
2.6.2 Time course of drug accumulation 
To investigate the time course of DHA and CQ accumulation, drug accumulation 
studies were carried out by direct measurement of the amount of radio labelled DHA or 
CQ accumulated by uninfected and infected RBC. Synchronous trophozoites were 
suspended in fresh CM, adjusted to 5% parasitaemia at 1 % haematocrit and held at 37 
°C. If required, VP was added to the parasite suspensions 45 min before the uptake 
experiment was started at a final concentration of either 1 J-lM or 5 J-lM. 
The accumulation experiment was initiated by the addition of eH]-DHA (final 
concentration 3 nM) or eH]-CQ (final concentration 5 nM), followed by a brief gentle 
vortex, and incubation at 37°C. At the desired time point (see Section 5.2.1.1 and 
5.2.2.1), duplicate 500 J-ll aliquots were removed from each sample and diluted with an 
equal volume ofice-cold medium containing a 100-fold excess of non-radioactive drug 
in a 1.5 ml microtube. These aliquots were immediately spun through a 250 J-li layer of 
silicon oil at 13 000 g for 30 sec to separate the cells from the aqueous medium 
containing the unincorporated radio labelled drug. At each time point 100 J-li of medium 
above the silicon oil layer was transferred to 5 ml scintillation vials to measure the 
amount of unincorporated drug remaining in the incubation medium. The microtubes 
containing the cell pellet were stored at -80°C until processed for scintillation counting 
described in section 2.6.4. 
2.6.3 Effect of drugs on DHA and CQ uptake 
To assess the effect of standard antimalarials, VP and PEN on DHA and CQ 
uptake, drug accumulation studies were carried out by direct measurement of the amount 
of radio labelled DHA or CQ accumulated by uninfected and infected RBC. Synchronous 
cultures at trophozoite stage were suspended in fresh CM, adjusted to a final 
concentration of 5% parasitaemia at 1.5% haematocrit and held at 37°C. All drug 
solutions were prepared in fresh CM at to-fold desired final concentration. Aliquots of 
50 JlI of unlabelled drug followed by 50 J-li of eH]-DHA (final conc. 3 nM) or eH]-CQ 
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(final cone. 2.S nM), was made in 1.5 ml microtubes. The uninfected control (RBC + 
radiolabelled drug in CM) and the infected control (pRBC + radio labelled drug in CM) 
had no drug. The experiment was initiated with the 400 J.lI addition of either packed 
infected or uninfected erythrocytes in each tube. All samples were placed in a water bath 
at 37°C and incubated for 90 min, with regular shaking. Samples were then centrifuged 
at 13 000 g for 30 sec through silicon oil as described above; or centrifuged directly 
without oil, the remaining supernatant discarded and the pellet washed twice with cold 
PBS. As for the time course studies, 100 J.lI of the supernatant was transferred to S ml 
scintillation vials. Microtubes containing the pellet were stored at -80°C until processed 
for scintillation counting described in section 2.6.4. 
2.6.4 Processing of radio/abe/led samples 
The frozen cell pellet was retrieved from cold storage. The bottom end of the 
microtube containing the pellet was immediately cut (through the frozen silicon oil layer 
if present) above the pellet. And transferred to S rol scintillation vials. Then 300 J.lI of 
distilled water was added to each vial and cells were lysed by vortexing or thorough 
mixing by repeated pipetting. Celllysates were treated with 2S0 J.lI of a freshly prepared 
mixture of glacial acetic acid, ethyl acetate and 30% hydrogen peroxide (all AnalaR, 
BDH) in equal volumes (1:1:1) to bleach the solution (Gu et al., 1984). Vials were 
loosely capped to allow gas to escape and placed on a flask shaker overnight. Three 
millilitres of Ecoscint scintillation fluid (National Diagnostics) was added to the treated 
pellet and the 100 J.11 of medium removed during the time course studies. Radioactivity 
was determined on a Beckman liquid scintillation spectrometer and values recorded as 
disintegrations per minute (dpm) or counts per minute (cpm) on a printer connected to 
the counter. Each uptake experiment was repeated at least twice. 
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2.6.5 Calculations 
2.6.5.1 Time course for drug accumulation 
In order to convert the cpm readings into femtomoles per 1 x 106 parasites, the 
following calculations were performed (Sanchez et al., 1997). eH]-drug refers to eH]-
CQ or eH]-DHA: 
RBCp = 
= 
= 
No. of RBC in packed pellet per ~I = 1.16 x 107 cells I ~I 
amount of [3 H] - drug in pellet (fmol) 
1x106 pRBC 
x 
amount of [3 H] -drug in pellet (dpm) 
(2.2 x 1012 dpm/Ci) x (specific activity [3 H] - drug in Ci/fmol) 
The Sp values were normalised to 1 x 106 parasites based on the haematocrit and 
the parasitaemia. Time course curves were drawn on SigmaPlot 2000 using the hyperbola 
regression fit. 
2.6.5.2 Uptake of combined drugs 
The effect of a cold drug on the uptake of radio labelled drug was calculated (see 
below). The uninfected control was subtracted from all the dpm values as this represents 
drug bound to erythrocytes only - i.e. 0% uptake. The infected control represents 100% 
uptake, amount of radiolabelled drug accumulated in absence of 'cold' drug. Therefore 
the percentage uptake in a drug combination sample can be calculated using the formula: 
% drug uptake in = avo drug uptake in x 100 
combination sample combination sample (dpm) avo drug uptake in pRBC control sample (dpm) 
The relative standard deviation is calculated along with the percentage uptake of 
a sample and is calculated using the formula: 
relative standard deviation = (standard deviation I mean) x 100 
Chapter 2: Materials and Methods 107 
The unpaired Student's t-test (SigmaPlot 2000) was used to compare the 
parametric uptake values between the infected control and the investigated drug. If P < 
0.05, the results were considered significant. 
CHAPTER 3 
DRUG SUSCEPTIBILITY AND GENETIC 
CHARACTERISTICS OF P. FALCIPARUM 
3. 1 Introduction 
108 
Antimalarial drug resistance has become one of the major causes of malaria 
treatment failure and the situation is worsening. P. falciparum is thought to become 
resistant to antimalarial drugs through spontaneous genetic mutations (Nosten and 
Brasseur, 2002). The determinants of antifolate and atovaquone resistance have been 
thought to be successfully predicted, as in both cases a single point mutation or series of 
mutations in a single gene can lead to over a lOOO-fold decrease in susceptibility (see 
Section 1.3). However, the mechanisms of resistance to the quinolines are more complex 
and probably multigenic (see Section 1.3.1 and 1.3.2). Recent studies using transfection 
techniques of P. falciparum parasite lines (Reed et al. , 2000; Sidhu et al. , 2002) have 
added further support to the major role of two genes, pfmdr 1 and pfert, in predicting CQ 
resistance. Susceptibility changes among structurally different antimalarials of the 4-
aminoquinoline, arylaminoa1cohol and artemisinin classes were clearly demonstrated in 
parasite lines which had been transfected with either mutated or wild-type pfmdr 1 or 
pfert; confirming that these two gene-products may be playing an important role in the 
sensitivity of P. falciparum to these drugs. 
In this study, a wide range of antimalarials were evaluated against twelve P. 
falciparum parasite lines. A new bisquinoline, piperaquine, was also included in the 
study. In the investigations involving the pfmdrl transfectants (Reed et al., 2000) and 
pfert transformants (Fidock et al., 2000b), a limited number of antimalarials were 
assessed against the resultant parasite lines. Here, sensitivities of these parasite lines to 
other quinoline based antimalarials were examined and their genetic characteristics 
assessed. 
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3.2 Clinical details of Malarone® treatment failure 
A forty-five year old Nigerian male, resident in the UK, presented with a fever 
and 1.5% P. falciparum parasitaemia two weeks after returning from a 4-week visit to 
Lagos, Nigeria without taking prophylaxis. The patient was given a standard 3-day 
treatment course of Malarone®; four tablets daily (one tablet is equivalent to 250 mg of 
atovaquone and 100 mg of proguanil hydrochloride) with food which he tolerated well 
without vomiting and he was later discharged. Twenty-eight days later, his malaria 
symptoms returned. After a further five days, the patient was readmitted to hospital with 
a parasitaemia of less than 1 %. A blood sample taken at this point was placed into 
culture. The patient was successfully treated with quinine 600 mg three times per day for 
three days, followed by doxycycline 100 mg per day for seven days. 
3.3 Materials and methods 
3.3.1 Malarone® treatment failure parasite isolation and cultivation 
Blood was withdrawn from the patient by venipuncture before the administration 
of the second course of antimalarials and the 2 ml heparinised blood sample was 
transferred to a 15 ml sterile tube. The blood sample was washed twice in 10 ml WM and 
placed into culture in CM as previously described (see Section 2.2). Continuous 
propagation of the culture was as described earlier. Parasite isolation and initial 
cultivation in vitro was by Dr. Geoff Butcher ofImperial College, London. 
3.3.2 ICso determination of parasite lines 
3.3.2.1 Drug solutions 
Drug stock solutions were prepared as in Section 2.3.1. The compounds tested, 
the solvent used to prepare the stock solution, and their source are as follows: 
amodiaquine (water, Sigma), artemisinin (DMSO; Sigma), artemether (DMSO; 
Novartis), atovaquone (DMSO; Dr. S.L. Croft), chloroquine diphosphate (H20; Sigma), 
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dihydroartemisinin (DMSO; Prof. D.C. Warhurst), halofantrine HCI (ethanol; Prof. D.C. 
Warhurst), lumefantrine HCI (DMSO; Novartis), mefloquine HCI (ethanol; Prof. D.C. 
Warhurst), piperaquine phosphate (dilute HCI; WHO), proguanil base (ethanol; Prof. 
D.C. Warhurst), pyrimethamine base (DMSO; Sigma), quinine base (ethanol; Sigma), 
sulfadoxine (DMSO; Prof. D.C. Warhurst) and (±)-verapamil HCI (water; Sigma). 
3.3.2.2 In vitro dose-response curve calculations 
Compounds were tested for their in vitro activity against CQS and CQR P. 
Jalciparum parasite lines using the incorporation of eH]-hypoxanthine as a measure of 
the inhibition of parasite growth. Plates were prepared and ICso values calculated as 
described in Section 2.3. 
3.3.3 Genetic analysis of parasite lines 
See Appendix 1-1 for further details ofthe primers used. 
3.3.3.1 Amplification of cytb gene (codon 133) 
A PCRlRFLP protocol was employed in order to detect the point mutation in 
codon 133 of cytb gene. Primers cytb-S and cytb-6 were selected to amplify a region of 
the cytb gene containing a putative ATV resistance-associated mutation in codon 133. 
PCR reactions contained 1 J.lM of each primer, SO ng of parasite DNA, and 200 J.lM of 
each of the four dNTPs. PCR conditions were as follows: an initial denaturation at 94°C 
for 2.S min, followed by 40 cycles of 94°C for 4S sec, 4S °c for 1 min and 72°C for 1 
min, and a final extension at 72 °c for 10 min. 
In order to detect a mutation in codon met133ile (base change ATG to ATT), 
restriction digest of the amplified product using TspS091 (S' ... lAATT ... 3') was carried 
out. The amplicon contains five Tsp509I sites in the wild-type gene and six sites in the 
mutant gene. The restriction digestion was at 65°C for 16 hours and the digest mix 
contained 1.0 U Tsp509I, 1.S J.lI NEBI buffer and 2.S J.lI ofPCR product in a total volume 
of IS J.lI (Technique: Ms. Imogen Nandi Simpson, personal communication). 
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3.3.3.2 Sequencing of cytb gene 
The amplicon of the cytb gene (corresponding to nucleotides 12 to 950) was 
obtained using primers cytb-l and cytb-2 in PCR using NH4 buffer (16 mM NH4S04, 67 
mM Tris-HCI, pH 8.8), 2 mM Mg2+, 200 J-lM of each dNTP, and 1 J-lM of each primer. 
The reaction mixture was initially heated at 93°C for 10 min and then cycled at 93°C 
for 50 s, 45°C for 50 s, and 70°C for 1 min over 40 cycles. PCR products were purified 
and sequenced in opposite directions using internal primers, cytb-3 and cytb-4 
(Korsinczky et al., 2000). 
3.3.3.3 Amplification of pfmdr1 gene 
A semi-nested allele-specific PCR was performed III a single tube for the 
detection of point mutations in the pfmdr 1 gene. Each reaction contained 50 ng of 
parasite DNA and 150 J-lM of each of the four dNTPs, except for codon 1246 which had 
a slightly higher concentration of 200 J-lM for each dNTP. All reaction conditions and 
procedures were as described by Grobusch et al. (1998), and Adagu and Warhurst 
(1999a). See brief description below in Sections 3.3.3.3.1 to 3.3.3.3.4. 
3.3.3.3.1 pfmdrl codon 86 
The forward (ISA-2) and reverse (DCW-2) primers flanked codon 86 while the 
allele specific forward primers (DCW-3) or wild-type sequence (DCW-4) were 
mismatched to specifically amplify mutant or wild-type sequence. Primers were used at 
0.3 J-lM for ISA-2 and 0.5 J-lM for DCW-2, DCW-3 and DCW-4. PCR amplifications 
were performed first for 8 cycles, at 94°C for 30 sec, 50°C for 30 sec and 72 °C for 30 
sec then for another 32 cycles at 94°C for 30 sec, 45°C for 30 sec and 72 °C for 30 sec. 
3.3.3.3.2 pfmdr 1 codon 1034 
The forward (1034F) and reverse (1034R) primers flanked codon 1034. The allele 
specific forward primers amplify either mutant sequence (MT1034F), specific for 
1034cys, or wild-type sequence (WT1034F), specific for seT} 034. Primers were used at 0.3 
J-lM and 0.5 J-lM for 1034R and 1034F, respectively, in both mutant and wild-type 
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reactions; while MTI034F and WT1034F were used at 0.025 J.1M and 0.1 J.1M, 
respectively. PCR amplifications were perfonned for 40 cycles, at 94°C for 45 sec, 49 
°c for 1 min and 72°C for 1 min for the wild-type reaction, and 94 °c for 45 sec, 47°C 
for 1 min and 72 °c for 1 min for the mutant reaction. 
3.3.3.3.3 pfmdrl codon 1042 
The polymorphisms in codons 1034 and 1042 occur within the transmembrane 
segment 11 of Pgh-l and were only 24 bp apart in pfmdr 1. The same forward (l034F) 
and reverse (1034R) primers were therefore used to flank both polymorphisms and were 
used at 0.1 J.1M and 0.4 J.1M, respectively. Allele specific forward primers for the mutant 
sequence (MTI042F), specific for 1042asp, or wild-type sequence (WTI042F), specific 
for asn1042, were both used at 0.5 J.lM. PCR amplifications were perfonned for 40 cycles, 
at 94°C for 45 sec, 46°C for 1 min and 72 °c for 1 min for the wild-type reaction, and 
94°C for 45 sec, 49°C for 1 min and 72 °c for 1 min for the mutant reaction. 
3.3.3.3.4 pfmdrl codon 1246 
The forward (1246F) and reverse (1246R) primers flanked codon 1246 while the 
allele specific forward primers were mismatched to specifically amplify mutant sequence 
(MT1246F) or wild-type sequence (WTI246F). Primers were used at 0.1 J.lM, 0.5 J.lM 
and 0.4 J.1M for 1 246F, MT1246FIWT1246F and 1246R, respectively. PCR 
amplifications were perfonned for 40 cycles at 94°C for 30 sec, 50°C for 1 min and 72 
°C for 1 min. 
3.3.3.4 Amplification of pfcrt gene 
A nested PCRlRFLP protocol was employed. Forward TCRPI and reverse 
TCRP2 primers were selected to flank a region of the pfer! gene containing the putative 
codon 76 point mutation. Each reaction contained 50 ng of parasite DNA and 200 J.lM of 
each of the four dNTPs. PCR conditions for nest I was an initial denaturation at 94°C for 
3 min, followed by 45 cycles of 94 °C for 30 sec, 56°C for 30 sec and 60 °C for 1 min, 
and a final extension at 60°C for 3 min (Adagu and Warhurst, 2001). 
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TCRDI and TCRD2 primers (forward and reverse) were internal to TCRPI and 
TCRP2 and were used in the nest II reaction, which utilised TCRP lITCRP2 nest reaction 
product as template. Nest II reactions were the same as for nest I except that 2 J.lI of nest I 
product was used as DNA template for nest II reactions. The PCR conditions for the nest 
II reaction involved an initial denaturation at 94°C for 5 min, followed by 30 cycles of 
94 °c for 30 sec, 48°C for 30 sec and 65 °c for 3 min, and a final extension at 65°C for 
3 min (Adagu and Warhurst, 2001). 
The nest II amplicon from primers TCRD 1 and TCRD2 contains one ApoI 
restriction site (5' ... (A/G) ~AATT(Crr) ... 3') in the wild-type sequence while the 
mutant sequence has no ApoI site (Adagu and Warhurst, 2001). Restriction enzyme 
digestion of nest II PCR product was carried out at 50°C for -16 hours. The reaction 
consisted of 5 J.lI of nest II reaction product, 0.5 U ApoI, and 1 J.lI of ApoI reaction buffer 
in a total volume of 10 J.ll. 
3.3.3.5 Strain-typing peR 
Primers were chosen from conserved regions flanking the variable repeats in the 
genes MSA-l and MSA-2. The PCR products amplified from these genes differed in size 
and allowed differentiation between parasite lines. A semi-nested PCR protocol was 
adapted from Wooden et al. (1992). MSPI (MSPIF and MSPIR) and MSP2 (MSP2F 
and MSP2R) primers were each used at 0.2 J.lM. The reaction contained 50 ng of parasite 
DNA, and 200 J.lM of each of the four dNTPs. PCR conditions were as follows: an initial 
denaturation at 94°C for 2 min, followed by 40 cycles of 94 °c for 30 sec, 50°C for 30 
sec and 72 °c for 30 sec, and a final extension at 72°C for 10 min. 
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3.4 Results 
3.4.1 Propagation of isolate from Malarone® treatment failure 
Isolate NGATVOI obtained from the patient who failed Malarone® treatment was 
successfully continuously cultured. The adaptation of the isolate to culture was slow 
compared to other field isolates from Zaria, Northern Nigeria (Dr. Ipemida Adagu, 
personal communication) or standard laboratory strains, e.g. Kl. The highest 
parasitaemia attained, even using culture shaking, was 3.5% (data not shown). 
Table 3.1: In vitro IC50 cut-off pOints as previously reported (nM). 
Drug Resistance cut off or reduced Reference drug sensitivity range (nM) 
DHA not reported -
ATM not reported -
CQ > 100nM (Pradines et al., 1998a) (moderate resistance 40 - 100 nM) 
AQ >80nM (Pradines et al., 1998a) 
PPQ not reported -
MQ >30nM (Reed et al., 2000) 
HAL >5nM (Pradines et al., 1998a) 
QN > 500nM (Pradines et al., 1998a) 
LM not reported -
PYR > 2000 nM (Basco et al., 1994b) 
PG not reported -
ATV >50nM (Korsinczky et al., 2000) 
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3.4.2 In vitro drug sensitivity or drug response 
In vitro ICso cut-off values for determining antimalarial drug resistance are listed 
in Table 3.1. These values were taken from previously published data. 
3.4.2.1 Patient isolate NGATV01 
Table 3.2 presents the sensitivity profile of isolate NGATVOI to antimalarial 
drugs CQ, MQ, PYR, ATV, PG and DHA. As presented in the table, the -1888 nM ICso 
value obtained for ATV shows that NGATVOI is clearly resistant to the drug as well as 
PYR (compared to values in Table 3.1). Although cut-off values for DHA and PG 
resistance are not yet established, NGATVOI had a PG ICso of 4206 nM which indicates 
susceptibility to the drug compared to 37957 nM and 34267 nM obtained for T996 and 
Kl, respectively (Table 3.3B). 
Table 3.2: In vitro sensitivity of isolate NGATV01 to antimalarial drugs with SEM (nM). 
NGATVOI 
Drug 
ICso ± SEM 
CQ 9.54 ± 0.83 
MQ 24.14 ± 3.67 
PYR 16012.8 ± 1869.27 
ATV 1888.15 ± 75.41 
PG 4205.50 ± 506.99 
DHA 2.39 ± 0.05 
3.4.2.2 Laboratory lines and transfectant parasite lines 
Certain laboratory lines and transfected parasite lines studied were examined for 
in vitro sensitivity to a range of antimalarial drugs (Table 3.3) and two resistance 
reversers PEN and VP (Table 3.6). See Section 3.4.2.2.2 for further analysis of the 
transfectants, 106/1 and K76I ICso values. 
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3.4.2.2.1 Antimalarials 
The sensitivities of the twelve laboratory parasite lines, four of which were 
transfectants, were assessed to a range of antimalarial drugs (Tables 3.3A and 3.3B). 
Overall, five of the parasite lines were CQS, five were CQR and the remaining two 
(106/1 and 7G8-md~IO) were moderately CQR (see Table 3.1 for resistance cut-off 
values). In section A, 106/1 had a significantly higher CQ ICso compared to CQS DlO-
mdr7G8 (P = 0.048) and the other CQS parasite lines (P ~ 0.024). Parasite lines in 
section B are clearly resistant to CQ as their ICso values indicate (excluding 7G8_mdrD10 
which falls below the 100 nM cut-off point), but none of these parasite lines showed AQ 
resistance according to the in vitro ICso cut-off points in Table 3.1. The new bisquinoline 
PPQ was active in both CQS and CQR parasite lines; although it showed some cross-
resistance with CQ in CQR lines Kl, RSAll and 7G8_mdr7G8 - PPQ ICso values were 
approximately 2-fold higher in these three CQR lines. 
Both CQR and CQS parasite lines showed high susceptibility to the 
endoperoxides DHA and ATM. Excluding DlO_mdr7G8 and 7G8-m~IO, CQS parasite 
lines showed significantly higher ICso values than CQR parasites to DHA (P = 0.034) 
andATM (P= 0.016). 
In comparison to MQ ICso values in section A, all parasite lines in section B, 
except 7G8-mdrDlO, had MQ ICso values around the cut-off mark of 30 nM. The 
relatively high baseline sensitive MQ ICso values could be due to the 2.5% haematocrit 
used for the in vitro dose-response assays. Dose response assays performed at 1 % 
haematocrit gave MQ ICso values over 2-fold lower for all parasite lines (data not shown) 
- closer to the MQ cut-off value quoted in Table 3.1. Judging by the cut-off points in 
Table 3.1, other parasite lines in section B would be classed as marginally resistant to 
MQ or showing reduced sensitivity. DIO-md~lo showed the lowest sensitivity of all 
lines tested with a MQ ICso value of 119.35 nM and parasite line B303 was highly 
sensitive to MQ with a MQ ICso of 14.45 nM. Interestingly, 106/1 displayed a similar 
drug response of approximately 49 nM for both CQ and MQ. All parasite lines were 
sensitive to HAL with CQR lines showing a significantly higher susceptibility than CQS 
lines (P = 0.008) - excluding transfectants DIO_mdr7G8 and 7G8-mdrDlO. 
Except for K76I and 7G8-md~IO, all the parasite lines in section B were 
marginally resistant to QN. Excluding DlO_mdr7G8, 7G8-mdrDIO, 106/1 and K76I, the QN 
ICso values were significantly higher in the CQR lines (P = 0.029). 106/1 and RSAll 
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showed QN ICso values of over 580 nM - above the 500 nM QN resistance cut-off value. 
LM showed a marked effect on all parasite lines; however RSAll and B303 were highly 
susceptible to the drugs. Excluding the transfectants DlO_mdr7G8 and 7G8-mdrP lO, CQS 
lines showed significantly higher LM ICso values (P = 0.008). 
All parasite lines were highly sensitive to ATV (Table 3.3B). The parasite lines in 
both sections had ICso values ranging from 0.69 nM to 1.54 nM except for 7G8_mdr7G8 
and 708-mdrDlo. These two transfectants had values which were -2-fold higher than the 
other parasite lines; however these values still fall within the ATV -sensitive range (Table 
3.1). Kl and B303 displayed PYR resistance with B303 over 4 times as resistant as Kl. 
Both FC27 and T996 demonstrated moderate susceptibility to PO. 
ICso values of the parasite lines (excluding DI0_mdr7G8 and 7G8-m~lO) were 
compared using two Pearson's correlation matrices (top and bottom Table 3.4). In both 
matrices, the ICso values for MQ, HAL, LM and DHA were highly correlated (r> 0.75). 
There was also a significant negative correlation (r ~ -0.72) between three 
arylaminoa1cohols (MQ, HAL and LM), and the two 4-aminoquinolines (CQ and AQ). 
There was also a correlation between CQ and AQ in both matrices and a strong negative 
correlation between LM and QN. When 106/1 and K76I parasite lines were excluded 
(bottom matrix), the correlation between QN and CQ became very high (r = 0.923) and 
the correlation of AQ with both CQ and QN strengthened. The negative correlation 
between CQ and DHA, and the positive correlation between ATM and DHA were lost 
with the exclusion of the two parasite lines. 
Table 3.3A: ICsa values of parasite lines to standard antimalarial drugs with SEM (nM). • 
DHA ATM CQ AQ PPQ MQ HAL QN LM 
Parasite 
ICso ± SEM ICso ± SEM ICso±SEM ICso ± SEM ICso ± SEM ICso ± SEM ICso ± SEM ICso ±SEM ICso±SEM 
FC27 6.88 ± 0.96 14.97 ± 0.90 24.64 ± 1.18 15.39 ± 0.39 29.61 ± 3.75 82.10 ± 3.27 12.36 ± 0.12 111.79 ± 3.83 186.54 ± 0.12 
T996 7.77 ± 0.14 16.89 ± 0.98 23.37 ± 0.21 14.78 ± 0.21 19.93 ± 2.01 54.81 ± 0.21 11.46 ± 1.21 112.05 ± 5.64 389.09 ± 5.97 
A 3D7 3.94 ± 0.11 l3.51 ± 0.62 22.76 ± 0.51 18.36 ± 0.52 36.90 ± 2.16 58.45 ± 2.55 11.14 ± 0.54 83.27 ±0.93 248.78 ± 6.06 
D10-mcrrD lO 8.28 ± 0.13 11.31 ± 0.62 25.07 ± 1.51 9.16 ± 0.34 not determined 119.35 ± 3.30 14.60 ± 1.22 74.67 ±2.44 428.89 ± 6.18 
D10_mdr7G8 5.24 ± 0.19 11.68 ± 0.19 32.78 ±2.99 11.68 ± 0.19 not determined 73.32 ± 4.35 9.08 ± 0.86 150.04 ± 15.32 262.76 ± 16.46 
106/1 4.56 ± 0.16 12.54 ± 0.59 48.52 ± 5.12 17.48 ± 0.55 22.22 ± 1.78 48.90 ± 1.06 7.02 ± 0.07 584.94 ± 17.73 149.38 ± 6.02 
K1 3.36 ± 0.26 9.33 ± 1.23 329.01 ±9.12 20.57 ± 0.17 49.03 ± 1.79 34.17 ± 3.00 4.16 ± 0.25 460.74 ± 16.99 105.09 ± 5.68 
RSAII 4.33 ± 0.13 9.73 ± 0.23 220.36 ± 6.63 26.66 ± 1.89 51.38 ± 1.68 48.26 ± 2.63 6.18 ± 0.51 587.17 ±24.73 57.91 ± 2.75 
B303 3.08 ± 0.16 7.82 ± 0.49 228.09 ± 6.36 23.16 ± 3.41 not determined 14.45 ± 1.32 3.82 ± 0.54 400.10 ±39.77 39.85 ±4.79 
B 
7G8_mdr7G8 5.20 ± 0.11 8.48 ± 0.18 290.05 ± 12.09 32.71 ± 4.03 49.71 ± 1.33 35.90 ± 1.32 4.88 ± 0.21 483.19 ±45.01 112.58 ± 0.61 
7G8_mdrD1O 6.56 ± 0.24 13.13 ± 1.75 87.42 ±4.73 13.20 ± 1.72 not determined 80.75 ± 6.16 13.64 ± 2.31 59.06 ±3.05 254.75 ± 11.32 
K761 3.28 ± 0.24 9.41 ± 0.65 299.45 ± 1.60 17.24 ± 0.51 16.38 ± 1.20 39.23 ± 1.65 5.83 ± 0.22 181.41 ±22.76 100.70 ± 7.29 
- - - - - - - - --
a Parasite lines in section A demonstrate ca sensitivity seen in cas parasite lines carrying a IYS76 PfCRT. Those in section B demonstrate ca resistance 
and carried a mutated PfCRT codon 76. 
Table 3.38: As for Table 3.3A. 
ATV PYR PG J Parasite 
I ICso ± SEM ICso ± SEM ICso ± SEM 
FC27 0.69 ± 0.06 0.97 ± 0.90 not determined 
T996 1.40 ± 0.07 3.19 ± 0.98 37956.66 ± 3609.99 
A 
3D7 1.36 ± 0.08 7.04 ± 0.62 not determined 
DIO-mdrP1O 1.15 ± 0.07 not detennined not determined 
DIO_mdr7G8 0.88 ± 0.04 not determined not determined 
KI 1.54 ± 0.11 8210.28 ± 486.55 34266.72 ± 2893.63 
! 
RSAll 1.28 ± 0.08 23.21 ± 2.75 not determined 
B B303 0.53 ± 0.07 35730.82 ± 1385.40 not determined 
7G8_mdr7G8 3.75 ± 0.27 not determined not determined 
I 
7G8-mdrP lO 3.39 ± 0.31 not determined I not determined 
I 
I 
-
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Table 3.4: Pearson's correlation matrices of leso values a 
DHA ATM CQ AQ MQ HAL QN LM 
DHA -0.673* -0.521 0.799* 0.824* -0.519 0.839* (0.033) (0.122) (0.006) (0.003) (0.124) (0.002) 
ATM 0.676 -0.384 0.435 0.698* -0.503 0.663* (0.066) (0.274) (0.209) (0.025) (0.139) (0.037) 
CQ -0.689 -0.682* -0.868* 0.542 -0.739* (0.059) (0.030) (0.001) (0.106) (0.015) 
AQ -0.627 -0.436 -0.747* 0.697* -0.721* (0.096) (0.281) (0.013) (0.025) (0.019) 
MQ 0.797* 0.417 -0.721* -0.584 0.773* (0.018) (0.304) (0.043) (0.076) (0.009) 
HAL 0.814· 0.699 -0.943* -0.825* 0.899* 0.879* (0.014) (0.054) «0.001) (0.012) (0.002) (0.001) 
QN -0.646 -0.708* 0.923* 0.839* -0.682 (0.084) (0.050) (0.001) (0.009) (0.063) 
LM 0.831* 0.657 -0.787* -0.795* 0.763* 0.871* (0.0\1) (0.077) (0.021) (0.018) (0.028) (0.005) 
a Values above the diagonal line included the 10611 and K761 parasite lines in the analysis. Values 
below the dark-shaded diagonal cells excluded the 106/1 and K761 parasite lines. Analyses 
excluded D10_mdr7G8 and 7G8_mdrD10 parasite lines. Top value in each cell is the Pearson 
correlation coefficient (r) and the bottom value in parentheses is the P value. 
* Shaded cells indicate a significant correlation at the 0.05 level (2-tailed). 
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3.4.2.2.2 ICso variation between control parents and transfectants or transformants 
Table 3.5 shows the variation in the ICso values between control parent and 
transfectant or transformed lines. The mean differences in ICso and P values are indicated 
for each drug tested and against the two parasite lines. The corresponding dose response 
curves are shown in Figure 3.1A to 3.1C. 
In the DI0-md~lo and DI0_mdr7G8 column, the allelic exchange produced a 
significant decrease in susceptibility to AQ and QN. There was a decrease in 
susceptibility to CQ in D 1 0_mdr7G8, but this was not significant. A significant increase in 
susceptibility to MQ, HAL, LM and DHA was also demonstrated. DIO_mdrDIO was 
resistant to MQ with an ICso value of -119 nM, but the allelic replacement with mutant 
pfmdrl in DI0_mdr7G8 had a pronounced effect, lowering the MQ ICso to -73 nM (Table 
3.3A). The DlO_mdr7G8 MQ ICso was, however, greater than the MQ-resistant cut-off 
value but similar to that of 7G8-mdrDlo. There was a small ATM ICso increase in DlO-
mdr7G8 compared to DI0-m~IO, but this was not significant. 
The introduction of the DIO wild-type pfmdrl into 7G8 produced a significant 
increase in susceptibility to CQ, AQ and QN. 7G8_mdr7G8 was CQR, but introduction of 
wild-type pfmdrllowered CQ ICso from -290 nM to -87 nM. A significant decrease in 
susceptibility to MQ, HAL, LM and DHA was also demonstrated. There was a small 
increase of the ATM ICso in 7G8-m~IO compared to 7G8_mdr7G8, but this was not 
significant. 
In the K76I parasite line, isoleucine at the PfCRT codon 76 was substituted for 
lysine in the 106/1 parasite line. A significant decrease in susceptibility to CQ was seen 
with the mutant pfert - CQ ICso value increased from -49 nM in 106/1 to -299 nM in 
K76I. A significant increase in susceptibility to MQ, HAL, QN, LM and DHA was also 
demonstrated. There was a small but insignificant decrease of the AQ, ATM and PPQ 
ICso values in K76I compared to 106/1. 
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Table 3.5: Differences in susceptibility between parent controls and transfected or 
transformed parasite lines. 
Mean ICso difference (oM) a 
(Significance) b 
Drug 
DI0_mdrD10 and 7G8_mdr7G8 and 10611 and 
DI0_mdr7G8 7G8_mdrD1O K761 
CQ 7.71 -202.63 250.93 (0.100) (0.024*) (0.002*) 
AQ 2.52 -19.51 -0.24 (0.036*) (0.024*) (0.328) 
MQ -46.03 44.85 -9.67 (0.006*) (0.010*) (0.004*) 
HAL -5.52 8.76 -1.19 (0.024*) (0.017*) (0.008*) 
QN 75.37 -424.13 -403.53 (0.016*) (0.024*) (0.002*) 
LM -166.13 142.17 -48.68 
« 0.001*) (0.001*) (0.004*) 
DHA -3.04 1.36 -1.28 
« 0.001*) (0.009*) (0.001*) 
ATM 0.37 4.65 -3.13 (0.071) (0.057) (0.100) 
PPQ not determined not determined -5.84 (0.093) 
122 
a Calculated by subtracting the ICso of control parent line from transfected or transformed line. A 
positive sign indicates a decrease in susceptibility (more resistant). A negative sign indicates an 
increase in susceptibility (less resistant). 
b P value calculated using the Mann-Whitney U test in parentheses. 
• Difference in ICso value is statistically different from control parent line (P < 0.05). 
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Figure 3.1: Comparative dose-response for control parent and transfected or transformed 
parasite lines. 
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3.4.2.2.3 Resistance reversers 
The in vitro susceptibility results of three of the 12 parasite lines to PEN and VP 
are listed in Table 3.6. PEN was surprisingly active against both FC27 and T996, and 
FC27 showed a significantly -3-fold higher ICso than K1 for VP (P < 0.001). 
Table 3.6: In vitro sensitivity of parasite lines to resistance reversers with ICso in nM. 
PEN VP 
Parasite 
ICso ±SEM ICso±SEM 
FC27 551.03 ± 44.66 15764.99 ± 729.24 
T996 512.09 ±46.95 not determined 
Kl not determined 7211.65 ± 452.06 
3.4.3 Genetic analysis of parasite lines 
3.4.3.1 cytb codon 133 PCRlRFLP analysis 
DNA from 4 parasite lines was amplified (Lanes 1-5; Figure A2.1, Appendix 2). 
The amplicons which contained codon 133 (Le. met133 or 133i1e) of the cytb gene were 
365 bp, as expected. The 365 bp fragment was digested with Tsp509I which resulted in 5 
fragments in all four parasite lines. Of these, 2 fragments were of same size (92 bp) and 
other fragments were 17 bp, 36 bp and 128 bp. The two 92 bp (assumed two co-
migrating fragments) and 128 bp fragments were the only fragments visualised (Lane 7-
11; Figure A2.I, Appendix 2). The presence of the 128 bp band in the digestion from 
NGATVOI indicated that it contains a wild-type met133 cytb suggesting that this ATV-
resistant parasite line probably harboured another mutation which may be novel. For 
technical reasons, DNA material from a parasite line carrying the codon 133 mutation 
was not available for use as a positive control. Therefore PCR amplicons were sequenced 
for confirmation of sequence identity. 
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3.4.3.2 cytb sequence analysis 
The NGATV01, Kl and FC27 sequences were compared to the previously 
published cytb sequences by Korsinczky et al. (2000), which included the sequence of an 
ATV treatment failure parasite, TM93-C1088. The NGATVOI sequence showed a 
change from TAT to AA T in codon 268 (Figure A2.2, Appendix 2), specifying a change 
from tyrosine (Tyr) to asparagine (Asn): tyr268asn (Figure 3.2); and confirmed that the 
NGATVOI parasite line carried the wild-type sequence of codon 133 (met133). The FC27 
and Kl parasite lines did not have any of the ATV resistance associated polymorphisms 
(Figure 3.2) and both parasite lines were sensitive to the drug (Table 3.3B). 
Figure 3.2: Sequence analysis of P. fa/ciparum cytochrome b gene from Isolate NGATV01 ~ 
published TM93-C1088, and controls K1 and FC27 showing amino acid residues 9 to 314. 
K1 
FC27 
TM93-C1088 
NGATV01 
K1 
FC27 
TM93-C1088 
NGATV01 
K1 
FC27 
TM93-C1088 
NGATV01 
K1 
FC27 
TM93-C1088 
NGATV01 
K1 
FC27 
TM93-Cl088 
NGATV01 
K1 
FC27 
TM93-C1088 
NGATV01 
KAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYSIQHILRELW 69 
KAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYSIQHILRELW 69 
KAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYSIQHILRELW 69 
KAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYSIQHILRELW 69 
SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 129 
SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 129 
SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 129 
SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 129 
W~SYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 
W~SYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 
W~SYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 
W~SYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 
189 
189 
189 
189 
FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
NTYVTPSQIVPEWYFLP~LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 
NTYVTPSQIVPEWYFLP LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 
NTYVTPSQIVPEWYFLP LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 
NTYVTPSQIVPEWYFLP LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 
FGARD 314 
FGARD 314 
FGARD 314 
FGARD 314 
309 
309 
309 
309 
* Residue 268 highlighted shows the change from tyrosine (Y) to asparagine (N) compared to 
ATV-sensitive strains K1 and FC27 and the change to serine (5) in the ATV-resistant isolate 
TM93-C1088 (Korsinczky et al., 2000). Residue 133 highlighted shows no change in any 
parasite. 
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3.4.3.3 pfmdr1 and pfcrt analysis 
Table 3.7 shows the polymorphisms in the pfmdr 1 and pfer! genes of the parasite 
lines studied. All CQS parasite lines in section A carried the wild-type pfmdr 1 except for 
T996, DlO_mdr7G8 and 106/1. DlO_mdr7G8 is a transfectant and carried the '7G8-like' 
mutated pfmdr 1. 106/1 had mutated codon 86 but had wild-type sequence in the 
remaining CQ-resistant associated codons (184, 1034, 1042 and 1246) of the pfmdrl. 
T996 carried wild-type sequences in all pfmdr 1 codons except 184. All CQS parasite 
lines carried the wild-type lysine at pfert codon 76. 
Section B shows the CQR parasite lines which all have CQ ICso of over 80 nM 
and carried mutated pfert gene. All these parasite lines carried the typical threonine at 
codon 76 of the pfert gene, except for K76I which had the amino acid isoleucine. Kl, 
RSAll and K76I had one pfmdrl mutation at codon 86 typically seen in South-East 
Asian and African parasite lines (Appendix I-A). 7G8_mdr7G8 had wild-type pfmdrl 86, 
but mutations at other 3 codons, typical of a South American mutated pfmdr 1. 7G8-
mdrD lO is a transfectant and carried the 'D 1 O-like' wild-type pfmdr 1, but mutated pfert. 
In the two transfectants D10_mdr7G8 and 7G8-md~IO, both mutated and wild-type 
allelic-specific bands were seen for the pfmdrl 1034, 1042 and 1246. The transfectants 
were transformed using an allelic replacement method (Reed et al., 2000) which does not 
replace the entire gene, but integrates within the pfmdr 1 gene. This resulted in the 
original gene sequence still being present, but the integrated gene is expressed. 
3.4.3.4 Strain typing 
DNA from the 12 parasite lines was amplified (Figure 3.3). The MSA-l and 
MSA-2 genes amplified showed unique variations in size due to blocks of repeats within 
the genes (Wooden et al., 1992) allowing differentiation among the 12 parasite lines. The 
two amplicons for D10_mdr7G8, 7G8-mdrD10 and K76I were identical in size to the 
control parent lines DlO-mdrDlo, 7G8_mdr7G8 and 106/1, respectively. For technical 
reasons, the amount of K76I peR product in Figure 3.3 was not sufficient to allow 
verification of the upper band; but the lower band size was of the same size as 106/1. 
Both DI0 transfectants had the same band size as FC27 as the DlO parasite line was a 
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clone of FC27 (McColl et al., 1994). The rest of the parasite lines had uniquely sized 
amplicons. 
A 
B 
Table 3.7: pfmdr1 and pfcrt polymorph isms In parasite lines studied. • 
plmdrl amino acid plert 
Parasite amino acid 
86 b 184 b,d 1034 b 1042 b 1246 b 76 c 
FC27 N Y S N D K 
T996 N F S N D K 
3D7 N n1d S N D K 
DI0-mdrD1o N Y S N D K 
DIO-mdr7G8 N Y C D Y K 
10611 Y Y S N D K 
Kl Y Y S N D T 
RSAll Y n1d S N D T 
B303 N n1d C D Y T 
7G8_mdr7G8 N F C D Y T 
7G8_mdrD1O N F S N D T 
K761 Y Y S N D I 
a Parasite lines in section A carried PfCRT codon 1ys76. Parasite lines in section B carried 
mutated PfCRT codon 76. 
b Amino acid abbreviations. Y: tyrosine, N: asparagine, S: serine, C: cysteine, 0: aspartic 
acid, F: phenylalanine. 
C Amino acid abbreviations. K: lysine, T: threonine, I: isoleucine. 
d From previously published data (Adagu and Warhurst, 1999a; Reed et a/., 2000; Fidock et 
a/., 2000b). n/d: not determined. 
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Figure 3.3: Gel electrophoresis of strain typing peR products (MSA-1 and MSA-2) of 
parasite lines used In the combination studies. t 
500 bp-+ 
300 bp-+ 
1 2 3 4 5 6 7 8 9 10 11 12 13 
; Lane 1: 100 bp ladder. Lanes 2-7: FC27, 307, T996, D10-md.-D1o, D10-mdr7G8, 106/1 . 
Lanes 8-13: K1, RSA11, 8303, 7G8_mdr7G8, 7G8-md.-D10, K761 
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3.5 Discussion 
3.5.1 Malarone® treatment failure isolate 
The target of ATV, CYT b, plays an important role in electron transport during 
mitochondrial respiration. It is thought that ATV, an analogue of coenzyme Q 
(ubiquinone), interrupts electron transport and leads to loss of the mitochondrial 
membrane potential (see Section 1.2.4). The NGATVOI isolate showed a mutation in 
cytb gene leading to a tyr268asn change in the CYT b protein product. This mutation has 
not been reported previously. A different mutation in this codon leading to serine was 
reported earlier in a sample (TM93-CI088) from an ATV + PYR treatment failure in a 
Thai patient (Korsinczky et al., 2000). The conserved hydrophobic contact of the drug 
with bulky residue tyr268 is in the Qo II region of the ubiquinol oxidation site. 
Substitution of the less bulky 268aso should affect the fit and binding of the drug (Figure 
3.4). Resistance rapidly emerges when ATV is used alone (Looareesuwan et al., 1996). It 
has been hypothesised that the mode of action of the drug might contribute to the rapid 
appearance of resistant parasite lines (see Section 1.2.4.2). PG is believed to speed the 
loss of the membrane potential, and ensure that replication of DNA stops before 
mutagenesis can occur (Vaidya and Mather, 2000). 
The NGATVOI isolate displayed a particularly slow growth rate compared to 
other parasite lines under the same culturing conditions. It has recently been reported that 
mutations in the cytb gene are associated with a loss of' fitness' in P. Jalciparum in vitro 
(Peters et al., 2002). The authors demonstrated decreased parasite growth with the 
double amino acid changes of met133ile and glY280asp compared to a CYT b wild-type 
strain (see Section 1.3.4). Although NGATVOI has a single tyr268aso amino acid change, 
it probably also has additional mutation(s) within the dhfr gene as the strain displays 
PYR resistance. 
This is an unusual example of resistance detected during a single course of 
Malarone® on only a moderate parasitaemia. The ATV + PG combination has not been 
widely used yet in West Africa so it is unlikely that the patient was initially infected with 
an ATV -resistant strain. The presence of multi drug resistant strains such as this example 
raises concern to the recent move to consider using Malarone® as first-line therapy in 
Africa (Shretta et al., 2000). The case questions the potential useful life of this 
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combination, especially as A TV may persist alone in plasma for up to 6 weeks after 
treatment (Butcher et ai. , 2000). It appears that the synergistic interaction with PG is not 
seen in ATV -resistant mutants (Srivastava et ai. , 1999), and higher resistance levels are 
achievable. 
Figure 3.4: ATV in P. falciparum CYT b active site illustrating the modification in the active 
site with the IYr26Sasn codon change. t 
B 
t A: ATV built and docked using HyperChem release 6, in the active site of a model of P. 
falciparum CYT b. Homology model prepared using the structure of the chicken enzyme (Crofts et 
al. , 1999) with the aid of the Swiss Model Protein Modelling Server and observed in the Swiss 
Model Viewer (Guex et al. , 1999). B: As A, with active site tyrosine 268 replaced by asparagine. 
Picture from Fivelman et al. (2002). 
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3.5.2 In vitro dose-response assay and genetic characteristics 
Twelve P. falciparum parasite lines were examined for in vitro sensitivity to a 
range of antimalarial drugs (Table 3.3A and B). PYR dose-response assays were not 
performed on the transfectants as they express non-Plasmodial dihydrofolate reductases 
which were used as a selectable resistance marker (Reed et al., 2000). Parasite line 
identity was assessed using PCR amplification of the variable repeats MSP-l and MSP-2. 
This method is sufficiently sensitive to detect a contamination of as low as 1 % of another 
line (Wooden et al., 1992). This is a particularly useful method for strain typing and 
monitoring cross-contamination of lines when different isolates are grown at the same 
time or in the same laboratory. The results presented here show that all parasite lines 
used in the study were not contaminated and had remained clean of other lines for the 
period kept in culture. Polymorphisms in the genespfmdrl andpfcrt (listed in Table 3.7) 
were confirmed using allele-specific PCR and PCR-RFLP, respectively. 
The sensitivities of the strains to DHA confirmed its greater in vitro potency 
compared with the conventional antimalarials (Table 3.3). The threshold ICso values for 
resistance are reported in Table 3.1 based on previous publications. These threshold ICso 
values are not necessarily fixed standards and cannot be taken as absolute values, as it 
has been previously demonstrated that ICso values for MQ and QHS-derivatives are 
highly dependent on the starting parasitaemia and haematocrit of the drug assay 
(Duraisingh et al., 1999). MQ and DHA are particularly vulnerable to this effect as 
demonstrated with the difference in MQ ICso values between the 1 % and 2.5% 
haematocrit dose response tests (data not shown). Parasite lines Kl, RSAll, B303, 7G8-
mdr7G8, and K76I were confirmed to be resistant to CQ. Although T996 has been 
previously shown to harbour mutatedpfmdrl184Phe (Adagu and Warhurst, 1999a), it was 
clearly CQS, confirming previous reports of codon 184 having no correlation with CQ 
resistance in laboratory (Foote et al., 1990b) or field (Omar et al., 2001a) strains. 7G8-
mdrD10 showed reduced CQ sensitivity, although it was under the 100 nM CQR 
threshold. Both Kl and B303 displayed resistance to PYR - it has been previously 
reported that Kl is PYR-resistant and has dhfr polymorphisms (Duraisingh et al., 1998). 
In the pfmdrl transfectants, the introduction of the '7G8-like' pfmdrl mutations 
into DI0 increased the AQ and QN ICso values significantly; and there was a significant 
decrease in the MQ, HAL, LM and DHA ICso values (Tables 3.3 and 3.5). Reed et al. 
Chapter 3: Drug susceptibility and genetic characteristics of P. falciparum 134 
(2000) noted a comparable increase in the ICso values of CQ and QN in the same 
transfectants, although similarly, the CQ increase was not significant. It is interesting to 
note that there was a significant increase in the AQ ICso but not the CQ ICso. These two 
drugs are thought to share similar mechanisms of action (see Section 1.2.2.1), cross-
resistance between the drugs has been reported (Misra et a/., 1995; Bray et a/., 1996b; 
Pradines et a/., 1998a; Basco et a/., 2002) and a significant correlation between 
sensitivity to the two drugs was seen in this study (Table 3.4). However, possible cross-
resistance with the metabolite mono-desethylamodiaquine (Ringwald et a/., 1998) was 
not investigated. Reed et a/. (2000) reported a similar decrease in MQ, HAL and QHS 
ICso values between DlO-mctrD1o and DlO_mdr7G8• The arylaminoalcohol LM shares 
many properties and modes of action as MQ and HAL (see Section 1.2.2.3) so a decrease 
in ICso was expected. This marked decrease in LM ICso was also seen with MQ, and both 
drugs displayed an almost identical drop in ICso of about 40%. Reed et a/. (2000) also 
reported a drop in ICso to the structurally unrelated antimalarial QHS in the DlO_mdr7G8 
parasite. However, a significant drop in the DHA, but not ATM ICso value was noted in 
the results presented here. This could be regarded as a surprising result as the two drugs 
are both QHS-derivatives and showed a weak positive correlation in the Pearson's 
analysis including 106/1 and K76I (Table 3.4); although this correlation was lost with the 
exclusion of these two parasite lines. Although the number of parasite lines studied was 
small, there was a strong correlation (r> 0.75) between MQ, HAL, LM and DHA ICso 
values, suggesting cross-resistance. Previous studies from many different geographical 
areas have observed cross-resistance between QHS-derivatives and MQ or HAL, or 
between all three drugs (Doury et a/., 1992; Basco and Le Bras, 1993; Bustos et a/., 
1994; Gay et a/., 1997; Le Bras, 1998; Pradines et a/., 1998b; Brockman et a/., 2000; 
Duraisingh et a/., 2000a) and this may indicate a common mechanism for acquiring 
resistance (Price et a/., 1999). Cross resistance in vitro does not necessarily predict cross 
resistance in vivo, since the immune status of people and pharmacokinetic factors are not 
taken into account (Brockman et a/., 2000). 
The introduction of the 'DlO-like' wild-type pfmdrl into 7G8 had a marked 
effect on the CQ, AQ and QN ICso values. 7G8_mdrD10 displayed a decreased CQ 
sensitivity although it expressed wild-type Pgh-l. This transfectant still harboured 
mutated pfert which was sufficient to provide moderate CQ resistance. The AQ ICso, 
however, was decreased significantly and this result, combined with the above 
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observation in the D 1 0_mdr7G8 parasite, suggests that mutations in pfmdr 1 may play an 
important role in determining resistance to AQ than CQ. Similarly, a large increase and 
decrease in QN ICso in both transfectants DIO_mdr7G8 and 7G8-mdrDIO, respectively, 
supports the suggestion thatpfmdrl mutations playa major role in QN resistance (Reed 
et al., 2000). An increase in the ICso values of MQ, HAL, LM and DHA was 
demonstrated with the introduction of the wild-type pfmdr 1 into 7G8. As reported by 
Reed et al. (2000), an inverse relationship between CQ and the more lipophilic MQ and 
HAL was shown with the introduction of wild-type pfmdr 1 into 7G8. This result agrees 
well with the observation that arylaminoa1cohols MQ, HAL and LM all showed a 
significant negative correlation of ICso values (r < -0.72) with CQ and AQ (Table 3.4). 
DHA displayed a significant change in ICso comparing 7G8-mdr7G8 and 7G8-md~JO, but 
this was not seen for ATM - a result similarly shown in the D 1 0 transfectants. 
The CQS 106/1 clone contains all of the 'ancillary' PfCRT mutations associated 
with CQ resistance but lacks the crucial mutation to threonine in codon 76 seen in all 
resistant isolates, neither does it have the lys76i1e PfCRT mutation seen in the 
experimentally produced CQR K761 (see Sections 1.3.1.2.3 and 2.1.1). Parent (10611) 
and daughter (K76I) parasite lines also carried mutated codon 86tyr of pfmdr 1 (Fidock et 
al., 2000b). The marked increase in CQ ICso with the single mutation in pfcrt supports 
the observations of Fidock et al. (2000b) and Sidhu et al. (2002). It is noteworthy that the 
CQ ICso for 106/1 was significantly higher than in the other CQS parasite lines. 106/1 
CQ ICso value reported by Fidock et al. (2000b) was only slightly higher compared to 
CQS 3D7 and GC-03 ICso values, although the difference reported was not significant. 
Cooper et al. (2002) reported a CQ ICso for 106/1 5 nM higher than Fidock's value, but 
no CQS strains were included for comparison. A different haematocrit and parasitaemia 
was used in these two studies compared to the results presented here (Fidock et al., 1998; 
Fidock et al., 2000b) which can influence the ICso values (Duraisingh et al., 1999). It 
could be possible that in the presence of a pfmdr 1 mutation, one or more of the other 
codon changes in pfert is capable of causing a marginal decrease in CQ-sensitivity. There 
was no significant change in either the AQ or PPQ ICso in the K761 parasite. A similar 
result was shown by Sidhu et al. (2002) with AQ in a CQS parasite line transfected with 
a mutated 'K76I-like' pfcrt; although the mono-desethylamodiaquine ICso did increase 
significantly in the K76I transfectants. The significant drop in ICso ofMQ, HAL, LM and 
DHA again illustrates the inverse relationship between the more lipophilic drugs and CQ. 
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This decrease in ICso to these drugs was similarly reported by Cooper et al. (2002) and 
Sidhu et al. (2002). The transfection of Dd2, K76I and 7G8 mutated pfcrt alleles into 
CQS GC03, which carried mutated pfmdrl 1042asP (Sidhu et al., 2002), and the 
introduction of a single point mutation (pfcrt 76i1e) in 106/1 to obtain K76I (Cooper et al., 
2002) largely increased susceptibility to QN. This decrease of QN ICso was, however, 
not seen with the parasite line carrying the pfcrt 76asn mutation (Cooper et al., 2002) 
which, conversely, had an increased QN ICso compared to parent 106/1. Puzzlingly, Kl 
and RSAll, by comparison, also carried mutated Pgh-l 86tyr (like 10611) and mutated 
PfCRT 76thr but showed a decreased sensitivity to QN. These results support the 
suggestion that there might be different stereospecific interactions between with QN and 
PfCRT due to changes of affinity between QN and the codon 76 amino acid (Cooper et 
al., 2002), but concurrent polymorphisms inpfmdrl (and possibly other genes) may still 
playa role. 
Overall, these results further implicate sequence changes or variations in both 
pfmdr 1 and pfcrt in drug resistance, supporting the suggestion that the susceptibility of 
malaria parasites to these antimalarials is governed in a multigenic fashion (Sidhu et al., 
2002). The results presented in this chapter lend support to previous reports indicating 
that bothpfmdrl andpfcrt- and perhaps additional, unidentified gene(s) - are important 
determinates of parasite sensitivity to 4-aminoquinolines, arylaminoalcohols and QHS-
derivatives. 
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3.6 Conclusions 
This chapter further highlighted strong links between decreased susceptibility to a 
range of antimalarials and mutations in genes cytb, pfmdrl and pfert. The in vitro 
susceptibility results from the pfmdr 1 transfectants confirmed the results of Reed et al. 
(2000) and support the correlation of polymorphisms in this gene with resistance against 
a structurally diverse range of antimalarials. The introduction of mutated pfmdr 1 into 
DI0 (giving rise to DIO_mdr7G8) did not raise the CQ ICso significantly but, the 
introduction of the wild-type pfmdrl gene in 7G8 (resulting in 7G8-mruJ>lO), significantly 
lowered the CQ ICso. These observations provide further evidence for a role of the 
pfmdr 1 gene product in the susceptibility of P. falciparum to 4-aminoquinolines and 
arylaminoalcohols. The role of the pfcrt codon 76 mutation (in parasite line K76I) in 
antimalarial sensitivity supports the observations of Cooper et al. (2002) and Sidhu et al. 
(2002) with the K76I line displaying a six-fold increased CQ ICso with the introduction 
of the single mutation. Further evidence correlating the CQ ICso values with 
accumulation of eH]-CQ in sensitive and resistant parasites lines is presented in Chapter 
5. 
These results clearly showed that pfcrt and pfmdr 1 played vital roles In 
multifactorial processes which govern parasite susceptibility to a wide range of 
antimalarials. The differences in antimalarial drug interactions among parasite lines with 
varying mutations in the above genes will be investigated in the following chapter. 
4. 1 Introduction 
4.1.1 /sob%grams 
CHAPTER 4 
DRUG COMBINATIONS 
Isobolograms are graphical representations of the dosage-dependent effects of 
two compounds in a mixture (Nelson and Kursar, 1999) where for each point on the 
graph, the x-coordinate is the 50% fractional inhibitory concentration (FICso) of one of 
the combined drugs, e.g. concentration of drug A, required to kill 50% of the parasite 
population (the ICso value); and the y-coordinate is the value for drug B (Figure 4.1). The 
ICso value for each drug alone is standardised as one isobolar unit on each axis. These 2 
points can be joined by a straight line which represents a line of additivity or no 
interaction (Rideout and Chou, 1991). 
The ICso for a particular drug or drug combination is measured by performing an 
in vitro dose-response assay. From the ICso value, the FIC of each drug in a combination 
can be calculated using the equation (Berenbaum, 1978): 
C f d u - IC50 of drug in combination FI 500 r g - IC500f drug alone ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 1 
Using Equation I, the straight line of additivity can also be represented 
mathematically and it is true for all points along the line of additivity: 
ICso of drug A in combination + ICso of drug B in combination 1 2 
ICso of drug A alone ICso of drug B alone = ................................. . 
or 
FIC of drug A + FIC of drug B = 1 ...................................................................... 3 
For each data point in the isobologram, a value for the sum of the component FIC 
values can be calculated using equations I, 2 and 3: 
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~FIC = FICA + FICs ................................................................................................................................ 4 
If a chosen dose of A and B in combination is plotted on an isobologram and the 
point falls on the straight line, the interaction of the two drugs is said to be additive 
(Figure 4.1, point y) and the ~FIC (or mean FIC) equal to 1. Antagonism is indicated by 
points above this line (in which the ~FIC is greater than 1; Figure 4.1, point x), and 
synergy by points below this line (the ~FIC is less than 1; Figure 4.1, point z). 
Furthermore, an overall mean value ~FIC (with error term) can be computed for each 
drug combination from the ~FIC values for all the points in the combination experiment. 
Figure 4.1: An isobologram showing antagonistic, additive and synergistic Interactions. 
Obviously a synergistic combination is desirable, and to detect potential drug-
drug antagonism, in vitro interaction studies are essential. Detailed methodologies for 
these studies are rarely published and often the relevant statistical and mathematical 
calculations are lacking or too complicated. In this chapter, an overview of the 
checkerboard and fixed ratio procedures is presented. The fixed ratio method was 
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validated and generally adopted In the assessment of drug-drug interactions or 
combination studies reported here. 
4.1.2 Checkerboard method 
The checkerboard method has been widely used to assess antimalarial drug 
interactions (Ekong and Warhurst, 1990; Canfield et al., 1995; Hassan Alin et al., 1999). 
This method relies on predetermined ICso values of component drugs, e.g. drug A and 
drug B alone. In the combination assay, the concentration of drug A is kept constant and 
that of drug B varied and vice versa. This is achieved by performing a two-fold dilution 
of drug B in the presence of the fixed concentration of drug A. The solutions to be used 
for the serial dilutions within the interaction experiment are prepared in varying 
proportions of their ICso values (Table 4.1). Across two 96-well microtitre plates, the 
combination solutions and two solutions of the drugs alone are serially diluted. A series 
of dose-response curves are obtained (usually four per plate) and linear regression 
analysis is performed to obtain ICso values for each drug in the presence of various 
concentrations of the second drug (Figure 4.2). From these values the FIC can be 
calculated and the results plotted on an isobologram. 
The checkerboard procedure suffers technical limitations. Synergistic or 
antagonistic isobolograms often show the graph points at the extremities of the axes as 
the FIC for one of the drugs is close to 1 and that of the second drug close to zero. This 
makes the construction of the isobologram difficult and often misleading. The day-to-day 
variations associated with testing ICso values often produce a shift in the dose-response 
curves and the resulting ICso deduced from the curve may exceed the predetermined IC50 
value thus complicating the calculation of the IC50 of the drug in varying concentrations. 
It is not uncommon that the analysis produces a dose-response result on which it is 
impossible to perform a sigmoidal curve fit (e.g. combinational curve 1, Figure 4.2). 
Furthermore, a poor estimation of parasitaemia and haematocrit could cause variations in 
the IC50 values especially when certain drugs (e.g. mefloquine or artemisinin derivatives) 
are used (Duraisingh et al., 1999). This method is highly reliant on accurate initial ICso 
values. 
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Table 4.1: An example of the final drug concentrations as fractions of the predetermined 
ICso values prepared for the checkerboard combination experiment. 
Solution Drug A constant, Drug B constant, 
Drug B varied Drug A varied 
A-1.2x A -1.2x 
1 
B -1.2x B -1.2x 
A-1.2x A-O.6x 
2 
B-O.6x B-1.2x 
A-1.2x A-O.3x 
3 
B-O.3x B-1.2x 
A -1.2x A - O.15x 
4 
B-O.15x B -1.2x 
4.1.3 Fixed ratio method 
The fixed ratio method was originally developed for drug interaction studies on 
bacteria (Hall et al., 1983) but the principles are easily applied to investigate drug 
interactions on other organisms such as P. Jalciparum. The fixed ratio procedure 
described here is a modification or improvement on those described elsewhere (Allen, 
1993) although publication on this procedure is lacking, and where available, it is 
cumbersome and difficult to follow. 
The method uses serial dilutions of fixed ratios of both drugs over a concentration 
range. For the combination assay, top concentration is prepared to allow the IC50 of the 
individual drug to fall around the midpoint (or 4th well) in a two-fold serial dilution. The 
dilutions for each of the 2 drugs are then prepared in fixed ratios as in Table 2.1 and two-
fold serial dilutions are performed across two 96-well microtitre plates. Of the resulting 
six dose-response curves, two would represent each of the drugs alone and the remaining 
four would each have a component relating to each of the two drugs in the combination. 
Although there are only four combinational curves, one can construct eight dose-
response curves using the same percentage inhibition data, but over two different 
concentration ranges relating to each of the two drugs within the combination (Figure 
4.3). The IC50 values can then be calculated and could be used in constructing 
isobolograms. 
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This method has some advantages over the checkerboard method. First, the 
combination dose-response curves depend on drug concentration ratios as opposed to the 
predetermined ICso values on which the checkerboard method depends. Other advantages 
include the wide range of drug concentrations upon which the dose-response curves were 
constructed. Inhibition of parasite growth varied over a wide range from at least 0% to 
100%. This provides a better linear portion of the regression curve from which ICso 
values could be accurately calculated. The daily variation in ICso values may not 
dramatically affect the FIC calculations and incorrectly estimated initial ICso could still 
produce a valid result. Calculation steps are fewer in the fixed ratio method compared to 
the checkerboard and only an approximate estimation of the ICso is required before 
preparing the combination solutions. Isobolograms are easier to construct and the results 
are far less ambiguous, as there is no problem of points on the axes or almost off the 
scale. 
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Figure 4.2: One set of typical dose-response curves obtained using checkerboard method. 
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Figure 4.3: Typical dose-response curves produced using fixed ratio method. In this 
example an additive interaction is demonstrated. 
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4.2 Materials and Methods 
4.2.1 Drug combination assay 
The fixed-ratio method was used to determine the interactions between the 
various antimalarials. The incorporation of eH]-hypoxanthine was used as a measure of 
parasite viability in all combination experiments. The lactate dehydrogenase assay was 
used to confirm the fixed-ratio results obtained using eH]-hypoxanthine uptake method 
for the assessment of the activity of DHA in combination with other drugs against Kl 
and FC27 parasite lines. 
4.2.2 Validating the fixed-ratio method 
In validating the fixed ratio method, additive effect was assessed using QHS and 
DHA. These were assayed in combination against CQR 7G8 and CQS FC27 strains. VP 
in combination with CQ (Martin et al., 1987), and QN with CQ (Stahel et al., 1988) were 
assayed against Kl (CQR) to validate synergism and antagonism respectively. 
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4.3 Results 
4.3.1 Fixed-ratio method validation 
Figure 4.4 presents isobols for synergistic, antagonistic and additive drug 
interactions, verifying the modified fixed ratio procedure. Results are consistent with 
published data (Martin et al., 1987; Stahel et al., 1988) and were similar for both lactate 
dehydrogenase and eH]-hypoxanthine uptake methods in both FC27 and Kl. 
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Figure 4.4: Validation isobolograms for the fixed ratio isobologram method. * 
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4.3.2 Interaction of antimalarials with dihydroartemisinin and artemether 
4.3.2.1 Dihydroartemisinin and chloroquine, amodiaquine or piperaquine 
The interaction of DHA with 4-arninoquinolines CQ and AQ, and bisquinoline 
PPQ was examined. As presented in Figure 4.6A,B the interaction between DHA and CQ 
was antagonistic in all CQS and CQR parasite lines examined. The isobols in the Figure 
clearly depict antagonistic interactions. Figure 4.5A shows the mean FIC values which 
for CQS parasite lines range between 1.25 and 1.S0 compared to 1.25 and 1.60 for CQR 
parasite lines. This mean FIC difference between CQS and CQR parasite lines was 
significantly higher in CQS parasite lines (P = 0.006). There was no significant 
difference with the mean FIC values between parent and transfectant lines DIO-mdrDIO 
and DIO_mdr7G8, 7GS_mdr7G8 and 7G8-mdrDlO, or between 106/1 and K76I. 
The interaction between DHA and AQ in all the 12 parasite lines tested was 
antagonistic. The corresponding isobolograms (Figure 4.6C,D) were similar to those of 
DHA and CQ in Figure 4.6A,B. However, unlike the DHA + CQ combinations (Figure 
4.5A), there was no significant difference between the mean FIC values for CQS and 
CQR parasite lines (Figure 4.5B). 
Similarly, the isobolograms In Figure 4.6E clearly indicate antagonistic 
interactions between DHA and PPQ. Only 6 of the 12 parasite lines were examined. 
There was no significant difference between the mean FIC values for CQS and CQR 
parasite lines (Figure 4.5C). 
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Figure 4.5: Mean FIC values (± SEM) for DHA combined with CQ (A), AQ (B) or PPQ (e) in 
P. falciparum parasite lines. See Figure 2.3 for explanation of the figures. 
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c: DHA combined with PPQ 
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Figure 4.6: Isobolograms of combination effect of DHA and CQ (A,B), AQ (C,D) or PPQ (El. 
Each point is an average of at least 2 experiments. Axes represent normalised FIC values. 
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B: DHA combined with CQ in CQR P. fa/ciparum parasite lines. 
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C: DHA combined with AQ in CQS P. fa/ciparum parasite lines. 
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0: DHA combined with AQ in CgR P. falciparum parasite lines. 
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E: DHA combined with PPQ in P. fa/ciparum parasite lines. 
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4.3.2.2 Dihydroartemisinin and mefloquine, or halofantrine 
DRA + MQ: The interaction between DRA and MQ was synergistic when the 
drug combination was assayed against CQS parasite lines, except 106/1 (Figures 4.7 A 
and 4.SA). Although the isobologram for D 1 0_mdr7G8 tends towards the line of additivity 
(Figure 4.SA), the points were clearly within the synergistic zone. This is not so clear for 
parasite line 106/1 in which the drug combination appears to have exerted an overall 
additive effect significantly different to the other CQS parasite lines (P :s; 0.006), 
although two of its points just lied on the synergistic side of the line. In the CQR parasite 
lines, the combination of DRA and MQ produced an additive effect except for 7GS-
mdrD10 where it was synergistic (Figures 4.7A and 4.SB). Excluding 106/1 and 7GS-
mmDlO, the difference in mean FIC between the CQR and CQS parasite lines was 
significant (P < 0.04S). Kl showed a 'biphasic-like' effect with two of the points lying 
on the synergistic side and one on the antagonistic side, although the overall effect was 
regarded as additive according to mean FIC. The RSAll isobol was taken to indicate an 
additive effect as all four points lie just below the additive line, but its mean FIC is that 
of an additive interaction. The allelic exchange - replacing 7GS pfmdrl mutant allele 
with DI0 wild-type allele - had a pronounced effect on the activity of the combined 
DHA and MQ on the transfectant. Contrary to the additive effect seen in other parasite 
lines, the interaction for the 7GS-md~IO transfectant was synergistic and the difference 
was statistically significant from all other CQR parasite lines (P :s; 0.015). 
DHA + HAL: Similarly, the interaction between DHA and HAL was synergistic 
in CQS parasite lines, except 106/1 (Figures 4.7B and 4.SC). The interaction in 106/1 
was additive, although two of the points were on the antagonistic side; but the overall 
difference in effect was significantly different from the other CQS parasite lines (P < 
0.002). Although FC27 had one point which was on the line of additivity, the overall 
effect was taken to be synergistic according to the mean FIC. As for MQ, the CQR 
parasite lines showed an additive effect except for 7GS-mdrDlO which was synergistic 
(Figures 4.7B and 4.SD). Excluding 106/1 and 7GS-mdrDlO, the difference in mean FIC 
between the CQR and CQS parasite lines was significant (P ::::;; 0.048). The difference in 
mean FIC between additive 7GS_mdr7G8 and synergistic 7G8-mdrDlo was statistically 
significant (P < 0.001). K76I had a similar additive interaction to 106/1 with 2 of the 
points lying above the additive line, but the mean FIC values were both close to 1. 
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Although RSAll, Kl and B303 had one or two points which was either side of the line 
of additivity, the overall effect was additive. 
Figure 4.7: Mean Fie values (± SEM) for DHA combined with MQ (A) or HAL (6) in P. 
fa!c;parum parasite lines. See Figure 2.3 for explanation of the figures. 
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Figure 4.8: Isobolograms of combination effect of DHA and MQ (A,B) or HAL (C,D). Each 
point is an average of at least 2 experiments. Axes represent normalised FIC values. 
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B: DHA combined with MQ in CgR P. falciparum parasite lines. 
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c: DHA combined with HAL in cas P. fa/ciparum parasite lines. 
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0: DHA combined with HAL in CQR P. fa/ciparum parasite lines. 
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4.3.2.3 Lumefantrine and dihydroartemisinin or artemether 
LM + DHA: The response of the DHA and LM combination was synergistic in 
the CQS parasite lines, except 106/1 and DI0_mdr7G8 (Figures 4.9A and 4.10A). The 
combination exerted an additive effect on D 1 0_mdr7G8 and 106/1; although 106/1 did 
have two points slightly off the additive line, but according to its mean FIC the 
interaction was additive. The T996 interaction appeared synergistic, but it was not 
significantly different from other additive interactions seen here. For the CQR parasite 
lines, the DHA + LM effect on Kl, RSAll, B303 and 7GS_mdr7G8 was taken to be 
additive (Figures 4.9A and 4.10B). Although some points fell in either synergistic or 
antagonistic region, the mean FIC values clearly indicated additive effects (Figure 4.9A). 
The difference in mean FIC values between CQR (excluding 7GS-mdrDIO) and CQS 
interactions (excluding T996, 10611 and DlO_mdr7G8) was significant (P ~ 0.04S). The 
difference in mean FIC between DlO_mdr7G8 (additive) and DlO_mif10 (synergistic) 
was highly statistically significant (P < 0.001), but the difference between DI0_mdr7G8 
(additive) and T996 (synergistic) was not significantly different. Interestingly, the 
combined effect of the two drugs on 7GS_mdrD10 was synergistic, while the combination 
appeared to have a 'biphasic' interaction (weak synergy and antagonism) in K76I (Figure 
4.10B), giving an overall additive mean FIC (Figure 4.9A). The difference in mean FIC 
values between 7GS_mdr7G8 (additive) and 7GS_mdrD10 (synergistic) was significant (P = 
0.004). 
LM + ATM: The ATM and LM combination was synergistic in the CQS parasite 
lines except for T996, 106/1 and DlO_mdr7G8 (Figures 4.9B and 4.lOC). Three of the four 
points of the T996 interaction were on the synergistic side, but the overall mean FIC 
indicated that the interaction was additive (Figure 4.9B). The effect of the two drugs on 
106/1 gave an additive interaction although two of the points were antagonistic (Figure 
4.10C). The difference in mean FIC between DlO_mdrD10 and DI0_mdr7G8 was 
statistically significant (P < 0.001). The interaction was additive in the CQR parasite 
lines except in moderately CQR 7GS-mmPlO (Figures 4.9B and 4.1 OD). The difference in 
interaction between 7GS-mdr7G8 and 7G8-mdrD10 was significant (P ~ 0.015). The 
combinations of ATM + LM had identical responses to the DHA + LM combinations 
except with T996 - the former combination was additive (this difference was not 
statistically significant). Similarly, the difference in mean FIC values between CQR 
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(excluding 7G8-mctrD10) and CQS interactions (excluding T996, 106/1 and D10_mdr7G8) 
was significant (P =::; 0.030). 
Figure 4.9: Mean Fie values (± SEM) for LM combined with DHA (A) or ArM (B) in P. 
falciparum parasite lines. See Figure 2.3 for explanation of the figures. 
A: DHA combined with LM. 
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Figure 4.10: Isobolograms of combination effect of LM and DHA (A,B) or ATM (C,D). Each 
point is an average of at least 2 experiments. Axes represent normalised FIC values. 
::E 
...J 
'6 
o 
u: 
::E 
..J 
'6 
o 
u: 
A: DHA combined with LM in cas P. fa/ciparum parasite lines. 
FC27 
FICofDHA 
307 
FICof DHA 
010_mdr7G8 
FIC of DHA 
::E 
..J 
o 
o 
u: 
::E 
...J 
'6 
o 
u: 
::E 
...J 
'6 
o 
u: 
T996 
FICofDHA 
010_mdrD10 
o 
FICofDHA 
106/1 
o 
FICofDHA 
Chapter 4: Drug Combinations 
B: DHA combined with LM in COR P. falclparum parasite lines. 
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C: ATM combined with LM in CQS P. falc;parum parasite lines. 
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D: ATM combined with LM in CQR P. falciparum parasite lines. 
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4.3.2.4 Dihydroartemisinin and quinine 
Unlike the arylaminoalcohols MQ, HAL and LM, the QN + DHA combinations 
showed a varied interaction among CQS and CQR parasite lines. The CQS parasite lines 
showed varying responses even among parasite lines thought to carry wild-type 
sequences of resistance associated genes (Figures 4.11 and 4.12A). An overall additive 
effect of the combination with lines FC27, 106/1, and DI0-md~10 was seen, although all 
three parasite lines had points around the line of additivity (Figure 4.12A). FC27 
appeared to have a 'biphasic' response to the effect of the combined drugs. Although 
response of D 1 0_mdr7G8 appeared to be synergistic, the difference in mean FIC between 
DI0_mdr7G8 and DIO-mdrDIO (additive) was not significant. This can be seen in the DlO-
md~lo isobol which had three points in the synergistic region below the line of 
additivity, while DlO_mdr7G8 had all four points within the synergistic region. DHA + 
QN combination produced a synergistic effect on both T996 and 3D7, although the 
synergistic effect on T996 was remarkably greater than the effect on 3D7 which had an 
isobol tending toward the line of additivity. 
The interaction was overall additive in the CQR parasite lines Kl, RSAl1, B303 
and 7G8_mdr7G8, although the interaction ofK1 did have two antagonistic points (Figures 
4.11 and 4.12B). The interaction was synergistic on K76I and 7G8-mctrD1o. The 
difference in interaction between the synergy seen with K76I and addition seen with 
106/1 was significant (P < 0.001). This DHA + QN interaction was 'reversible' using 1 
JlM VP in K76I (see Section 4.3.3). The mean FIC of the synergistic response seen with 
7G8-md~10 was significantly lower than the additive response seen with Kl, RSAll, 
B303 and 7G8_mdr7G8 (P < 0.001). 
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Figure 4.11: Mean Fie values (± SEM) for DHA combined with aN in P. fa/ciparum parasite 
lines. See Figure 2.3 for explanation of the figure. 
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Figure 4.12: Isobolograms of combination effect of DHA and ON. Each point is an average 
of at least 2 experiments. Axes represent normalised FIC values. 
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B: DHA combined with QN in CQR P. falciparum parasite lines. 
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4.3.2.5 Dihydroartemisinin and atovaquone or pyrimethamine 
The effect of ATV and DHA on parasite lines examined, except NGATV01, was 
antagonistic (Figures 4.13A and 4.14A,B). The drug combination had an additive effect 
on the ATV-resistant field isolate NGATVOI. This response seen with NGATVOI was 
statistically different (P ~ 0.012) from that seen in the other eight strains. The mean FIe 
scatter graph as shown in Figure 4.13A and the mean FICso and FIC90 values with 
confidence intervals are listed in Table A2.1 (Appendix 2). 
When antifolate PYR was combined with DHA, the combination was shown to 
produce antagonistic effect on the PYR-sensitive parasite lines and a clear additive effect 
on one of the two (B303) PYR-resistant parasite lines (P ~ 0.003; Figures 4.13B and 
4.14C). In Kl, which is also PYR-resistant, the combined drug effect on the parasite line 
borders between addition and antagonism. Considering the mean FIC value (Figure 
4.13B), the effect of the two drugs could be classed as addition or weak antagonism; 
however, the interaction in Kl was significantly different (P ~ 0.040) from the PYR-
sensitive parasite lines. 
The parasite lines 106/1 and K761 were not tested with these two combinations. 
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Figure 4.13: Mean Fie values (± SEM) for CHA combined with ATV (A) or PYR (B) In P. 
faiciparum parasite lines. See Figure 2.3 for explanation of the figures. 
A: CHA combined with ATV. 
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Figure 4.14: Isobolograms of combination effect of OHA and ATV (A,B) or PYR (C). Each 
point is an average of at least 2 experiments. Axes represent normalised FIC values. 
A: OHA combined with ATV in CQS P. falciparum parasite lines. 
FC27 T996 
o 
FICofDHA FICofDHA 
307 D10_mdrD1D 
FICof DHA FICofDHA 
010_mdr7G8 NGATV01 
FICof DHA FICofDHA 
Chapter 4: Drug Combinations 
B: DHA combined with ATV in COR P. fa/ciparum parasite lines. 
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c: DHA combined with PYR in PYR-sensitive and PYR-resistant (K1 and 8303) P. 
falciparum parasite lines. 
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4.3.3 Interaction of antimalarials with dihydroartemisinin and artemether 
in the presence of verapamil or penfluridol 
The effects ofDHA + QN and DHA + LM combinations were examined, together 
with the reversal effect of VP on the interactions of the combined drugs. DHA + QN 
exerted an additive effect on 106/1, and addition of 1 J.lM VP produced no change as the 
interaction remained additive (Figure 4.15A). However, combined drugs DHA + QN had 
a synergistic effect on K76I and addition of 1 J.lM VP had a pronounced effect -
changing the interaction significantly (P = 0.002) from synergy to addition (Figure 
4.1SB). 
DHA + LM in DI0-md~\O was synergistic and 1 J.lM VP had no effect on this 
interaction (Figure 4.15C). Conversely to the reversal effect seen above with K76I, the 
DHA + LM combination produced an additive effect on DlO_mdr7G8 and 1 J.lM VP had 
no effect on this interaction (Figure 4.1SD). The effect of 1 J.lM VP on the combined 
effect of DHA + MQ and DHA + HAL was also examined on Kl and RSAll. VP 
produced no change in the observed interactions (Figure A2.3; Appendix 2). 
PEN had an additive effect with DHA on both FC27 and T996. However, while 
PEN had the same interaction with DHA in these two parasite lines, when combined with 
MQ it was additive in FC27 and synergistic in T996 (Figure 4.16). PEN and CQ 
produced antagonism in T996. 
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Figure 4.15: Isobolograms indicating the reversal effect of 1 uM VP and combinational 
effect of OHA with aN (A,B) and LM (C,O). t 
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Figure 4.16: Isobolograms of combination effect of PEN and MQ, DHA or CQ in P. 
faiciparum parasite lines. Each point is an average of at least two experiments. Axes 
represent normalised FIC values. 
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4.3.4 Interaction of atovaquone and proguanil 
The isobolograms for the interactions between ATV and PG are presented in 
Figure 4.17 and the corresponding FIC values (calculated from ICso values) are in Table 
4.2. The effect of the combination on ATV-sensitive T996 and Kl was strongly 
synergistic. ATV -resistant isolate NGATVO 1 displayed a moderately synergistic 
response which was significantly different to T996 (P = 0.011) and Kl (P = 0.007). 
Table 4.2: The Mean Fie of the interactions between ATV and PG with 95% confidence 
intervals. 
Parasite ATV+PG
a 
Mean FIe (95% CI) 
NGATVOI 0.80* (0.75-0.85) 
T996 0.29 (0.21 - 0.37) 
Kl 0.17 (0.l3 -0.21) 
a The asterisk indicates a significantly different result in comparison with the determinations on 
the other strains (P < 0.05). 
Figure 4.17: Isobolograms showing the interaction between ATV and PG in NGATV01. 
T996 and K1. Axes represent normalised Fie values. 
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4.4 Discussion 
4.4.1 Fixed ratio method 
The fixed ratio method was easy to prepare and the mean FIC values for the 
combinations were consistent between experiments. The validation experiments (Figure 
4.4) were consistent with published data (Martin et al., 1987; Stahel et al., 1988). 
4.4.2 Interaction between DHA and CQ or AQ 
The combination of DHA with CQ was antagonistic in both CQS and CQR 
parasite lines (Figure 4.SA). An antagonistic interaction between DHA and AQ (Figure 
4.5B) was expected for both types of parasite lines as AQ has similar structure and 
physical chemistry to CQ (see Section 1.2.2.1). AQ accumulates to levels 2- to 3-fold 
higher than CQ in a CQS parasite line and it has been suggested that AQ has a greater 
affinity for FPIX (Hawley et al., 1996). Chawira and Warhurst (1987) reported 
antagonistic interactions against CQR and CQS strains with the QHS and CQ 
combination in vitro. Stahel et al. (1988) reported antagonism between QHS and CQ in 
vitro and showed lower antagonism in the CQS strain than in the CQR strain. Fivelman 
et al. (1999) showed antagonism between artesunate and CQ in a CQR strain, but an 
additive effect in a CQS strain. These two latter reports suggested that CQS strains of P. 
falciparum are less likely to show antagonism between CQ and QHS-derivatives. A 
significant difference was seen between overall mean FIC values of the CQS and CQR 
parasite lines in this study, although differing from Fivelman et al. (1999) in that the 
DHA + CQ interactions were antagonistic in both CQS and CQR parasite lines. 
However, there was no difference in the antagonistic interaction seen with the 
transfectants DI0_mdr7G8 and 7G8-mdrDlO compared to the parent transfectant lines. The 
method used by Fivelman et al. (1999) was less accurate and prone to large statistical 
errors. Strain specific interactions cannot explain this difference as the same strains (DI0 
and RSA 11) were used in these studies as in the report by Fivelman et al. (1999). It is 
unlikely that the interaction with CQ would differ among the artemisinin derivatives; 
although DHA has been reported to show high potency against all stages of P. 
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fa/ciparum parasites in vitro while QHS was shown to be only effective against rings and 
schizonts (Skinner et a/., 1996). Artesunate is also reported to be intrinsically unstable at 
neutral pH and is thought to dissociate to DHA in vitro (Brockman et a/., 2000). An 
additive interaction has been reported in vivo when QHS and CQ are combined. 
Although antagonism was not detected in vivo, it was suggested that the in vitro system 
was likely to be more sensitive to this effect (Chawira et a/., 1987). 
There has been increasing evidence that there is an inverse relation between 
resistance to 4-aminoquinolines and QHS-derivatives (Reed et a/., 2000; Duraisingh et 
a/., 2000b; Cooper et aI., 2002; Sidhu et a/., 2002). It is possible that there is competition 
for uptake of both types of drugs at the same site, which has been suggested previously 
(Gu et a/., 1984). CQ binds to FPIX extremely avidly (Chou et a/., 1980) and this 
saturable CQ uptake into the digestive vacuole has been proposed as the cause of the 
intracellular accumulation of drug by the parasite (Bray et a/., 1998). QHS reacts with 
FPIX in aqueous solution to form an adduct (Meshnick et a/., 1991; Hong et a/., 1994) 
and molecular modelling studies have shown a stable docked configuration of QHS and 
FPIX could exist (Shukla et a/., 1995). A competition for FPIX might exist between CQ 
and DHA. Bound DHA would sterically protect the CQ from interacting with FPIX, 
which could cause a decrease in CQ accumulation. Drugs which bind to FPIX have been 
shown to competitively inhibit CQ uptake (Bray et a/., 1999a). On the other hand, bound 
CQ would sterically protect FPIX from DHA interaction. DHA depends on iron-
mediated cleavage for activation, and the ring-ring interaction between the CQ and FPIX 
could prevent this activation from occurring (Figure 4.18). This could lead to 
antagonism. While it is probable that interaction of DHA with the haem iron is 
irreversible, CQ binding might protect FPIX from the free-radical producing reaction 
with the QHS-derivatives (Wright and Warhurst, 2002). QHS appears to partially inhibit 
CQ-induced pigment clumping, further evidence in support of an antagonistic drug 
interaction (Peters et a/., 1986). 
The endoperoxide antimalarials are fast acting drugs and cause rapid parasite 
damage (Ellis et a/., 1985; Maeno et a/., 1993) and DHA, in particular, acts on all the 
stages of the parasite achieving complete growth inhibition 2 - 4 hours after exposure 
(Skinner et a/., 1996). One likely primary mode of uptake and action of CQ and AQ 
involves binding to FPIX (Bray et a/., 1998). In addition, inhibitors which prevent the 
breakdown of Hb decrease CQ accumulation into infected RBC and are strongly 
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antagonistic with CQ (Mungthin et aI., 1998; Bray et al., 1999a). It may be possible that 
the rapid action of DHA on the parasite could inhibit the release of FPIX due to rapid 
parasite damage. QHS has been shown to inhibit Hb degradation both in vitro using cell 
lysates and intact parasites (Pandey et al., 1999). This could result in lower levels of 
intracellular FPIX as there would be an inhibition of Hb breakdown, leading to decreased 
CQ uptake. 
Chawira et al. (1987) suggested that the antagonism of QHS and CQ may be due 
to less CQ accumulating because of the damaged membrane integrity caused by QHS. 
QHS has been shown to affect all parasite membranes including the digestive vacuole 
(Ellis et al., 1985; Maeno et al., 1993). A decreased CQ concentration within the vacuole 
has been shown to be linked to an increased CQ ICso (Verdier et al., 1985; Krogstad et 
aI. , 1992; Bray et aI., 1992b) and the basis of antagonism in a drug combination is an 
increase in ICso values. 
PPQ has two quinoline ring nuclei combined through an aliphatic linker and is 
thought to have the same mode of action as the 4-aminoquinolines (Raynes, 1999). PPQ 
shows a similar interaction with DHA in combination as CQ and AQ (Figure 4.SC). It 
probably interacts in a similar fashion with FPIX, has been shown to prevent tJ-haematin 
formation (Prof. David Warhurst, personal communication) and could therefore 
antagonise similarly. As it is a relatively new drug, little is known about the mechanism 
of action ofPPQ. 
Figure 4.18: An illustration of the FPIXlguinine complex co-ordination. Picture by D.C. 
Fe-O 
Warhurst. Inset: The structure of haem. 
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4.4.3 Interaction between DHA and MQ or HAL 
The combinations ofDHA and MQ were synergistic in CQS lines and additive in 
CQR lines - with polymorphisms in pfmdr 1 and pfcrt causing exceptions (Figure 4.7 A). 
HAL is an aryl amino alcohol like MQ and has a similar structure and function to MQ (see 
Section 1.2.2.3). It is therefore not surprising that the HAL results are similar to MQ 
(Figure 4.7B). Synergy has been previously demonstrated with combinations of QHS-
derivatives and MQ in vitro (Chawira and Warhurst, 1987; Ekong and Warhurst, 1990; 
Fivelman et a/., 1999) and in vivo (Chawira et a/., 1987). An additive interaction or 
difference in interaction due to polymorphisms in CQ resistance related genes has not 
been reported. 
The introduction of the 7G8 mutations into the DI0 pfmdrl gene (DIO_mdr7G8) or 
the change in codon 76 of pfcrt (K76I) led to no change in the synergistic interaction 
between DHA and either MQ or HAL. However, a difference in interaction was observed 
between mutated pfmdrl 7G8_mdr7G8 and wild-type pfmdrl 7G8-mdrDlo transfectants. 
This significant change from additive to synergistic effect was also observed in the DHA 
+ QN, DHA + LM and ATM + LM combinations. The CQS 106/1 parasite line has 
mutated pfmdrl 86tyr and wild-type pfcrt lys76, but showed an additive response to DHA . 
and MQ or HAL. The interactions were similarly additive in CQR K76I which carried 
mutatedpfmdrl 86tyr and mutatedpfcrt 76i1c• The 10611 parasite line was an exception as 
it was the only CQS parasite line to display an additive interaction. However, 106/1 did 
have a significantly higher CQ ICso and lower MQ ICso compared to the other CQS 
parasite lines and was classified as moderately CQR (see Section 3.4.2.2.1). Parasite 
lines 7G8_mdr7G8, 7G8-mdrD10 and K76I all carried mutated plcrt codon 76 (Table 3.7), 
and 106/1 carries pfcrt mutations associated with resistance in Africa and Asia except the 
essential amino acid change at codon 76 seen in CQR parasites (Fidock et a/., 2000b). 
The six of the seven pfcrt mutations, along with the pfmdr 1 mutation 86tyr, which 106/1 
carried could be a factor mediating the additive response as the other CQS parasite lines 
had wild-type plert gene and wild-type pfmdr 1 codon 86. These results suggest that 
plmdr 1 may be playing an important role in the interaction between DHA and MQ or 
HAL. It appears that the pfmdr 1 mutations in addition to other sequence changes, e.g. in 
pfcrt gene, are required for additive interactions seen in this study. Additionally, it has 
been suggested that genes other than pfmdr 1 and plcrt may be involved in highly 
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resistant CQ phenotypes (Basco and Ringwald, 2001; Chen et al., 2002; Sidhu et al., 
2002; Thomas et al., 2002). It is possible that another mutated gene could have further 
effect, thus influencing the combinational effect of the drugs. The introduced mutated 
pfmdrl in DI0_mdr7G8 significantly increased the MQ cellular accumulation ratio 
suggesting that in the field, parasites carrying wild-type pfmdrl accumulate less MQ 
(Reed et al., 2000). Perhaps 7G8-m~lo MQ accumulation capacity may be lower than 
that of 7G8_mdr7G8 which may have led to the differing response to the combined effect 
of the drugs. This observation is consistent with other reports demonstrating MQ 
sensitivity in parasites carrying mutated pfmdrl (see Section 1.3.2.2) and a significant 
difference in MQ and HAL ICso values between 7G8_mdr7G8 and 7G8-mdrP10 was seen 
(Table 3.5). Evidence of cross-resistance between MQ and QHS-derivatives in vitro 
(Duraisingh et al., 1999; Duraisingh et al., 2000b) and in the field (Doury et al., 1992; 
Basco and Le Bras, 1993; Le Bras. 1998; Pradines et al., 1998a; Wongsrichanalai et al., 
1999) has been widely published. and the link of QHS-derivatives and MQ sensitivity 
with pfmdr 1 mutations is demonstrated here and elsewhere (Reed et al., 2000). 
MQ has similar FPIX binding properties as CQ (Chou et al., 1980; Sullivan et al., 
1998) although affinity of the arylaminoalcohols for FPIX was originally reported 103_ to 
104-fold lower than for CQ (Chou et al., 1980). Bound MQ. as for CQ. could sterically 
protect the FPIX from DHA interaction (Figure 4.18). This would predict an antagonistic 
interaction. But. the primary accumulation mechanism may be different to CQ due to the 
lower affinity of MQ for FPIX (Chou et al., 1980) and lower accumulation due to its 
weak base effect (Yayon et al., 1984; Ginsburg et al., 1989). It has been suggested that 
the accumulation of MQ could be enhanced by a secondary active transport system 
(Vanderkooi et al., 1988) or MQ-binding parasite proteins (Desneves et al., 1996). 
Common features between MQ and DHA uptake could explain the synergism of the 
combination. A possible target for both MQ and QHS-derivatives are membrane 
phospholipids. MQ binds with high affinity to membrane phospholipids and this could be 
an important feature of its antimalarial action (Chevli and Fitch. 1982; Desneves et al., 
1996). QHS, similarly. binds to membranes, but causes severe membrane damage (Ellis 
et al., 1985), and the TCTP protein has been suggested to be a target of the QHS-
derivatives and is located in parasite cytoplasm. digestive vacuole and limiting 
membranes (Bhisutthibhan et al., 1999). It may be possible that an interaction of QHS 
Chapter 4: Drug Combinations 184 
with the parasite membranes enhances the effect of MQ (Chawira et al., 1987; Chawira 
and Warhurst, 1987). 
4.4.4 Interaction between LM and DHA or A 1M 
LM was found to have synergistic effects with DHA in all parasite lines 
harbouring wild-type pfmdr 1, but had additive effect in all parasite lines carrying 
mutated pfmdrl genes (Figure 4.9A). This was clearly supported in the responses 
displayed by the transfectants: synergism with DIO-mruP1o becoming additive with DIO-
mdr7G8, and addition with 7G8_mdr7G8 becoming synergistic with 7G8-mdrDJO• These 
results, which could suggest an association or link between LM activity and mutations in 
pfmdrl gene, were similarly seen when LM was combined with ATM (Figure 4.9B). 
Surprisingly however, CQ and LM sensitive T996 displayed an additive response to the 
LM + ATM combination but this difference was statistically insignificant. There should 
be little difference between the mode of action of DHA and ATM, although DHA has 
been reported to have greater potency than ATM against all stages of P. falciparum 
parasites in vitro (Skinner et aI., 1996). However, T996 carried mutated pfmdr 1 184phe 
(Table 3.7) and this single polymorphism (which does not confer reduced CQ sensitivity 
as seen in Table 3.3) resulted in a more additive response in this line, further highlighting 
the sensitivity of these LM interactions to mutations inpfmdrl. 
LM and HAL share some chemical and biological properties - both very 
lipophilic, and poorly water soluble (Ezzet et al., 2000). This may be one explanation or 
reason for similar results obtained for this combination as well as MQ or HAL with 
DHA. However, the introduction of mutated pfmdr 1 into D 1 0 significantly altered the 
responses for the LM + DHA or LM + ATM combinations; this was not seen in MQ, 
HAL or QN combinations. The LM interactions were repeated in the presence of 1 JlM 
VP but no change in the observed effects of the drug interaction was seen (Figure 4.15). 
This may be due to the high lipophilic nature of LM. As for MQIHAL combinations, 
mutations in pfmdr 1 may be playing an important role in the interaction between LM and 
DHA or ATM. However, the LM interactions appear to be less dependent on the 
presence of other CQ resistance polymorphisms such as in pfert. This is further 
supported by the similar additive interactions seen in 106/1 and K761 both of which 
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carried mutated pfmdr 1 but differed in pfert; although LM ICso was strongly influenced 
by polymorphisms in pfert (Table 3.3A). 
Links between pfmdrl and LM resistance have been reported previously. In 
samples from co-artemether clinical trials carried out in children, Duraisingh et al. 
(1999) reported a significantly reduced prevalence of mutated pfmdr 1 86tyr in recurring 
infections. In both the Gambian and Tanzanian trial areas, one of the hypothesised 
resistance determinants, i.e. wild-type pfmdr 1 as"86, was selected; whilst a CQ-only 
treatment trial carried out as a control for the Tanzanian study showed a significantly 
reduced prevalence of pfmdr 1 as"86 recurrences. This highlighted the difference in allele 
selection between the two drugs. 
4.4.5 Interaction between DHA and QN 
QN as seen here had varied effect on the strains. In vitro synergism between QN 
and arteether (Ekong and Warhurst, 1990) or artesunate (Fivelman et al., 1999) has been 
reported previously. In the CQS strains the interactions were additive in FC27, 106/1 and 
D10-md~lo and synergistic in T996, 3D7 and DI0_mdr7G8 (Figure 4.11). Interestingly, 
the interaction in FC27 and DlO-m~\O was identical which was not surprising in view 
of the fact that D 1 0 was originally cloned from FC27 (McColl et al., 1994). The allelic 
replacement of mutated pfmdrl (7G8_mdr7G8) by wild-type pfmdrl (7G8-md~lo) 
conferred a significant change in the response seen with the two drugs from addition to 
synergy. The change in drug interaction effect on 106/1 carrying wild-type pfert codon 
76 (lys76) and the drug selected line K761 which harboured mutated pfert (76i1e) was 
significant - changing it from additive to synergistic. The addition of 1 J.lM VP in the QN 
+ DHA K76I combination 'reversed' the interaction effect on K76I from synergy to 
addition as seen in the parent line 106/1 (Figure 4.15). 
Mutations in both pfert (Cooper et al., 2002; Sidhu et al., 2002) and pfmdrl 
(Reed et al., 2000) have been reported to influence QN ICso values. A large drop in QN 
ICso was seen between mutated pfmdr 1 7G8-mdr7G8 and wild-type pfmdr 1 7G8-mdrDlo 
(Tables 3.3A and 3.7). As shown in Table 3.3A, there was almost a 4-fold decrease in 
QN ICso between 106/1 and K761. Cooper et al. (2002) reported a similar drop in ICso 
and which could be raised -5-fold by 0.9 JlM VP; although the raised QN ICso for K76I 
was still significantly lower than that for 106/1. It has been suggested that QN could have 
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a direct interaction with PtCRT (Cooper et al., 2002). Additionally, it was suggested that 
a CQR VP-reversible phenotype may reflect a physical association between VP and 
mutant PtCRT and/or mutant PtCRT-mediated physiological changes within the 
digestive vacuole that alter the activity ofVP on haem binding and drug-FPIX formation 
(Sidhu et al., 2002). QN has similar FPIX binding properties as MQ (Chou et al., 1980), 
so bound QN, as for CQ and MQ, could sterically protect the FPIX from DHA 
interaction (Figure 4.18). However, it could be possible that there is an altered 
interaction ofQN with the mutated PtCRT in the presence ofVP, resulting in a change in 
interaction. The varied interaction of QN with the different parasite lines supports the 
suggestion that the QN ICso may be dependent on the type of PtCRT mutation(s) the 
parasite carries related to differences in drug affinity of the altered amino acids within 
the protein (Cooper et al., 2002); and there is a possibility that alternative QN resistance 
genes exist (prof. David Warhurst, personal communication). 
4.4.6 Interaction between DHA and A TV 
Antagonism between ATV and common antimalarials such as chloroquine and 
mefloquine has been previously reported including a moderately antagonistic 
combination with the QHS-derivative, artesunate, in CQR strain W2 (Canfield et al., 
1995). Accumulation studies of eH]-DHA and e4C]-QHS show that these drugs 
accumulate in the mitochondria (Maeno et al., 1993) and ultrastructural changes induced 
in P. falciparum in vitro and in vivo by QHS, ATM or DHA include early swelling of 
parasite mitochondria (Jiang et al., 1985; Maeno et al., 1993; Kawai et al., 1993). The 
antimitochondrial effects of both ATV and DHA may bear some relationship to their 
exerted antagonism, and it is interesting that an additive effect was seen here with an 
ATV-resistant isolate (Figure 4.13A). ATV-resistant strains are reported to resist the 
ATV -mediated membrane potential collapse and electron transport inhibition (Srivastava 
et al., 1999). Recently, Gupta et al. (2002b) reported an additive and synergistic 
interaction between QHS and ATV in ATV-sensitive parasite lines using FIC values 
obtained from the ICso and IC90 respectively determined by the checkerboard technique. 
Although, using the ICso values the authors show an additive interaction, all the points on 
the isobologram lie above the line of additivity. This would indicate an antagonistic 
result which would be consistent with our results and that of Canfield et al. (Canfield et 
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al., 1995). The re-analysis of our results presented here using the ICoo values to calculate 
the FIC values revealed antagonism for all parasite lines (Table A2.1, Appendix 2). 
Therefore, no difference in interaction was seen using either the FIC90 or FICso values 
questioning the large differences in FIC values between the two FIC analyses reported by 
Gupta et al. (2002b). 
4.4.7 Interaction between DHA and PYR 
Antagonism of the DHA and PYR combination was seen in PYR-sensitive lines, 
but the interaction was additive in PYR-resistant lines (Figure 4.13B). Antifolates have 
been repeatedly shown, in vitro and in vivo, to be antagonistic with QHS (Chawira et al., 
1987; Chawira and Warhurst, 1987; Fivelman et al., 1999), although none of the reported 
interactions have been tested on PYR-resistant strains. 
The antagonism of the PYR with structurally and mechanistically unrelated drugs 
such as QHS-derivatives or MQ (Figure A2.4, Appendix 2) cannot be fully explained. 
One possible explanation could involve the differences in stage-specificity and time 
course of drug action. DHA acts on all the stages of the parasite achieving 50% growth 
inhibition 1 - 3 hours after exposure (Skinner et al., 1996). However, PYR has been 
reported to only show a change in parasite morphology during the maturation of 
merozoites during the schizont stage; and it was reported that no morphology change was 
seen when P. knowlesi parasites were grown from rings to trophozoites (Gutteridge and 
Trigg, 1971). PYR blocks the DHFR protein of the tetrahydrofolate synthesis pathway 
(see Section 1.2.3) and these drugs require parasites to be using these pathways in order 
for the drug to be effective. DHA causes wide-spread damage to the parasite (Ellis et al., 
1985; Maeno et al., 1993) and -100% growth inhibition is seen within 2 - 4 hours 
(Skinner et al., 1996). The interaction experiments were prepared with the parasites at an 
early ring stage (see Section 2.3.2) so few parasites could reach the schizont stage where 
PYR would have its effect due to the rapid DHA damage. The antifolate SDX 
accumulates slowly within the parasite and displays a linear time course of cellular 
accumulation (Dieckmann and Jung, 1986) which could be true for PYR. DHA, 
conversely, rapidly reaches maximum accumulation within the parasite in about 1 hour 
(Gu et al., 1984). This, ultimately, could result in DHA acting alone and an antagonistic 
interaction seen. The change in interaction from antagonistic to additive in the PYR-
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resistant parasite lines could be due to the higher PYR concentrations needed to inhibit 
parasite growth. Morphological changes during ring to trophozoite stages were shown 
after the addition of high PYR concentrations of 10-4 M to cultures (Gutteridge and 
Trigg, 1971). These studies demonstrated vacuolated cytoplasm and pigment extrusion at 
these high drug concentrations, some of them within 4 hr after the addition of the drug. It 
may be possible that PYR causes increased damage at different locations within the 
parasite at high concentrations. The DHA and PYR could be interacting at different 
places within the parasite but at similar times which could cause an additive effect. 
However, an antagonistic response was seen with the DHA + PYR combination in FC27 
using the LDH assay which requires parasites to be in early trophozoites stages during 
combination assay preparation (data not shown). Additionally, Fivelman et al. (1999) 
reported an antagonistic response in two PYR-sensitive parasites with artesunate and 
PYR combination using the LDH assay to measure parasite viability. Although it must be 
pointed out that the early trophozoite stage is still early in the parasite life cycle before 
PYR has its maximum efficacy on the parasite (Gutteridge and Trigg, 1971). 
Chawira et al. (1987) had an alternative suggestion to explain the antagonism. 
The authors suggested that antifolates such as SDX (Dieckmann and Jung, 1986) depend 
on being actively concentrated, or at least transported, across P. Jalciparum membranes. 
They suggested that PYR could accumulate similarly. Membrane damage by the QHS-
derivative could cause destruction of the membrane integrity, preventing PYR 
concentration. Evidence to support this has not been reported, although QHS has been 
reported to damage the fluidity of the infected RBC membrane (Sibmooh et al., 2000). 
Another possible explanation of antagonism with PYR has been shown with the 
antifolate sulfadiazine in yeast. In Candida albicans, sulfadiazine induces the expression 
of a multidrug exporter for the unrelated antifungal drug fluconazole by inducing RNA 
transcription, leading to antagonism (Henry et al., 1999). Furthermore, tetracycline 
resistance in Gram-negative bacteria is thought to be mediated by a secondary transporter 
(TetA) which pumps small substrates across cell membranes (Yin et al., 2000). The 
induced expression of this protein is controlled by binding of the drug to a repressor 
protein that reduces the drug-repressor protein complex's affinity for the DNA sequence 
controlling the TetA transcription (Orth et al., 2000). The Pgh-l exporter protein has 
been associated with resistance to QHS-derivatives and MQ (Reed et al., 2000) and this 
could playa role in their export. It is possible that the anti folate drug is inducing changes 
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in the expression or function of Pgh-l, resulting in the observed antagonism seen 
between PYR and DHA or MQ. 
4.4.8 Interaction of antimalarials with penfluridol 
The antipsychotic drug, PEN, has been shown to improve MQ sensitivity in vitro 
(Oduola et a/., 1993) and in vivo (Peters and Robinson, 1991). It is thought that the drug 
could interact with the wild-type Pgh-l protein leading to a shift in the MQ ICso. As MQ 
and QHS-derivatives share similar susceptibility patterns with respect to wild-type 
pfmdr 1 and pfert (Reed et al., 2000; Sidhu et a/., 2002), it was thought that penfluridol 
could possibly influence the action of DHA. In these studies it was shown to have an 
additive effect with DHA in both FC27 and T996. The PEN and MQ interaction was 
additive in FC27 and synergistic in T996 (Figure 4.16). Previous unpublished results 
have suggested, however, that resistance to MQ, HAL and QHS can be modulated by 
PEN, but not VP; although both 'resistance-reversers' share calcium-channel blocking 
activity (Wilson et al., 1993). The interaction between PEN and CQ was antagonistic in 
T996 (Figure 4.16) and increases in CQ ICso values have been shown with the addition 
of PEN supporting this observation (Oduola et a/., 1993). 
The ICso values of both lines to PEN were far lower than expected and both 
parasite lines showed a similar sensitivity (Table 3.6), though in vivo, the drug has shown 
not to have any antimalarial properties (Peters and Robinson, 1991). Oduola et at. (1993) 
used a constant concentration of 500 nM in order to demonstrate the reversal of 
resistance to MQ. As presented in Table 3.6, penfluridol ICso values for both strains are 
close to the dose used by Oduola et al. (1993) for reversal. Although the authors did not 
report a specific ICso value for penfluridol, their findings reveal that the 500 nM 
concentrations used had little or sub-inhibitory effects on all strains tested. Both FC27 
and T996 show reduced MQ sensitivity, thought to be due to the presence of wild-type 
pfmdrl andpfcrt genes (see Section 1.3.2.2). However, T996 does carry mutatedpfmdrl 
184phe and has a lower MQ ICso than FC27 which could be responsible for the difference 
in PEN + MQ interaction seen. It is possible that the PEN-related drop in MQ ICso 
reported by Oduola et al. (1993) was seen in highly MQ-resistant parasites only which 
have an increased pfmdr 1 copy number. 
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4.4.9 Interaction between A TV and PG 
The interaction of ATV with PG was strongly synergistic in two ATV -sensitive 
parasite lines: CQS T996 and CQR Kl (Figure 4.17 and Table 4.2). This is in agreement 
with previous reports (Canfield et al., 1995; Srivastava and Vaidya, 1999). PG on its own 
has no effect on electron transport or mitochondrial membrane potential, but it strongly 
enhances the ability of ATV to collapse the membrane potential which results in synergy 
(Srivastava and Vaidya, 1999). A similar synergistic effect was reported by Canfield et 
al. (1995) using the combination in the hydroxynaphthoquinone-resistant strain C2B, and 
this interaction was of an equal potency (i.e. equivalent FIC values) to that seen in the 
ATV-sensitive strains W2 and D6. The report of Srivastava et al. (1999) on ATV-
resistant P. yoelii strain ARI shows that the addition of PG to ATV did not alter the 
mitochondrial membrane potential, leading the authors to suggest that the interaction 
between the two drugs was probably not synergistic. As these results indicate (Figure 
4.17), the synergy in the ATV -resistant strain NGATVO 1 was significantly lower than 
that of ATV-sensitive strains T996 and Kl. The P. yoelii strain ARI has both cytb 
leu271val and lys272arg mutations (Srivastava et al., 1999) whilst P.falciparum NGATVOI 
has a tyr26Sasn mutation. The P. falciparum C2B isolate, isolated from a patient displaying 
an Rl-type treatment failure, has ATV resistance 95 times that of the pre-treatment 
isolate (Canfield et al., 1995) but the mutations in the cylb gene are unreported. The 
NGATVOI isolate has a decreased sensitivity in vitro to ATV of over 2000-fold 
compared to some ATV-sensitive parasite lines (Table 3.2). 
The efficacy of Malarone® is strongly dependent on the synergism between ATV 
and PG (Srivastava and Vaidya, 1999). Once ATV resistance is present, the potency of 
the combination may be markedly reduced and can lead to treatment failure. In this 
example of a Malarone® treatment failure case, reduced efficacy in vivo is predicted by 
reduced synergy in vitro. 
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4.5 Conclusions 
Combination chemotherapy allows improved drug efficacy through synergistic 
interactions and could allow development of resistance to be inhibited or at least delayed. 
Major differences in interaction among parasite lines with varying plmdrl and plert 
polymorphisms were seen when arylaminoalcohols were combined with DHA. The 
responses from CQS lines were synergistic in parasite lines which carried wild-type 
plmdrl and plert. Conversely, the CQR lines showed additive response to the three 
arylaminoalcohol combinations. The slightly CQR 10611 line was an exception as it 
displayed an additive response. The significant difference in synergistic responses in the 
ATV + PG combination seen between ATV-sensitive lines and ATV-resistant 
NGATVOI demonstrated how resistance mutations to one drug may affect the efficacy of 
a combination regimen. 
The mechanisms altering the interactions between DHA and antimalarials are not 
well understood. It has been shown that drugs which increase or decrease the 
accumulation of antimalarials can result in antagonism or synergism, respectively (for 
example see Section 1.3.1.1.1). It is possible that the differences in antimalarial 
interactions could be due to changes in drug accumulation of either antimalarial. In order 
to further investigate this hypothesis, the uptake of eH]-DHA and eH]-CQ was studied 
and the results are reported in Chapter 5. 
5. 1 Introduction 
CHAPTER 5 
DRUG UPTAKE 
It is commonly thought that malarial parasites can become resistant to a drug by 
preventing or lowering the amount of drug reaching its target. Reduced CQ accumulation 
seen in CQR parasite lines has been suggested to be one of the major factors leading to 
decreased CQ sensitivity (Verdier et al., 1985; Krogstad et al., 1992; Bray et al., 1992b). 
The exact mechanism by which a CQR parasite accumulates less CQ is still not fully 
understood (see Section 1.3.1.1). Recent transfection and transformation experiments 
(Reed et al., 2000; Cooper et al., 2002; Sidhu et al., 2002) have added support to the 
hypothesis that malaria parasites can become resistant to an antimalarial drug (or group 
of drugs) by accumulating less of the compound. It has been demonstrated that CQ 
accumulation in CQR parasite lines could be partially increased by the calcium-channel 
blocker VP (Martin et al., 1987; Krogstad et al., 1987) and other chemosensitising 
compounds (Kyle et al., 1990; Taylor et al., 2000; van Schalkwyk et al., 2001). 
The accumulation of QHS-derivatives has not been studied in detail. Ellis et al. 
(1985) showed that eH]-DHA is localised within the parasite (particularly parasite 
membranes) when incubated with parasitised RBC. Gu et al. (1984) demonstrated that 
eH]-DHA is concentrated by infected RBC over 300 times the concentration of the 
medium and that CQ decreases the amount ofeH]-DHA accumulated. More recently, the 
uptake of [14C]_QHS was studied by Vyas et al. (2002) and the uptake was shown to be 
rapid, saturable, temperature dependent, irreversible, and subject to competitive 
inhibition with unlabelled QHS. The authors also showed that the drug was partitioned 
into uninfected RBC to the same level as infected RBC at 4°C, but at 37°C infected 
RBC accumulated significantly higher amounts. It was hypothesised that [14C]_QHS 
uptake involves carrier mediation across the infected RBC membrane. The effects of 
polymorphisms in pfmdr 1 or pfert in the uptake of QHS-derivatives have never been 
investigated. 
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In this study, the effect of these mutations on DHA and CQ uptake was examined 
in a range of parasite lines with differing genotypes. The uptake of radiolabelled DHA 
and CQ alone, and in the presence of other antimalarials is also investigated. 
5.2 Results 
5.2.1 Dihydroartemisinin uptake 
5.2.1.1 Time course and effect of pfmdr1 and pfert mutations 
The time course study of eH]-DHA uptake in RBC, FC27 and K1 at 37°C 
(Figure 5.1) showed that accumulation by infected RBC increased with time and reached 
a steady-state after approximately 45 min. There was an initial rapid uptake in the first 15 
minutes followed by a slower uptake phase. There was binding to uninfected RBC, 
although this was relatively low. No difference in rate of uptake or final amount of drug 
accumulated was seen between the two parasite lines FC27 and Kl. The 3 nM 
concentration of eH]-DHA, utilised in all uptake studies, was lower than the DHA ICso 
values of the P.falciparum parasite lines used in these experiments (Table 3.3A). 
In order to investigate the effects of mutations in pfmdrl on eH]-DHA uptake, 
time course studies of3 nM eH]-DHA inpfmdrl transfectants DlO-mcJ.I»lO, DIO_mdr7G8, 
7G8_mdr7G8 and 7G8-md~lO at 37°C were performed. Representative uptake curves are 
shown in Figure 5.2. No large differences in rates of eH]-DHA uptake or amount of 
radiolabelled drug accumulated at steady-state were seen between the four transfectants. 
The 7G8-mdr7G8 transfectant did, however, show reduced uptake of eH]-DHA when 
compared to the other transfectants at three time points (maximum difference was -30 
femtomoles per 1 x 106 parasites at 60 min), but these were not significant. 
The time course of3 nM eH]-DHA uptake in Kl, FC27, K76I and 106/1 at 37°C 
is shown in Figure 5.3 and was performed in order to investigate the role of pfert 
polymorphisms in eH]-DHA accumulation. No large differences in rates of eH]-DHA 
uptake nor amount of radio labelled drug accumulated at steady-state were seen between 
the four parasite lines. Kl and K76I both carried mutated pfmdr 1 and pfert and there was 
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no statistical significant difference between these two parasite lines (maximum 
difference -44 femtomoles per lxl06 parasites at 115 min). 
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Figure 5.1: Time course of 3 nM rHl-DHA uptake by uninfected ReC and ReC infected 
with P. fa/ciparum parasite lines K1 and FC27. ; 
• RBC 
0 K1 
'Y FC27 
• • 
0 30 60 90 120 240 
Time (min) 
:j: [3H]-DHA incorporation is given in femtomoles per 5.8 x 107 cells/min to compare infected with 
uninfected RBC. Results from a representative experiment with SEM (repeated twice with same 
results). 
Chapter 5: Drug Uptake 195 
Figure 5.2: Time course of 3 nM fH]-OHA uptake by pfmdr1 transfectants. Results from a 
representative experiment with SEM (repeated twice with same results). 
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5.2.1.2 Effect of antimalarials on dihydroartemisinin uptake 
The effects of antimalarials DHA, ATM, CQ, AQ, PPQ, MQ, HAL, LM, QN, 
PYR, SDX and ATV at 3 JlM on the uptake of3 nM eH]-DHA at 37 DC in FC27, 3D7, 
KI and RSAII are shown in Figure 5.4A-D. In all four parasite lines, the two controls 
DHA and ATM blocked the uptake of eH]-DHA to between 0 and 28% of the pRBC 
control. The quinoline-related drugs CQ (P < 0.001), AQ (P < 0.001), PPQ (P ~ 0.001), 
MQ (P ~ 0.001), and HAL (P < 0.001) all significantly reduced eH]-DHA uptake 
compared to eH]-DHA uptake alone. The largest reduction of eH]-DHA uptake by CQ 
was seen in RSAll and smallest in Kl. AQ showed greater reduction of eH]-DHA 
uptake in 3D7, equivalent to the result seen in RSAll, although less of a reduction was 
seen in both FC27 and Kl. PPQ showed a lesser reduction than CQ in all cases except 
Kl in which PPQ showed the strongest reduction of eH]-DHA accumulation compared 
to all the quinoline-related drugs tested. In all four parasite lines, MQ and HAL blocked 
eH]-DHA uptake to a lesser degree than CQ, although HAL did show a slightly greater 
ability to decrease eH]-DHA uptake compared to MQ. 
LM and QN showed a varied effect on eH]-DHA uptake in the four parasite 
lines. LM was shown to reduce eH]-DHA uptake significantly in FC27 (P = 0.018) and 
KI (P = 0.018). No reduction was seen in the other two parasite lines 3D7 and RSAII. 
QN did not significantly reduce eH]-DHA uptake except in Kl (P = 0.025). 
The antifolates PYR and SDX, and antimitochondrial ATV had little effect on 
eH]-DHA uptake in all four parasite lines. The small increases in eH]-DHA uptake seen 
with these three drugs was not significant. 
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Figure 5.4: Effects of antimalarials at 3 uM on the uptake of 3 nM [3Hl-DHA after 90 min in 
RBC infected with P. fa/ciparum. t 
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5.2.1.3 The effect of verapamil and penfluridol on DHA uptake 
Figure 5.5 shows the effects of 1 J..lM VP (a CQ 'resistance-reverser') and 400 nM 
PEN (a MQ 'resistance-reverser') on the uptake of 3 nM eH]-DHA at 37 °C in FC27, 
Kl, 3D7 and RSAll. No significant change in uptake of eH]-DHA was displayed with 
the addition of 1 J..lM VP. A significant decrease (P < 0.01) in eH]-DHA accumulation, 
ranging between 5 to 22%, with the addition of 400 nM PEN was noted in all four 
parasite lines. 
Figure 5.5: Effects of VP and PEN on the uptake of 3 nM ~3H]-DHA after 90 min by RBC 
infected with P. falciparum. 
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* Uptake is represented as a percentage of the control minus uptake of eH]-OHA in uninfected 
erythrocytes (± relative SO). An asterisk signifies a statistically significant decrease compared to 
[3H]-OHA uptake alone (P < 0.05). 
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5.2.2 Chloroquine uptake 
5.2.2.1 Time course and effect of pfmdr1 and pfcrt mutations 
The time course study of 5 nM [3H]-CQ uptake at 37 °C with CQS FC27 and 
CQR Kl parasite lines (Figure 5.6) showed that accumulation by infected RBC increased 
with time and reached a steady-state after approximately an hour. There was an initial 
rapid uptake in the first 30 minutes followed by a slower steady state uptake phase. Kl 
accumulated -5-fold less eH]-CQ compared to FC27. VP was shown to partially 
'reverse' this difference in CQ accumulation in the CQR parasite lines. The addition of 1 
JlM VP decreased the difference between FC27 and Kl to -2.5-fold. There was little 
binding or uptake by uninfected RBC. The 5 nM eH]-CQ concentration used was lower 
than the CQ ICso for all parasite lines used in these studies (Table 3.3A). 
In order to investigate the effect of mutations in the gene pfmdr 1 on eH]-CQ 
uptake, time course studies of 2.5 nM eH]-CQ uptake in pfmdr 1 transfectants D 10-
mcrrD10, DI0_mdr7G8, 7GS_mdr7G8 and 7GS-mcrrD lO were performed at 37 °C and the 
results are shown in Figure 5.7. The two DIO transfectants, parent control transfectant 
DIO-md~lo and transfectant DI0_mdr7G8, displayed CQ ICso values of -25 and -33 nM 
respectively (Table 3.3A) and showed the highest accumulation of eH]-CQ. At steady-
state, transfectants 7GS_mdr7G8 and 7GS-mdrD10 showed the lowest accumulation of eH]-
CQ, although 7GS-mdrDlo displayed significantly greater accumulation of eH]-CQ than 
7GS_mdr7G8 both with (P < O.OOS) and without (P ~ 0.003) the addition of 5 JlM VP. 
The 7G8-md~10 had a lower CQ ICso of -S7 nM compared to -290 nM for 7G8_mdr7G8 
(Table 3.3A). The addition of 5 JlM VP to both 7GS transfectants equally increased the 
amount of eH]-CQ accumulated by -1.5-fold. 
The time course of eH]-CQ uptake in Kl, FC27, K761 and 10611 at 37 °C is 
shown in Figure 5.8. These four parasite lines have differing pierI alleles and eH]-CQ 
uptake was investigated. The two CQS parasite lines FC27 and 106/1 showed the highest 
accumulation of eH]-CQ, with FC27 showing a slightly higher, but not significant, 
accumulation of eH]-CQ than 106/1. At steady-state, the CQR parasite lines Kl and 
K76I showed an equally low accumulation of eH]-CQ. The addition of 5 JlM VP to both 
CQR parasite lines increased the eH]-CQ accumulation equally by about 3-fold, 
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although the amount of drug achieved at steady-state was not equal to the level of the 
two CQS parasite lines. 
Figure 5.6: Time course of 5 nM eHJ-CQ uptake by uninfected RBC and RBC Infected with 
K1 and FC27 P. falciparum parasite lines. t 
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Figure 5.7: Time course of 5 nM r3H]-CQ uptake by RBC infected with pfmdr1 transfectants 
demonstrating the role of pfmdr1 mutations in CQ uptake. f 
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Figure 5.8: Time course of 5 nM r3H]-CQ uptake by RBC infected with K1, FC27, K761 and 
106/1 parasite lines demonstrating the role of pfcrt mutations in CQ uptake. § 
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5.2.2.1.1 The effect of antimalarials on CQ uptake 
The effects of antimalarials DRA, ATM, QHS, CQ, PPQ, MQ and QN at 3 ~M 
on the uptake of2.5 nM eH]-CQ at 37°C in P.falciparum parasite lines FC27, 3D7, K1 
and RSA11 are displayed in Figure 5.9A-D. eH]-CQ uptake was significantly reduced in 
all four parasite lines by QHS-derivatives DHA (P < 0.001) and ATM (P ~ 0.008). In 
CQS FC27 and 3D7, ATM had a significantly weaker ability to reduce eH]-CQ uptake 
compared to DRA (P < 0.001), and QHS showed no ability to reduce eH]-CQ 
accumulation in either parasite line. In CQR K1 and RSA11 all three endoperoxides 
significantly reduced eH]-CQ uptake (P ~ 0.007) and little difference between the three 
drugs was seen, except in RSA 11 where the addition of QHS resulted in a -15% greater 
[3H]-CQ accumulation than either DHA or ATM. 
In all four parasite lines, unlabelled CQ strongly reduced eH]-CQ uptake to 
between 10 to 30% of the pRBC control, and had the greatest effect in reducing eH]-CQ 
uptake of all the drugs tested in parasite lines 3D7, K1 and RSA11. PPQ was the second 
best drug, after CQ, in tenns of significantly reducing eH]-CQ uptake in 3D7, K1 and 
RSA11 (P < 0.001); but had the greatest ability of all the antimalarials tested to reduce 
the uptake in FC27. The two arylaminoalcohols MQ (P ~ 0.003) and QN (P < 0.001) 
significantly reduced eH]-CQ uptake and were equivalent to each other with respect to 
the percentage of eH]-CQ uptake reduced in all four lines. 
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Figure 5.9: Effects of antimalarials at 3 uM on the uptake of 2.5 nM eHl-CQ after 90 min in 
RBC infected with P. falciparum. 't 
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5.3 Discussion 
5.3.1 Dihydroartemisinin uptake 
5.3.1.1 Time course and role of pfmdr1 and pfcrt mutations 
It was demonstrated that at 37 °C, infected RBC accumulated eH]-DHA 
approximately 180-fold higher than uninfected RBC from a 3 nM final concentration 
(correction made for 100% parasitaemia). The accumulation of the drug was very rapid 
in the first 15 min. This was followed by a plateau after approximately 45 min which 
continued for at least 195 min. The large difference of eH]-DHA accumulation between 
infected and uninfected RBC suggests that the infected cells have a eH]-DHA 
concentrating mechanism. In vitro and in vivo ultrastructural studies have demonstrated 
that the QHS-derivatives are rapidly acting (Ellis et al., 1985; Maeno et al., 1993) so the 
drug was expected to reach its target rapidly. Interestingly, there was no difference 
between FC27 and Kl with respect to the uptake rate or final amount of drug 
accumulated, in spite of differences in pfmdrl and pfcrt polymorphisms (Table 3.7). 
FC27 had both wild-type pfmdr 1 and pfcrt genes, while Kl had mutated alleles of these 
two genes. 
It has been demonstrated that at 37°C P. falciparom infected RBC accumulated 
both eH]-DHA (Gu et al., 1984) and [14C]_QHS (Meshnick et al., 1991; 
Kamchonwongpaisan et al., 1994) to a much higher intracellular concentration than 
uninfected RBC. It has been shown that at 4°C, infected RBC behave as non-parasitised 
RBC and QHS accumulation is due to passive diffusion; while at 37°C parasitised RBC 
actively accumulate the drug (Vyas et al., 2002). There has been a wide range of values 
quoted by many authors describing the amount of radio labelled QHS or QHS-derivative 
which accumulates into the parasite compared to the concentration in the medium (i.e. 
the uptake ratio or accumulation difference). Meshnick et al. (1991) reported an -8-fold 
uptake difference between medium and infected RBC with [14C]_QHS, while Gu et al. 
(1984) reported a difference of -300-fold using 12 nM eH]-DHA, and Janneh (2000) 
showed an accumulation ratio of -5500-fold using 4 nM eH]-DHA. Vyas et al. (2002) 
recently reported a large constant partitioning of 35 - 40% into uninfected RBC with 
[14c]_QHS at different concentrations ranging from 0.88 /lM to 3.52 /lM. The authors 
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suggested that the hydrophobic drug has an inherent ability to passively diffuse across 
the RBC membrane, and that this value was equivalent to the amount of drug present in 
the medium. Meshnick et al. (1991) showed that little or no [ 14C]_QHS was detected in 
uninfected RBC cytoplasm after 3 hour incubation supporting these later results. It may 
be possible that a wide variation of results could be dependent on the concentration of 
the radio labelled drug in the medium or the haematocrit at which the experiment was 
performed - emphasising the importance of controlling for the inoculum effect when 
working with QHS-derivatives (Duraisingh et al., 1999). 
The time course of eH]-DHA uptake at 37°C did not show any large differences 
between thepfmdrl transfectants expressing wild-type and mutated Pgh-l (Figure 5.2)-
even though both 7G8 transfectants carried mutated pfert and both DIO transfectants 
carried wild-type pfert. This indicates that neither Pgh-l nor PfCRT had an influence 
here. The wild-type pfmdr 1 gene has been previously linked to reduced susceptibility to 
QHS-derivatives (Reed et al., 2000; Duraisingh et al., 2000b), but the difference in 
uptake between the transfectants seen here was small and not statistically significance. 
Reed et al. (2000) showed that transfection of mutated pfmdrl to obtain DI0_mdr7G8 
significantly increased the cellular accumulation ratio of the lipophilic drug MQ 
suggesting that parasites carrying wild-type pfmdrl accumulate less MQ. In this same 
report there is a strong correlation between the MQ ICso and QHS ICso which brings the 
question to mind whether parasites carrying wild-type pfmdr 1 could accumulate lower 
amounts ofQHS-derivatives. However. the differences in ICso values ofQHS-derivatives 
between paras'ites with 'increased' and 'decreased' susceptibility to these drugs is often 
only about two to three-fold and even lower with the more potent endoperoxides such as 
artesunate (Duraisingh et aI., 1999; Price et al., 1999). Although parasite line 7G8-
mdr7G8 harboured the mutated pfmdr 1, it had the lowest DHA ICso of the four 
transfectants (Table 3.3A) and would, based on the idea that mutated Pgh-l is 
moderating the increased susceptibility to DHA, be expected to accumulate eH]-DHA to 
a higher level. 
No large differences were seen with range of pfert mutations in the 106/1, K76I, 
Kl or FC27 parasite lines (Figure 5.3). These four parasite lines differ in both pfert and 
pfmdrl genotypes (Table 3.7) and it was thought that the role ofeH]-DHA accumulation 
and mutations inpfert codon 76 could be investigated. Kl and K761 both carried mutated 
pfmdr 1 and plert genes. While Kl harboured threonine in pfcrt codon 76, the drug 
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selected K76I carried isoleucine and both parasites carried tyrosine inpfmdrl codon 86. 
The wild-type pfcrt gene has been previously linked with reduced susceptibility to QHS-
derivatives (Cooper et al., 2002; Sidhu et al., 2002), but as mentioned for pfmdr I-related 
susceptibility, there is often only a two- to three-fold difference in ICso values between 
susceptible and less susceptible parasite lines. 
The results here indicate that neither pfcrt nor pfmdr 1 polyrnorphisms had a 
significant influence on DHA uptake, though DHA sensitivity results in Chapter 3 were 
significantly different between certain parasite lines. There have been reports suggesting 
mutations in both pfmdr 1 and pfcrt may influence susceptibility of P. falciparum parasite 
lines to QHS-derivatives (see Section 1.3.5.4). The results presented here indicate that 
the small differences seen in ICso values might not necessarily correspond to large 
changes in accumulation of these drugs. However, reduced accumulation of eH]-DHA 
has been shown in a strain of P. yoelii 4-fold more resistant to QHS than a wild-type 
strain, but the difference in accumulation between this QHS-resistant and a QHS-
sensitive strain was less than 2-fold and the mechanism of resistance was unknown 
(Walker et al., 2000). 
5.3.1.2 The effect of antimalarials on dihydroartemisinin uptake 
In all four parasite lines tested, the quinoline-based drugs CQ, AQ, PPQ, MQ and 
HAL, significantly reduced the uptake of eH]-DHA. The QHS-derivatives DHA and 
ATM strongly decreased the uptake of eH]-DHA. This was to be expected as all these 
drugs are QHS-derivatives and the only difference between eH]-DHA and DHA is the 
tritium radiolabelled (positive control). This is consistent with previous reports which 
suggested that all the QHS-derivatives bind to same receptor (Gu et al., 1984) and that 
this binding is irreversible (Vyas et al., 2002). LM reduced the eH]-DHA uptake in 
FC27 and Kl, although this reduction was relatively small « 8%). PYR, SDX and ATV 
however, did not reduce eH]-DHA accumulation. These three drugs have different 
modes of action not related to binding or interaction with haem (Gutteridge and Trigg, 
1971; Dieckmann and Jung, 1986; Fry and Pudney, 1992). 
There has been increasing evidence that there is a relationship between resistance 
to the more lipophilic quinoline-related drugs and QHS-derivatives (see Section 
1.3.5.3.3), and this has been confirmed with recent transfection experiments (Reed et al., 
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2000; Sidhu et al., 2002). It is possible that there is competition for uptake of both drugs 
at the same site, which has been suggested previously (Gu et al., 1984). All quinoline-
based antimalarials and QHS-derivatives bind to FPIX with varying affinities (see 
Sections 1.2.1.1.2, 1.2.2.3 and 1.2.5.1.1). There are conflicting views on whether binding 
of the endoperoxides to FPIX and to haemozoin is sufficient to explain concentrative 
uptake (Pandey et a/., 1999), or that the major contributor to QHS uptake is intracellular 
free iron and only a marginal contribution of drug uptake can be accounted for by 
binding to FPIX (Janneh, 2000). CQ binds to FPIX extremely avidly (Chou et al., 1980) 
and this binding within the digestive vacuole could possibly account for the saturable 
intracellular accumulation of drug by the parasite (Bray et al., 1998). QHS reacts with 
FPIX in aqueous solution to form an adduct and this formation may not be reversible 
(Meshnick et al., 1991; Hong et al., 1994). The interaction of QHS with the iron FPIX 
may be vital for 'activation' of the QHS endoperoxide bridge, to produce free radicals, 
and thus form covalent bonds with proteins leading to parasite damage (Wu, 2002). 
Molecular modelling studies have predicted a stable docked configuration of QHS and 
FPIX - with the endoperoxide bridge in close proximity to the FPIX iron - further 
suggesting that FPIX may play an important role in drug uptake or interaction between 
iron and the peroxide of these drugs (Shukla et al., 1995). A competition for FPIX might 
exist between the quinolines and DHA due to the higher affinity of the bound quinoline, 
sterically protecting the iron of FPIX from DHA interaction (Figure 4.18). This may lead 
to a decrease in DHA accumulation. Drugs which bind to FPIX or prevent FPIX release 
by inhibiting Hb breakdown have been shown to inhibit CQ uptake (Bray et al., 1998; 
Bray et al., 1999a). However, these same inhibitors have been shown not to reduce eH]-
DHA uptake, nor does DHA displace CQ from intact or freed parasites pre-loaded with 
CQ. EIP A - which displaces FPIX-binding drugs from their binding sites - does not 
displace DHA from binding sites on FPIX-Ioaded host membranes, which could lead to 
the conclusion that FPIX does not playa role in the uptake of QHS-derivatives (Janneh, 
2000). Janneh also suggested that DHA could irreversibly bind to a receptor, but this 
receptor may be different to the receptor to which CQ binds. It is also worth considering 
that the QHS-derivatives are lipophilic enough to equilibrate across the various 
membranes into the vacuole (Pandey et al., 1999; Vyas et al., 2002), without 
concentration (Vyas et al., 2002), and there become bound to proteins and membranes 
(Ellis et al., 1985; Maeno et al., 1993; Asawamahasakda et al., 1994c), after activation 
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by haem iron (Meshnick, 1994). This binding of the QHS-derivative could prevent these 
proteins (such as Hb digestion proteases) functioning normally (Wu, 2002) and release of 
FPIX could be stopped. 
5.3.1.3 The effect of verapamil and penfluridol on DHA uptake 
As seen in this study, CQ accumulation in CQR parasites could be partially 
increased by the calcium-channel blocker VP (Martin et a/., 1987) and other 
chemosensitisers (Kyle et a/., 1990; Taylor et a/., 2000; van Schalkwyk et a/., 2001). VP 
is thought to act on the PfCRT protein or on processes that could alter the activity of VP 
on haem binding and drug-FPIX complex formation (Sidhu et al., 2002), but the exact 
mechanisms are not known. PEN has been shown to improve MQ sensitivity in vitro 
(Oduola et at., 1993) and in vivo (peters and Robinson, 1991). VP did not affect the 
uptake of eH]-DHA in all four parasite lines, including two parasite lines with mutated 
plcrt genes (Kl and RSAll). VP has been demonstrated to have no significant effect on 
the QHS ICso values in a range of plcrt genotypes (Sidhu et al., 2002) and previous 
unpublished results have suggested VP does not effect QHS susceptibility (Wilson et a/., 
1993). 
PEN, however, decreased the amount of eH]-DHA accumulated within the 
infected RBC after 90 min. This does not correlate with the in vitro interactions study as 
there was an additive response seen on FC27 and T996 with DHA + PEN combination 
(Figure 4.16) The drop in eH]-DHA accumulation was less than 20% and this may be 
too small to cause a change in the in vitro drug interaction assay. Previous unpublished 
results have suggested that resistance to QHS can be modulated by PEN (Wilson et al., 
1993), which could suggest a possible increased eH]-DHA accumulation by the drug. 
Both VP and PEN were incubated at a concentration less than their ICso values and it 
may be possible that there is competition for the uptake of PEN and DHA at the same 
site resulting in the lower accumulation of eH]-DHA. 
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5.3.2 Chloroquine uptake 
5.3.2.1 Time course and role of pfmdr1 and pfcrt mutations 
RBC infected with CQS parasites accumulated approximately 400-fold more 
eH]-CQ than uninfected control RBC at 5 nM (correction made for 100% parasitaemia). 
The accumulation of the drug was very rapid in the first 30 min. This was followed by a 
long, slow steady state from -60 min. RBC infected with CQR parasites accumulated 
about 5-fold less eH]-CQ than CQS parasites which agrees with previously published 
data (Verdier et al., 1985; Krogstad et al., 1992; Bray et al., 1992b; Saliba et al., 1998). 
This reduced accumulation was improved -2.5-fold with the addition of 1 JlM VP as 
previously demonstrated (Martin et al., 1987). 
Uninfected RBC accumulated a low amount of eH]-CQ (Figure 5.6). Yayon and 
Ginsburg (1982) studied CQ transport across the RBC membrane and concluded that the 
membrane contains a simple symmetric carrier which allows CQ to equilibrate across the 
membrane according to its concentration gradient. The authors demonstrated that there 
was no active accumulation into uninfected RBC; although other studies have shown a 
small uptake of CQ by uninfected RBC from humans (Geary et al., 1986b) and mice 
(Fitch et al., 1974b; Vanderkooi et aI., 1988) and this uptake has been shown to be pH-
dependent (Vanderkooi et al., 1988). 
Comparing four pfmdrl transfectants, the two DIO transfectants (DIO-mdf1o and 
DIO_mdr7G8) demonstrated the highest accumulation of eH]-CQ (Figure 5.7). There was 
no change in the amount ofeH]-CQ accumulated with the transfection of the '7G8-like' 
pfmdrl polymorphisms which supports observations of Reed et al. (2000). Both parasite 
lines have been shown to have CQ ICso values similar to other CQS parasites, although 
DI0_mdr7G8 does have a slightly higher CQ ICso than DlO-mdflo (Table 3.3A). In 
contrast, there was an increase in eH]-CQ accumulation with the introduction of wild-
type pfmdrl into 7G8 (i.e. in 7G8_mdrD10) further supporting the role of wild-type Pgh-l 
in eH]-CQ accumulation (Reed et al., 2000) - in the presence of mutated PfCRT. With 
the addition of 5 JlM VP, both 7G8-mdrDIO and 7G8-mdr7G8 showed an equal -1.5-fold 
increase in eH]-CQ accumulation, suggesting that VP is interacting with the PfCRT 
protein and not the Pgh-l. This does not confirm the finding by Reed et al. (2000) which 
showed a larger increase of -4-fold for 7G8-mdrD10 and -7-fold for 7G8-mdr7G8 in the 
saturable accumulation of 1 nM eH]-CQ with the addition of 5 JlM VP. 
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There were large differences seen in the varied plert mutations among the 106/1, 
K76I, Kl and FC27 parasite lines (Figure 5.8). The FC27 parasite line showed the 
highest accumulation of 5 nM eH]-CQ over 120 min compared to the remaining three 
parasite lines. 106/1 displayed a statistically insignificant lower accumulation of eH]-CQ 
at steady state. Cooper et al. (2002) reported an intermediate 106/1 CQ accumulation 
profile which was between the CQS and CQR lines tested at 50 nM eH]-CQ. It is 
possible that at this low 1 nM eH]-CQ concentration used, the difference in CQ 
accumulation is not as apparent. 106/1 does carry all the plert changes accompanying CQ 
resistance in other lines, excluding that in codon 76, and mutated plmdrl (Fidock et al., 
2000b). It is conceivable that one or more other plert mutations may playa role in CQ 
sensitivity and uptake, and that there might be another unknown factor. K76I, however, 
showed a decreased accumulation of eH]-CQ which was equivalent to Kl. Both CQR 
strains with the 76 residue changed (Kl and K76I) displayed equivalent -3-fold 
increased eH]-CQ accumulation with addition of 5 J-lM VP. This again highlights the 
importance of the PfCRT 76 codon in overall CQ accumulation (Cooper et al., 2002; 
Sidhu et al., 2002). It has been reported that VP-reversibility of CQ resistance is more 
pronounced in parasites expressing mutant plert from 'Old World' origins than the 
recombinant 'New World', i.e. comparing Kl and K76I to 7G8 (Mehlotra et ai., 2001; 
Sidhu et al., 2002). However, there was no evidence of this in eH]-CQ accumulation 
comparisons between the three parasite lines (K76I, Kl and 7G8_mdr7G8) in the presence 
of5 J-lM VP (Figures 5.7 and 5.8). 
5.3.2.2 The effect of antimalarials on chloroquine uptake 
In all the four parasite lines, the quinoline-based drugs CQ, PPQ, MQ and QN, 
and the QHS-derivatives DHA and ATM significantly reduced the uptake ofeH]-CQ (P 
~ 0.008). The more lipophilic endoperoxide, QHS, only decreased eH]-CQ 
accumulation in the two CQR parasite lines Kl and RSA11 (Figure 5.9). Both QN and 
MQ have been shown to competitively inhibit CQ uptake suggesting a similar mode of 
accumulation (Fitch et a/., 1979). PPQ has two quinoline ring nuclei combined through 
an aliphatic linker and is thought to have the same mode of action as the 4-
aminoquinolines (Raynes, 1999). This could suggest a similar uptake mechanism and 
interaction with FPIX, although due to having two quinoline rings one molecule of the 
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drug could potentially interact with two FPIX molecules (prof. David Warhurst, personal 
communication). 
As mentioned earlier, the binding of CQ to FPIX is thought to possibly account 
for the accumulation of drug by the parasite (Bray et al., 1998). As the other quinoline-
based drugs similarly bind to FPIX - albeit with varying affinities (see Sections 1.2.1.1.2 
and 1.2.2.3) - competition for FPIX between eH]-CQ and the other drugs might exist. 
This could result in lower CQ accumulation since drugs which bind to FPIX have been 
shown to decrease CQ accumulation (e.g. Bray et al., 1999a). QHS is more lipophilic 
than both DRA and ATM and it is the least active QHS-derivative in vitro (White, 1994; 
Skinner et al., 1996). It may that this lower potency in vitro (compared to DRA and 
ATM) could lead to a lesser effect in decreasing CQ accumulation in CQS lines. In the 
case ofKl (Figures 5.6 and 5.8) and RSAll (Saliba et al., 1998), lower amounts of eH]-
CQ accumulate within these two parasite lines compared to CQS lines. In these two lines 
this lesser effect of eR]-CQ accumulation may not be as apparent in the presence of 
QRS, compared to DRA and ATM. 
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5.4 Conclusions 
These results indicated that polymorphisms in either pJcrt or pJmdr 1 had no 
significant influence on DHA uptake; although previous reports indicate that 
polymorphisms in these two genes may influence susceptibility of P. Jalciparum parasite 
lines to QHS-derivatives (See Section 1.3.5). However, large differences in eH]-CQ 
uptake between parasite lines which carried either wild-type or mutated pJmdr 1 and plcrt 
codon 76 were seen. An inverse association with CQ ICso and amount of eH]-CQ 
accumulated was seen and the amount of drug accumulated could be increased with the 
addition of VP in CQR lines. Small differences seen with DHA ICso values did not 
correlate well with eH]-DHA uptake in contrast with CQ results. 
Uptake studies ofeH]-DHA and eH]-CQ in combination with other antimalarials 
indicated that some of the quinoline-related drugs and QHS-derivatives competed with 
the uptake of these two radio labelled drugs. This uptake data disagrees with the data 
from the interaction studies and suggests that the underlying cause of antagonism may be 
due to reasons other than drug uptake. 
CHAPTER 6 
OVERALL SUMMARY AND CONCLUSIONS 
Drug resistance in P. falciparum, the most pathogenic of human malarias, 
remains one of the greatest obstacles posing limitations to treatment and control of the 
disease. The molecular and biochemical nature of antimalarial resistance is slowly being 
worked out, although more studies are required. Transfection studies by Reed et al. 
(2000) and Sidhu et al. (2002) have advanced our knowledge of the genetic basis of 
antimalarial resistance. To date, changes in two genes, pfmdrl and pfert, are implicated 
in the sensitivity of P. falciparum to 4-aminoquinolines, arylaminoalcohols and QHS-
derivatives. The work presented in this thesis provides further insight into the 
biochemical and genetic detenninants of resistance. The concentrative uptake of drugs 
into parasites; the mutual interactions of drugs in inhibiting parasite lines; and in vitro 
sensitivities to single drugs, were investigated in order to examine the role of putative 
drug resistance associated mutations. Changes in other genes, e.g. eytb gene implicated 
in ATV resistance, were examined in a clinical case study. 
In this chapter, the findings of these investigations presented in the preceding 
chapters are summarised and general conclusions drawn with relevant recommendations. 
In Chapter 3, mutations in genes eytb, pfmdr 1 and pfert were shown to be 
strongly associated with resistance to a range of antimalarials. The first in vitro and 
genetic confinnation of Malarone® resistance to treatment in P. falciparum acquired in 
Africa is presented and discussed. On presenting with malaria two weeks after returning 
from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a 
standard 3-day treatment course of Malarone®. Twenty-eight days later the parasitaemia 
recrudesced. Parasites were cultured from the blood and the isolate (NGATVOl) was 
shown to be resistant to PYR and ATV. The cytochrome b gene of NGATVOI was 
sequenced and compared to ATV -sensitive parasite lines. The isolate showed a single 
mutation, tyr2683sn which has not been seen previously. This novel mutation in a codon 
previously linked to drug resistance (Korsinczky et 01., 2000) demonstrates the ability of 
the malarial parasite to constantly adapt to new drugs or drug combinations. The 
appearance of a PYR- and ATV-resistant P. falciparum isolate from a single course of 
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Malarone® is particularly concerning as this is a recently introduced combination. It will 
be informative if more field isolates from Africa are characterised for sensitivity to 
Malarone® and examined for ATV resistance associated mutations. Surveillance studies 
leading to regional or geographical mapping of ATV resistance will be rewarding in view 
of updating travel advice. This will ultimately have positive bearing on antimalarial drug 
policy in such regions especially with the recent move to consider using Malarone® as 
first-line therapy in Africa (Shretta et al., 2000). 
The in vitro susceptibility results from the pfmdr 1 transfectants confirmed the 
results of Reed et al. (2000) and support the correlation of polymorphisms in this gene 
with resistance against a structurally diverse range of antimalarials. No reports describing 
the sensitivity of the pfmdr 1 transfectants to AQ, LM, ATM and DHA have been 
previously published. The 4-aminoquinoline AQ showed similar results to CQ; while the 
aryl amino alcohol LM displayed similar changes in sensitivities to MQ and HAL. This 
was expected in view of chemical similarities between these drugs. Differences between 
the more lipophilic drugs (i.e. arylaminoalcohols MQ, HAL, and LM, and QHS-
derivatives ATM and DHA) and 4-aminoquinolines were apparent in terms of parasite 
susceptibilities and inverse correlations, with respect to polymorphisms in both pfmdr 1 
and pfert genes. The CQ ICso values correlated well with eH]-CQ uptake values 
(discussed in Chapter 5) as the CQR parasite lines all accumulated significantly less 
eH]-CQ than the CQS parasite lines. This is in support of previous observations (Fitch, 
1970; Verdier et al., 1985; Krogstad et al., 1992; Bray et al., 1992b). The introduction of 
mutated pfmdr 1 into D 1 0 (giving rise to D 1 0_mdr7G8) did not raise the CQ ICso 
significantly and there was no significant change in the eH]-CQ accumulation. However, 
the introduction of the wild-type pfmdrl gene in 7G8 (resulting in 7G8-md~lO), 
significantly lowered the CQ IC50 which correlated with an increase in the accumulation 
of eH]-CQ seen in Chapter 5. These observations provide further evidence for a role of 
the pfmdr 1 gene product in the susceptibility of P. falciparum to 4-aminoquinolines and 
arylaminoalcohols. The transfectants used here were from laboratory adapted parasite 
lines or clones. Insight into the resultant effect of transfecting field isolates may be 
needed as field isolates would give further understanding of parasites which infect 
patients in malaria endemic areas. The role of pfmdr 1 codon 86 in antimalarial sensitivity 
was unfortunately not investigated in this way as there have been no successful 
transfectants obtained with that single mutation to date. 
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The role of the plert codon 76 mutation (in parasite line K76I) in antimalarial 
sensitivity supports the observations of Cooper et al. (2002) and Sidhu et al. (2002). This 
interesting line was selected during a failed transfection under CQ pressure from parasite 
line 106/1 isolated from a Sudanese patient. The parent line which harboured other plert 
mutations but not the lysine to threonine change in codon 76 was CQS. Following the 
CQ pressure, a lys76ile change was seen and the parasite was CQR. The 106/1 line (parent 
line of K76I), interestingly showed a -2-fold higher CQ ICso than the other CQS 
parasites, although no significant change was detected in the eH]-CQ uptake compared 
to other CQS parasite lines (Chapter 5). The significant decrease in ICso values of MQ, 
HAL, QN, LM and DHA with the introduction of the 76i1e mutation in K76I (Tables 3.3A 
and 3.5) was similarly seen with the transfection of mutated plert alleles into P. 
lalciparum clones with antimalarials MQ, QN, DHA and QHS (Sidhu et al., 2002). 
These results clearly showed that plert and plmdr 1 played vital roles m 
multifactorial processes which govern parasite susceptibility to a wide range of 
antimalarials. Certainly, changes in more than one gene are required for higher degrees 
of drug resistance. The modulation of baseline CQ resistance by changes in plmdr 1 alone 
or by codon changes other than that at 76 in plert, is evident with the comparison of 
parasite lines DIO_mdr7G8, 106/1, and 7G8-mcrrD lO (Table 3.3A). DI0_mdr7G8 showed a 
raised CQ ICso (-33 nM) compared to the other CQS parasite lines; 106/1 displayed a 
degree of CQ resistance with an increased CQ ICso (-49 nM) compared to D 10_mdr7G8; 
while 7G8-mruPlO showed the highest ICso (-87 nM) of all three lines falling just short of 
the CQ resistance 100 nM cut-off value - the latter two ICso values were statistically 
significant to the other CQS lines. All the other CQR lines (except 7G8-md~lo) had CQ 
ICso values of over 200 nM. This does emphasise that polymorphisms in both genes are 
needed concurrently, although the crucial mutation in plert 76 is needed for a line to 
display the full CQR phenotype - e.g. slightly CQR 106/1 carried mutated plmdr 1 and all 
other plert polymorphisms other than codon 76; although borderline CQR 7G8-mdrD10 
carried wild-type plmdr 1, it harboured mutated plert including codon 76. 
Transfection techniques are still at their infancy in malaria research. It is an 
important tool greatly needed in the understanding of the genetic basis of antimalarial 
drug resistance. If funding permits, such techniques coupled with microarray analysis 
should be employed in elucidating drug resistance mechanisms and search for drug 
targets. Statistically significant numbers of parasite lines, representative of parasite lines 
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from a range of geographical areas, should be investigated for further insight into drug 
action and resistance mechanisms. 
Combination chemotherapy allows improved drug efficacy through synergistic 
interactions; and allows development of resistance to be inhibited or at least delayed. It is 
imperative to understand the molecular mechanisms behind these interactions as the 
benefits of drug combinations could disappear if the interactions produce an antagonistic 
effect. Despite structural similarities between 4-aminoquinolines, bisquinolines and 
arylaminoa1cohols, when combined with DHA there were major differences in 
interaction among parasite lines with varying pfmdr 1 and pfert polymorphisms. The two 
4-aminoquinolines CQ and AQ, and the bisquinoline PPQ, produced an antagonistic 
response in all parasite lines (Figure 6.lA). However, arylaminoa1cohols MQ, HAL and 
LM in combination with DHA showed illuminating effects in relation to polymorphisms 
found in the two genes. The responses from CQS lines were synergistic in parasite lines 
which carried wild-type pfmdrl and pfert (Figure 6.lB). Conversely, the CQR lines 
showed additive response to the three arylaminoalcohol combinations. The slightly CQR 
106/1 line was an exception as it displayed an additive response - note that this parasite 
line carriedpfmdr1 codon 86 mutation and six polymorphisms inpfert gene (Chapter 3). 
The LM + DHA and LM + ATM interactions appear to be particularly dependent on 
mutations in pfmdr 1. An additive response was seen in transfectant D 1 O_mdr7G8 which 
harboured mutated pfmdr 1 and a synergistic response was seen with transfectant 7G8-
mdrD10 which carried wild-type sequence from parasite line DIO. Parasite line T996, 
which carried mutated pfmdr1 184phe, showed an intermediate response between addition 
and antagonism. To date, a mutation in this pfmdr 1 codon has not been associated with 
CQ resistance (Foote et ai., 1990b; Omar et al., 200la). However, MQ and HAL in 
combination with DHA exerted a synergistic response on 7G8_mdrD10 which carried 
wild-type pfmdrl, but mutated pfert. This could indicate that synergy seen in DHA 
combinations with MQ or HAL is dependent on the presence of wild-type pfmdrl along 
with other CQ resistance associated mutations such as polymorphisms in pfert. A mixed 
response was seen in parasite lines tested against QN + DRA, but all the lines which 
carried mutated pfmdr 1 and pfert 76thr showed an additive response. There were 
significant differences between control parent lines 7G8_mdr7G8 and 106/1 which 
displayed additive responses, and experimental lines 7G8_mdrD10 and K761 which 
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showed synergistic responses. The response of K761 to QN + DHA was VP-sensitive -
reversing the response from synergy to addition. Findings presented in this thesis show 
that mutations in both pfmdr 1 and pfcrt genes had an effect on QN ICso values (Chapter 
3), and it may be possible that the drug is interacting with the mutated PfCRT, 
particularly pfcrt codon 76 - with VP altering this interaction (Sidhu et al., 2002). Both 
antimitochondrial drugs ATV and PYR in combination with DHA produced antagonistic 
effects in ATV- and PYR-sensitive lines, but additive in ATV- and PYR-resistant line(s). 
The response seen in PYR-resistant lines could be due to higher concentration of PYR 
which may be causing alternative cellular damage not seen in the lower PYR 
concentrations used on PYR-sensitive lines. The significant difference in synergistic 
responses in the ATV + PG combination seen between ATV-sensitive Kl and T996, and 
ATV-resistant NGATVOI demonstrated how resistance to one drug may have a 
significant effect when the drug is used in a combination regimen - causing large 
decrease in the efficacy of the two drugs combined. This combination failure is 
particularly worrying as reduced potency seen in vivo in the Malarone® treatment failure 
could be predicted by reduced synergy shown in vitro. 
This thesis is the first report of polymorphisms in drug resistance associated 
genes conferring different responses with DHA and other antimalarial combinations. The 
significance of these findings lies in the choice of appropriate combination therapy which 
is gaining ground as alternative treatment needed to combat drug resistance (Nosten and 
Brasseur, 2002). Our results would suggest a cautious approach in the selection of drugs 
for combined treatment. Certainly, as shown here, the overall effect of the combined 
drugs should be desirably synergistic, and this highlights the importance of performing 
baseline drug-drug interaction studies. Although pharmacokinetic compatibility of the 
combined drugs is equally important, combinations should be made to ensure that the 
overall effect on parasites is synergistic. The combined role of mutations in pfmdr 1 and 
pfcrt in parasite sensitivity to 4-aminoquiolines and arylaminoalcohols is evident in the 
present study as it is elsewhere in the literature. Characterisation of both field and 
laboratory adapted parasite lines with putative drug-resistance associated mutations in 
parallel with in vitro drug efficacy studies and drug-drug interaction studies should be a 
major component of the drug selection process for efficacious combined treatment 
regimens. The resistance-reversing property of VP on CQ resistance as shown here and 
other chemosensitisers should be exploited in the design of newer drugs for the treatment 
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of infections resistant to CQ. Resistance to a component of a drug combination could 
adversely affect the overall response of the parasite to the combined drugs as shown here 
by PG + ATV combination. Cycloguanil response was not tested, owing to insufficient 
time, which reduces the force of this observation. Dose-dependent effects as a factor 
should not be overlooked and it is important to remember that drug uptake and drug-drug 
interactions in vivo may be quite different from in vitro due to many complex parameters. 
The future developments and general release of antagonistic combinations, e.g. 
antifolates combined with artesunate - antagonistic in vitro and in vivo (Chaw ira et al., 
1987) - demands further study of the cellular processes behind these interactions. 
The results presented in Chapter 5 indicated that polymorphisms in either pfert or 
pfmdr 1 had no significant influence on DHA uptake. Previous reports indicate that 
mutations in both pfmdr 1 and pfert may influence susceptibility of P. falciparum parasite 
lines to QHS-derivatives (Reed et al., 2000; Duraisingh et al., 2000b; Cooper et al., 
2002; Sidhu et al., 2002) and further support for this was presented in Chapter 3. 
However, large differences in eH]-CQ uptake between parasite lines which carried either 
wild-type or mutated pfmdrl and pfert codon 76 were seen. CQR parasites accumulated 
lower amounts of eH]-CQ than CQS parasites and there was an inverse association with 
CQ ICso and amount of eH]-CQ accumulated. The amount of drug accumulated could be 
increased with the addition of VP - although not to the levels of CQS parasites. The 
important role of polymorphisms in pfmdr 1 and pfert relating to decreased CQ sensitivity 
and uptake was clearly shown. The results presented do not correlate small differences 
seen with DHA ICso values with eH]-DHA uptake in contrast with CQ results. The small 
differences in susceptibility between susceptible and less susceptible parasite lines 
(Duraisingh et al., 1999; Gay et al., 1994; Price et al., 1999) may mean that the 
differences in uptake are not easily detected, or there may be, with such a hydrophobic 
drug, many unimportant sites of binding (sites of loss) which have no impact on 
susceptibility. These small differences in sensitivity are usually only 2 to 3-fold, 
compared to the large differences seen in CQ resistance which are often around 10-fold 
(Duraisingh et al., 1999). It has been demonstrated with another lipophilic drug, MQ, 
that a reduced MQ ICso of 3-fold correlates with an increase in MQ accumulation ratio 
(Reed et al., 2000). A decreased accumulation of ~60% of eH]-DHA has also been 
shown in a QHS-resistant strain of P. yoelii (Walker et al., 2000). 
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Uptake studies of eH]-DHA and eH]-CQ in combination with other antimalarials 
indicated that some of the quinoline-related drugs and QHS-derivatives competed with 
the uptake of these two radiolabelled drugs. Quinoline-related drugs CQ, AQ, PPQ, MQ, 
and HAL all significantly lowered eH]-DHA accumulation in FC27, 3D7, Kl and 
RSAl1. The antimalarials LM, QN, PYR, SDX, ATV had little or no effect on eH]-
DHA uptake. According to these data, one could expect an antagonistic interaction 
between the quinoline-related drugs and DHA; but arylaminoalcohol drugs MQ, HAL, 
LM and QN all had additive or synergistic effects in parasite lines when combined with 
DHA. However, the DHA combinations with antimalarials PYR and ATV exerted 
antagonistic effects in all four PYR- and ATV-sensitive lines but had no effect on eH]-
DHA uptake. That uptake data disagree with the sensitivity data from the interaction 
studies suggests that the underlying cause of antagonism may be due to reasons other 
than drug uptake. Uptake of eH]-CQ was significantly reduced over 50% by the 
quinoline-related drugs PPQ, MQ and QN in all four parasite lines. The QHS-based 
drugs DHA, QHS (except in CQS FC27 and 3D7), and ATM all significantly reduced the 
uptake of eH]-CQ, but not to the level seen with quinoline-related drugs. In the case of 
antagonism seen with the CQ, AQ and PPQ combinations (Chapter 4), it has been 
suggested previously that these 4-aminoquinoline drugs share common uptake 
mechanisms and reduce eH]-DHA accumulation (Gu et ai. J 1984). As it was shown that 
CQ reduces DHA accumulation, and vice versa, it may be possible that this could be a 
contributing factor towards antagonism seen in the in vitro interaction studies of these 
two drugs. 
It is hoped that the findings of this thesis have enhanced knowledge of 
artemisinin antimalarial drug combinations and the role of putative drug resistance 
associated mutations in determining the responses of parasite lines to the combined effect 
of antimalarial drugs. The understanding of this subject in conjunction with drug 
sensitivities and uptake studies is important as artemisinin treatment combinations are 
currently in the process of replacing conventional malaria treatment therapies in many 
parts of the world (Nosten and Brasseur, 2002). Ideally, antimalarial combination 
chemotherapy should take advantage of synergistic interaction, as this would enhance 
therapeutic efficacy and lower the risk of resistance emerging. It is important to 
understand the effect of drug combinations at the level of the parasite's response in vitro 
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as there is concern that if drugs in combination are antagonistic in vivo, the efficacy of 
such regimens might be compromised. It could be possible that antagonism could 
increase the chances of resistance developing and spreading, as less-effective drugs may 
be allowing weakly resistant clones to survive, be selected and transmitted. 
Additional studies of the effects of various mutations inpfcrt in combination with 
wild-type pfmdrl - with the Sidhu et al. (2002) transfectants as an example - would 
confinn the differing responses seen between CQS and CQR parasite lines and confinn 
which polymorphisms confer changes in the parasite's response to combinations with 
QHS-derivatives. The mutation in pfmdr 1 codon 86 and its roles in antimalarial 
sensitivity and drug combinations have not been investigated. Work on this mutation is 
important as it is the most common single pfmdr 1 polymorphism seen in Africa and was 
earlier prevalent in South-East Asia (Grobusch et al., 1998). Further studies on the 
biochemical mechanisms behind antagonism or synergy seen in the combinations studied 
here will allow us to understand the mode of action of these antimalarials in more detail, 
and to design more effective combinations for treatment. 
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Figure 6.1: A graphical representation of the interaction of DHA and CQ (A) or MQ (B) in 
the P. fa/ciparum digestive vacuole. f 
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i A: CQ accumulates in the vacuole where it becomes doubly protonated (1) and is thought to 
bind to haematin (FPIX) blocking its polymerisation. DHA simultaneously accumulates in the 
vacuole where it reacts with iron within the vacuole forming free radicals (2). Antagonism could be 
due to the CQ and DHA competing for binding to FPIX (3). The DHA free radicals cause cellular 
damage by reacting with vacuole membrane proteins (4) or blocking haemoglobin (Hb) 
breakdown (5) which could lead to further antagonism due to the decrease of FPIX within the 
vacuole. The acidic vacuole is thought to be regulated by the Pgh-1 protein. B: The synergism 
seen in the MQ and DHA combination could be due to similarities between the accumulated MQ 
(1) and DHA (2) as both drugs target cell membranes (4) and MQ has been shown to disrupt 
membrane trafficking which could lead to further decrease of Hb breakdown (6). It has also been 
suggested that MQ and DHA could compete for export on Pgh-1 and when it is mutated the 
export of both drugs is not so efficient and synergism is not demonstrated. 
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APPENDIX 1 
All chemicals are from Sigma Chemical Co., UK unless otherwise stated. 
I-A. Parasite lines 
Isolate Origin Resistance References features 
FC27 
Papua New Guinea 
-
(Chen et al., 1980) 
T996 Clone ofTak9 
(Thailand) - (Rosario, 1981) 
Clone ofNF54, 
3D7 airport malaria - (ponnudurai et al., 1981) 
case (Netherlands) 
Kl Thailand CQ,PYR (Thaithong and Beale, 1981) 
B303 Brazil CQ,PYR 
-
RSAll South Africa CQ (Freese et al., 1991) 
7G8_mdr7G8 Transfectant of CQ,PYRt (Graves et al., 1985; Reed et 7G8 (Brazil) al.,2000) 
Clone ofFC27; 
DIO_mdrD1O Transfectant of PYRt (McColl et al., 1994; Reed DIO (Papua New et al., 2000 ) 
Guinea) 
106/1 Sudan - (Fidock et al., 2000b) 
K761 106/1 with plert lys76i1e mutations CQ (Fidock et al., 2000b) 
* Parasites carry non-Plasmodial dhfr gene due to transfection protocol 
Appendix 1 261 
1-B. Incomplete culture medium (1M) 
RPMI-1640 with L-glutamine, without sodium bicarbonate, D-glucose (AnalaR, 
BDH), HEPES and gentamycin solution (50mglml). 
ComQonent Concentration (gIL) 
RMPI = 10.4 
HEPES = 6.0 
NaHC03 = 2.325 
D-glucose = 2.0 
gentamycin = 40mg/L 
dH20 = to make up to IL 
1-C. Complete culture medium 
Incomplete culture medium with the addition of 5% sterile NaHC03 (AnalaR, BDH) 
solution and AB+ human serum to pH 7.3 and a final concentration of 
NaHC03 = 42 mllL (2.125 gIL) 
AB+ human serum = 10% 
1-D. Giemsa stain buffer 
1-E. 
di-sodium hydrogen orthophosphate anhydrous = I gIL 
Potassium dihydrogen orthophosphate = 0.7 gIL 
pH = 7.2 
Malstat reagent 
Triton = 200).l1 
TRIS buffer = 0.66g 
L-Iactate = 2g 
APAD = 40mg 
dH20 = to make up to 200 ml 
pH = 9.0 with HCI 
Appendix 1 
1-F. NBTIPES reagent 
nitroblue tetrazolium = 180 mg 
phenazine ethosulfate = 8 mg 
dH20 = to make up to 100 ml 
1-G. Phosphate-buffered saline (PBS) pH 7.4 
NaCI = 8.0 gil 
KCI = 0.2 gil 
Na2P04 = 0.115 gil 
KH2P04 = 0.2 gil 
dH20 = to make up to lL 
1-H. Cryopreservation mixture 
NaCI = 0.65 g 
D-sorbital = 3.024 g 
glycerol = 28ml 
dH20 = to make up to 100ml 
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1-1. Primers 
All primers were from LifeTechnologies, UK. See Section 3.3.3 for more details. 
Primer name Primer sequence 
cytb-l 5' ... CTC TAT TAA TTT AGT TAA AGC ACA. .. 3 ' 
cytb-2 5' .. .ACA GAA TAA TCT CTA GCA CC ... 3' 
cytb-3 5' .. .AGC AGT AAT TTG GAT ATG TGG AGG ... 3' 
cytb-4 5' .. .ATT TTT AAT GCT GTA TCA TAC CCT ... 3' 
cytb-5 5' .. .ACA ACA CAT TTT AAG AGA ATT ATG ... 3' 
cytb-6 5' ... TAC ATA ATC CAA TAA ATG GTA AGA. .. 3' 
ISA-2 5' .. .AGA TGG TAA CCT CAG TAT CA. •• 3' 
DCW-2 5' ... TTA CAT CCA TAC AAT AAC TTG ... 3' 
DCW-3 5' ... GTG TAA TAT TAA AGA ACA TCT ... 3 ' 
DCW-4 5' ... GTG TAA TAT TAA AGA ACA TAA. .. 3 ' 
lO34F 5' ... GAT CCA AGT TTT TTA ATA CA. •• 3' 
lO34R 5' ... CTC AAA TGA TAA TTT TGC AT ... 3' 
MTI034F 5' ... CAG CTT TAT GGG GAT TGT ... 3' 
WTI034F 5' ... CAG CTT TAT GGG GAT ACA. .. 3' 
MTI042F 5' .. .AGC GCT CAA TTA TTT ATA G ... 3' 
WT1042F 5' •. .AGC GCT CAA TTA TTT ATA A. •• 3' 
1246F 5' ... TGG AAA ATC AAC TTT TAT GA. .. 3' 
1246R 5' ... TAG GTT CTC TTA ATA ATG CT ... 3' 
MT1246F 5' .. .ATG TGA TTA TAA CTT AAG CT ... 3' 
WT1246F 5' ... TGT GAT TAT AAC TTA AGC G ... 3 ' 
TCRPI 5' ... CCG TTA ATA ATA AAT ACA CGC AG ... 3' 
TCRP2 5' ... CGG ATG TTA CAA AAC TAT AGT TAC C ... 3' 
TCRDI 5' ... TGT GCT CAT GTG TTT AAA CTT ... 3' 
TCRD2 5' ... CAA AAC TAT AGT TAC CAA TTT TG ... 3' 
MSPIF 5' ... GAA GAT GCA GTA TTG ACA GG ... 3' 
MSPIR 5' ... GAG TTC TTT AAT AGT GAA CAA G ... 3' 
MSP2F 5' ... GAG TAT AAG GAG AAG TAT GG ... 3' 
MSP2R 5' ... CCT GTA CCT TTA TTC TCT GG ... 3' 
264 
APPENDIX 2 
SUPPLEMENTARY DATA 
2-A. Gel electrophoresis of cytb peR amplification products 
Figure A2.9.1: Cytb codon 133 ("",1133"") gel electrophoresis of PCR amplification products 
and Tsp5091 RFLP profile of parasite lines K1, FC27, NGATV01, T996. * 
1 2 3 4 5 6 7 8 9 10 11 12 
- 365 bp 
- 128 bp 
t Lanes 1-5: undigested PCR amplification products of K1 . FC27. NGATV01. T996. and negative 
control (365 bp). Lanes 7-11: Tsp5091 digested products of PCR amplification products K1. 
FC27. NGATV01. T996. and negative control (128. two 92.36. and 17 bp pattern). Lanes 6 and 
12: 100 bp ladder. 
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2-B. Nucleotide DNA sequence ofNGATVOl cytb gene 
Figure A2.9.2: Nucleotide sequence of P. falciparum cytochrome b gene from isolate 
NGATV01 showing codons 9 to 314. 
AAAGCACACTTAATAAATTACCCATGTCCATTGAACATAAACTTTTTATGGAATTAC 
GGATTCCTTTTAGGAATAATATTTTTTATTCAAATTATAACAGGTGTATTTTTAGCA 
AGTCGATATACACCAGATGTTTCATATGCATATTATAGTATACAACACATTTTAAGA 
GAATTATGGAGTGGATGGTGTTTTAGATACATGCACGCAACAGGTGCTTCTCTTGTA 
TTTTTATTAACATATCTTCATATTTTAAGAGGATTAAATTACTCATATATGTATTTA 
CCATTATCATGGATATCTGGATTGATTTTATTTATGATATTTATTGTAACTGCTTTC 
GTTGGTTATGTCTTACCATGGGGTCAAATGAGTTATTGGGGTGCAACTGTAATTACT 
AACTTGTTATCCTCTATTCCAGTAGCAGTAATTTGGATATGTGGAGGATATACTGTG 
AGTGATCCTACAATAAAACGATTTTTTGTACTACATTTTATCTTACCATTTATTGGA 
TTATGTATTGTATTTATACATATATTTTTCTTACATTTACATGGTAGCACAAATCCT 
TTAGGGTATGATACAGCATTAAAAATACCCTTTTATCCAAATCTATTAAGTCTTGAT 
GTTAAAGGATTTAATAATGTTATAATTTTATTTTTAATACAAAGTTTATTTGGAATT 
ATACCTTTATCACATCCTGATAATGCTATCGTAGTAAATACATATGTTACTCCATCT 
CAAATTGTACCTGAATGGTACTTTCTACCATTTAATGCAATGTTAAAAACTGTTCCA 
AGTAAACCAGCTGGTTTAGTAATTGTATTATTATCATTACAATTATTATTCTTATTA 
GCAGAACAAAGAAGTTTAACAACTATAATTCAATTTAAAATGATTTTTGGTGCTAGA 
GAT 
Appendix 2 
2-C. Differences in mean FICso and FIC90 between ATV in combination with 
either DHA or PG 
266 
Table A2.1: The mean FIC of the interactions between A TV and DHA or PG with 95% 
confidence intervals. Parasite lines in section B of the table are CQR 6 
ATV+DHA 
Parasite line 
Mean FICso (95% CW Mean FIC90 (95% CI)d 
NGATV01 0.96* (0.90 - 1.02) 0.89* (0.76 - 1.02) 
T996 1.35 (1.18 - 1.52) 1.49 (1.01 - 1.97) 
A 307 1.17 (1.08 - 1.26) 1.23 (1.13 - 1.33) 
010 1.17 (1.09-1.25) 1.29 (1.1 0 - 1.48) 
Fe27 1.14 (1.04 - 1.24) 1.60 (1.27 - 1.93) 
K1 1.51 (1.30 -1.72) 1.42 (1.20 - 1.64) 
B 
RSAll 1.36 (1.25 - 1.47) 1.64 (1.38 - 1.90) 
7G8 1.45 (1.32 -1.58) 1.43 (1.26 - 1.60) 
B303 1.27 (1.08 - 1.46) 1.40 (1.25 - 1.55) 
b The asterisk indicates a significant result in comparison with the determinations on the other 
parasite lines (P < 0.05). 
C Mean FIC calculated using ICoo values with 95% confidence intervals 
d Mean FIC calculated using ICgo values with 95% confidence intervals 
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2-D. Isobolograms indicating the lack of the reversible effect ofVP 
Figure A2.9.3: Isobolograms indicating the additive effect of DHA with MQ or HAL in K1 
and RSA11 in the presence of 1 uM VP. 
a 
~ 
'l5 
o 
u:: 
a 
~ 
'l5 
o 
u:: 
K1: DHA+MQ 
FICofDHA 
RSA11: DHA + MQ 
FICofDHA 
'l5 
o 
u:: 
'l5 
o 
u:: 
o 
K1: DHA+ HAL 
FIC ofDHA 
RSA11: DHA + HAL 
FICof DHA 
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2-E. Isobologram of PYR combined with MQ 
A combination ofPYR with MQ was assayed against P. Jalciparum parasite line Fe27. 
As seen in Figure A2A, the combination effect of the drug is well above the additive line 
demonstrating an antagonistic effect. 
Figure A2.9.4: Isobologram of PYR in combination with MQ against P. falciparum line 
FC27. 
0:: 
~ 
'0 
() 
u: 
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Artemisinin derivatives are effective antimalarials prQducing rapid 
.. . 
parasitological and dinical response in acute faldparum malaria induding 
severe and complicated cases and in multidrug·resistant infec!ons. It is likely 
that the emergence of resistance to artemisinin derivatives can be delayed or 
even prevented by using a combination of these derivatives with other 
antimalarials. Evidence is accumulating that poIymorphisms in pfmdr1, the 
gene encoding the P..glycoprotein homologue.1 (Pgtr 1) protein, are implicated 
in resistance to quinolines (chloroquine, mefloquine, halofantrine) and possibly 
artemisinin derivatives. Pgtr 1 belongs to the multiple drug resistance (MDR) 
type and has been suggested to be a transmembrane transporter protein. With 
this in mind, we studied the uptake of fH1--dihydroartemisinin and C·c]-
arteflene in combination with common antimalarials in a range of Plasmodium 
falcipsrum drug·resistant strains, induding strains with decreased artemisinin 
sensitivities. 
In vitro sensitivity and drug interaction studies using the standard isobologram 
method show that artemisinin In combination with either mefloquine or quinine 
is synergistic. The effect is antagonistic when the drug is combined with 
pyrimethamine or pyrimethamine/sutfadoxine. An antagonistic effect against 
chloroquine resistant strains was also observed when the drug was combined 
with chloroquine but partially additive in chloroquine sensitive strains. The 
radioIabeHed uptake studies indicated that some of the antimalarials competed 
with the artemisinin uptake, suggesting a similar mechanism of drug 
accumulation. This and other results will be discussed. 
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46. Investigations of Malarone Drug Resistance and Atovaquone Combinations 
With Proguanil and Dihydroartemisinin in a Plasmodium falciparum Isolate 
From Lagos, Nigeria. 
Quinton L. Fivelman, Geoffrey A. Butcher, Jpemida S. Adagu, Geoffrey;Pasvol, David C. 
Warhurst. 
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical 
Medicine, Keppel Street, London, UK 
We report the first in vitro and genetiC confirmation of Malarone® (GlaxoSmithKline; 
atovaquone and proguanil hydrochloride) resistance in P. fa!ciparum acquired in Africa. On 
presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria 
without prophylaxis, a male patient was given a standard 3-day treatment course of 
Malarone®. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured 
from the blood and the isolate (NGATV01) was show~, to be resistant to atovaquone and the 
antifolate pyrimethamine. The cytochrome b gene of isolate NGATVOl showed a single 
mutation, Tyr268Asn which has not been seen previously. A modifiedJfixed ratio isobologram 
method for studying in vitro interactions between anti plasmodial drugs was used to examine 
the interactions between atovaquone, proguanil and dihydroartemisinin. The interaction 
between atovaquone and proguanil was strongly synergistic in atovaquone-sensitive strains 
Kl and T996 and moderately synergistic in NGATVOl isolate. While the interaction between 
atovaquone and dihydroartemisinin was additive in the NGATVOl isolate, the interaction was 
antagonistic in the atovaquone-sensitive strains tested. 
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Abstract 
We report the first in vitro and genetic confirmation of Malarone® (GlaxoSmithKline; atovaquone 
and proguanil hydrochloride) resistance in Plasmodium faldparum acquired in Africa. On presenting 
with malaria two weeks after returning from a 4-week visit to Lagos. Nigeria without prophylaxis, 
a male patient was given a standard 3-day treatment course of Malarone®. Twenty-eight days later 
the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGA TVO I) 
was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene 
of isolate NGA TVO I showed a single mutation, Tyr268Asn which has not been seen previously. 
Introduction 
Increasing reports of drug-resistant P. falciparum through-
out the world have forced changes in both prevention and 
treatment. Malarone· (GlaxoSmithKline; atovaquone and 
proguanil hydrochloride) is a recently introduced new 
drug combination for the treatment (1,2) and prophylaxis 
(3.4) offalciparum malaria. We report the first in vitro and 
genetic confirmation of Malarone· resistance in a case of 
P. falciparum acquired in Africa. 
Case Report 
A forty-five year old Nigerian male, resident in the UK, 
presented with a fever and 1.5% P. !alciparum parasitae-
mia two weeks after returning from a 4-week visit to la-
gos, Nigeria without taking prophylaxis. The patient was 
given a standard 3-day treatment course of Malarone·; 
four tablets daily (one tablet is equivalent to 250 mg of 
atovaquone and 100 mg of proguanil hydrochloride) 
with food which he tolerated well without vomiting and 
was later discharged. Twenty-eight days later, his malaria 
symptoms returned. After a further five days the patient 
was readmitted to hospital with a parasitaemia of less 
than 1 %. A blood sample taken at this point was placed 
into culture. The patient was successfully treated with qui-
nine 600 mg three times per day for three days followed 
by doxycycline 100 mg per day for seven days. 
Drug sensitivity assays were performed at 1 % parasitae-
mia and 1 % haematocrit using tritiated hypoxanthine up-
take as a measure of parasite viability (5) and the isolate 
(NGA1V01) was shown to be resistant to atovaquone (Ta-
ble 1). The NGAlVOl isolate was also resistant to the an-
tifolate pyrimethamine. The standard laboratory strain KI 
was assayed as above and exhibited resistance to both 
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Table I: In vitro sensitivity of isolate NGA TVO I and strain K I to standard antimalarial drugs with standard deviations (nmoI/L). 
Drug NGATVOI KI Resistance Cut-off" 
Mean ICso ± SD Mean ICSO ± SD 
Chloroquine 
Mefloquine 
Pyrimethamine 
Atovaquone 
Proguanil 
Dihydroartemisinin 
9.54 ± 1.18 
24.14 ± 5.20 
16012.80 ± 2643.55 
1888.15 ± 106.65 
4205.50 ± 716.99 
2.39 ± 0.07 
133.29 ± 30.12 
8.55 ±0.29 
8082.84 ± 1202.69 
2.41 ± 1.01 
10239.94 ± 843.51 
1.26 ± 0.46 
100 
20 
100 
20 
not determined 
not determined 
Drug assay was performed at I % parasitaemia and I % haematocrit. Experiment was repeated twice In duplicate.· Cut-off poinu for resistance as 
previously reported [16.17.6] 
K1 SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 109 
TM93-C10BB SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 109 
NGATV01 SGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIVTAFVGYVLP 109 
K1 WGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 179 
TM93-C10B8 WGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 179 
NGATV01 WGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIGLCIVFIHIF 179 
K1 FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
TM93-C10B8 FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
NGATV01 FLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPLSHPDNAIVV 249 
K1 NTYVTPSQIVPEWYFLP~LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 309 
TM93-C10B8 NTYVTPSQIVPEWYFLP~LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 309 
NGATV01 NTYVTPSQIVPEWYFLP~LKTVPSKPAGLVIVLLSLQLLFLLAEQRSLTTIIQFKMI 309 
K1 FGARD 314 
TM93-C10B8 FGARD 314 . 
NGATV01 FGARD 314 
Figure I 
Sequence analysis of P. (alciparum CYT b gene from isolate NGATYOI showing codons 70 to 309. Residue 268 highlighted 
shows the change from tyrosine (Y) to asparagine (N) compared to atovaquone-sensitive strain K I and the change to serine (S) 
in the atovaquone-resistant strain TM93-C I 088 [6]. 
Page 2 of4 
(page number not for citetion purposes) 
Malaria Journal 2002, 1 http://www.malariajournal.com/contenU1/1/1 
Figure 2 
Atovaquone (A TV) in P. (alciparum cytochrome b active site. A: Atovaquone built and docked using HyperChem release 6, in 
the active site of a model of P. (alciparum cytochrome B. Homology model prepared using the structure of the chicken enzyme 
[14] with the aid of the SWISS-MODEL Protein Modelling Server and observed in the Swiss Model Viewer [15]. B: As A, with 
active site tyrosine268 replaced by asparagine. 
chloroquine and pyrimethamine. The DNA of NGATVOI 
was extracted and the cytochrome b coding region of mi-
tochondrial DNA (mtDNA) sequenced (6) in both direc-
tions together with DNA samples from P. falciparum 
control strains. The sequence showed a change from TAT 
to AAT in codon 268 (Figure 1), specifying a change from 
tyrosine (Tyr) to asparagine (Asn): Y268N . A different mu-
tation in this codon leading to serine was reported earlier 
in a sample (TM93-C1088) from an atovaquone and py-
rimethamine treatment failure in a Thai patient (6) 
Discussion 
The target of atovaquone, CIT b, plays an important role 
in electron transport during mitochondrial respiration. It 
is thought that the drug, an analogue of coenzyme Q (ubi-
quinone), interrupts electron transport and leads to loss 
of the mitochondrial membrane potential [7,8) . Tyr268 is 
a conserved bulky hydrophobic contact of the drug in the 
Qo II region of the ubiquinol oxidation site. Substitution 
of the less bulky Asn268 should affect the fit and binding 
of the drug (Figure 2) . 
Resistance rapidly emerges when atovaquone is used 
alone (9) . It has been hypothesised that the mode of ac-
tion of the drug might contribute to the rapid appearance 
of resistant parasites. During a stage in its interaction with 
the site when the drug is partially oxidised, the semiqui-
none formed would be capable of forming reactive oxy-
gen species (ROS) capable of acting as local mutagens 
during replication of the mtDNA. Proguanil is believed to 
speed the loss of the membrane potential, and ensure that 
replication of DNA stops before mutagenesis can occur 
(10). 
Conclusions 
This is an unusual example of resistance detected during a 
single course of Malarone" on only a moderate parasitae-
mia . The atovaquone/proguanil combination has not 
been widely used yet in West Africa so it is unlikely that 
the patient was initially infected with an atovaquone-re-
sistant. strain. The presence of multidrug-resistant strains 
such as this example raises concern about the recent move 
to consider using Malarone as first-line therapy in Africa 
(11). The case questions the potential useful life of this 
combination, especially as atovaquone may persist alone 
in plasma for up to 6 weeks after treatment (12) . It appears 
that the synergistic interaction with proguanil is not seen 
in atovaquone-resistant mutants (13), and higher resist-
ance levels are achievable. 
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Plasmodium frlkprum In vttro. 
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WC1E 7HT, United Kingdom 
Artemisinin derivatives are effective antimalarials producing rapid 
parasitological and clinical response in acute' faldparum malaria induding 
severe and complicated cases and in multidrug-resistant infec'-ons. It is likely 
that the emergence of resistance to artemisinin derivatives can be delayed or 
even prevented by using a combination of these derivatives with other 
antimalarials. Evidence is accumulating that poIymorphisms in pfmdr1, the 
gene encoding the P-glycoprotein homologue-1 (Pgh-1) protein, are implicated 
in resistance to Quinolines (chloroquine, mefloquine, halofantrine) and possibly 
artemisinin derivatives. Pgh-1 belongs to the multiple drug resistance (MDR) 
type and has been suggested to be a transmembrane transporter protein. With 
this In mind, we studied the uptake of [3H]-dihydroartemisinin and C4C)-
artef1ene in combination with common antimalarials in a range of Plasmodium 
falciparum drug-resistant strains, induding strains with decreased artemisinin 
sensitivities. 
In vitro sensitivity and drug Interaction studies using the standard isobologram 
method show that artemisinin In combination with either meftoquine or quinine 
is synergistic. The effect is antagonistic when the drug is combined with 
pyrimethamine or pyrimethamine/sulfadoxine. An antagonistic effect against 
chloroquine resistant strains was also observed when the drug was combined 
with chloroquine but partiaUy additive in chloroquine sensitive strains. The 
racfioIabelled uptake studies indicated that some of the antimalarials competed 
with the artemisinin uptake, suggesting a similar mechanism of drug 
accumulation. This and other results will be discussed. 
